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Atrial fibrillation (AF) is the most common cardiac dysrhythmia in the world, mainly affecting 
elderly individuals. The incidence and prevalence of AF are increasing globally owing to an 
increase in the aging population and associated risk factors. Epidemiological data show the 
overall prevalence of AF to be 1.5-2%, increasing from 0.7% in people aged 55-60 years to 
17.8% in those aged ≥ 85 years. AF adversely affects cardiac haemodynamics leading to 
thromboembolism, manifesting as ischaemic stroke/transient ischaemic attack (TIA), deep 
venous thrombosis, pulmonary embolism, and myocardial infarction. Patients with AF have a 
5-fold increase in the risk of stroke compared to patients without AF, and about 15-20% of all
strokes are due to AF. AF-related strokes are often more severe, resulting in greater disability, 
and higher fatality and recurrence rates than non-AF-related strokes.  
Oral anticoagulant (OAC) therapy is essential for thromboprophylaxis in AF. Evidence-based 
AF guidelines recommend OACs for patients with additional stroke risk factors. Optimal use 
of OAC therapy in AF reduces the risk of stroke by about 60-70% compared to placebo. For 
many decades, vitamin K antagonists (VKAs) such as warfarin have been the only OACs 
available for long-term anticoagulation in AF. However, VKAs are limited by their narrow 
therapeutic window requiring frequent monitoring and dose adjustment, drug-drug interactions, 
and adverse drug reactions, primarily fatal and non-fatal bleeding events. These limitations 
have resulted in guideline discordance, poor adherence, and suboptimal patient outcomes. 
According to contemporary AF guidelines, the majority of patients with AF are categorised as 
being at high risk of stroke according to the CHA2DS2-VASc score (i.e. CHA2DS2-VASc ≥ 2) 
and thus eligible for OAC therapy. However, observational studies confirm widespread under-
xv 
prescribing of OACs in at-risk AF patients. Despite changes in clinical guidelines, antiplatelet 
(APT) agents remain commonly used for stroke prevention in AF.  
The challenge of optimal anticoagulation in AF has prompted the search for “ideal OACs” that 
are safe, effective, and convenient to use in AF. Since 2008, four direct-acting OACs (DOACs), 
namely dabigatran, rivaroxaban, apixaban, and edoxaban, have been approved as alternative 
anticoagulants to VKAs for stroke prevention in patients with non-valvular AF (NVAF). 
Analysis of data from large randomised controlled trials (RCTs) has shown that DOACs have 
comparable efficacy, with a lower rate of major bleeding than warfarin. Moreover, DOACs are 
convenient for dosing, have predictable pharmacokinetics and routine monitoring is not 
required. With the introduction of DOACs, a new era has started resulting in a paradigm shift 
in the management of AF patients requiring anticoagulation. AF guidelines in most countries 
now recommend DOACs as first-line agents for stroke prevention in NVAF.  
DOACs were launched in Australia with market approval of dabigatran in 2011. However, 
these agents only became widely available after being listed on the Pharmaceutical Benefits 
Scheme (PBS) for subsidy by the government in August 2013. At the commencement of this 
study, limited data was available from the Australian perspective regarding the clinical 
integration of DOACs, their impact on anticoagulation practices, and clinical outcomes of 
antithrombotic therapy in AF. The Tasmanian Atrial Fibrillation study (TAFs) was established 
in 2011 to generate current data pertaining to the evolving antithrombotic therapy patterns and 
outcomes of antithrombotic treatment in AF. The TAFs was initiated at three Tasmanian 
Hospitals - the Royal Hobart Hospital (RHH), Launceston General Hospital, and North West 
Regional Hospital. The current study was part of the TAFs, specifically focussed on patients 
with AF as primary or secondary diagnosis who were admitted to the RHH between 2011 and 
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2015, for whom long-term follow-up data were readily available. It is intended that the findings 
from this study could be used by practitioners to inform decision making in the management 
of AF, and by policymakers to analyse the impacts of the new therapies on AF care and the 
overall health care system. 
The main objectives of the studies contained in this thesis were to: i) describe antithrombotic 
prescribing patterns in AF with a particular focus on the clinical integration of DOACs in the 
five years after they were introduced into Australian clinical practice, ii) investigate 
anticoagulation practices in relation to current AF guidelines before and after DOACs became 
widely available in Australia, iii) assess rates of, and risk factors for thrombosis and all-cause 
mortality in the pre- and post-DOAC eras, and iv) investigate bleeding-related hospitalisations 
in patients with AF who received antithrombotic therapy.  
 To describe antithrombotic prescribing patterns and assess the clinical integration of DOACs, 
we assessed patients with AF admitted to the RHH between 2011 and 2015. Digital medical 
records were used as the data source. Study participants were grouped into three cohorts based 
on the antithrombotic therapy prescribed at discharge of index admission (first admission 
during the study period): 1) warfarin - patients discharged with lone warfarin or warfarin-APT 
therapy, 2) DOAC - patients discharged with lone DOAC or DOAC-APT therapy, and 3) APT 
- patients prescribed lone or dual-APT therapy. Index admission dates were organised into
quarterly (Q) periods, and the proportion of antithrombotic prescribing in each cohort was 
determined by dividing the number of patients prescribed each agent by total patients receiving 
antithrombotic therapy within the respective period.  
In total, 3265 patient records were reviewed, of which 2390 were included in the assessment 
of antithrombotic prescribing patterns. Overall, participants of this study were relatively more 
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comorbid and had higher stroke and bleeding risk scores versus those observed in the RCTs 
that compared warfarin and DOACs. However, patient demographics and comorbidities in our 
study were broadly similar to large AF-registry data reported elsewhere. Antithrombotic agents 
were prescribed for the majority of our study population. DOACs accounted for 18.4% of 
patients receiving antithrombotic therapy in 2011-2015; the proportion of patients receiving a 
DOAC steadily increased from 3.9% among OAC users in Q3, 2011, to 67.6% in Q2, 2015 (p 
< 0.001). Accordingly, DOACs became the most commonly prescribed antithrombotic 
medications in AF soon after they became government subsidised and listed on the BPS for 
public use. Warfarin and APT prescribing, on the other hand, declined significantly, although 
a substantial proportion of patients continued to be prescribed APT therapy.  
In a subsequent study to investigate OAC prescribing in relation to AF guidelines and assess 
the impact of the availability of DOACs on anticoagulation practices, we reviewed patients 
with NVAF admitted to RHH between 2011 and 2015. Based on index admission periods, 
patients were grouped into two cohorts: pre-DOAC era - admission before the listing of 
DOACs on the PBS (January 2011 to July 2013), and post-DOAC era - admissions between 
August 2013 and July 2015. Patients’ stroke risk scores were estimated using the CHA2DS2-
VASc method. The proportion of OAC prescribing overall, and by stroke risk stratification was 
compared between the two eras. Logistic regression was used to identify factors associated 
with OAC prescribing in the pre-DOAC, post-DOAC, and overall study periods.  
In this analysis, we identified 2118 patients with NVAF (1089 vs 1029 from the pre- and post-
DOAC eras, respectively). Overall, anticoagulation increased from 52.5% in the pre-DOAC to 
60.7% in the post-DOAC era (p < 0.001). Furthermore, anticoagulation of high-risk patients 
(CHA2DS2-VASc ≥ 2) improved significantly (55.2% vs 63.1%, p = 0.001). In multivariate 
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analysis, DOAC era (OR 1.40, 95% CI 1.17-1.68) and CHA2DS2-VASc ≥ 2 (OR 1.95, 95% CI 
1.36 - 2.80) were independent predictors of OAC prescribing in both eras and the whole study 
period. Conversely, increasing age and prior bleeding were inversely associated with OAC 
prescribing. In summary, a significant increase in OAC prescribing was observed particularly 
among high-risk patients in the post-DOAC era. This was likely driven by the widespread 
availability of DOACs, as well as updates in the AF guidelines associated with the introduction 
of the new agents. However, OAC underuse in high-risk and overuse in low-risk patients was 
apparent throughout the study period highlighting the need for further improvement.  
The third study aimed to investigate the impact of DOAC availability on thromboembolic 
events (TEs) and all-cause mortality in patients with AF. We compared incidence rates of TEs 
and all-cause mortality in the pre-DOAC and post-DOAC time periods (as above). Primary 
outcome measures included TEs (ischaemic stroke/TIA, systemic embolic events, myocardial 
infarction), and all-cause mortality. Event rates were estimated by following patients with AF 
newly initiating antithrombotic therapy to the first TE event, treatment switch/discontinuation, 
death or end of study period, whichever occurred first. Cox regression analysis was used to 
identify risk factors associated with incident TE and all-cause mortality. Among 1125 patients 
newly initiated on antithrombotic agents (542 and 583 patients from the pre- and post-DOAC 
eras, respectively), we observed a significant decrease in the incidence rates of overall TE (rate 
per 100 PY, 2.2 vs 3.3, p < 0.001) and ischaemic stroke/TIA (1.8 vs 2.2, p = 0.023) in the post-
DOAC era compared to the pre-DOAC era. Furthermore, the rate of all-cause mortality was 
significantly lower in the post-DOAC era than the pre-DOAC era (2.5 vs 3.1, p = 0.002). 
Increasing age, prior stroke, and admission in the pre-DOAC era represented risk factors for 
incident TE, ischaemic stroke/TIA, and mortality in this study population.  
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In the final analysis, to evaluate hospital admission due to bleeding, we included all AF patients 
who received antithrombotic treatment during the study period. Bleeding rates were estimated 
by following patients newly initiating thromboprophylaxis to the first bleeding event, treatment 
switch/discontinuation, death or end of the study period. Multivariate logistic regression was 
used to identify predictors of bleeding-related hospitalisation. In total, 2202 AF patients who 
received antithrombotic agents were included; 113 presented to the hospital with a major or 
minor bleeding event during a mean follow-up period of 1.8 years. The combined incidence of 
major and minor bleeding was significantly higher in warfarin- vs DOAC- and APT-treated 
patients (4.1 vs 3.0 vs 1.2 per 100 PY, respectively; p = 0.002). Similarly, the rate of major 
bleeding was higher in the warfarin group as compared to the DOAC and APT cohorts (2.4 vs 
0.4 vs 0.6 per 100 PY, respectively; p = 0.001). Increasing age, a history of prior bleeding, and 
discharge antithrombotic choice of warfarin or multiple antithrombotic therapies were 
independently associated with bleeding events. 
In summary, in this real-world cohort of the TAFs, antithrombotic prescribing in patients with 
AF has changed profoundly over the study period, characterised by a major shift towards the 
prescribing of DOACs. The availability of DOACs has been associated with a significant 
increase in the rates of anticoagulation. However, a large proportion of high-risk patients still 
receive APT therapy or remain untreated. Conversely, a substantial proportion of low-risk 
patients with AF receive OACs highlighting the need for further improvement. This data also 
suggested that TEs and all-cause mortality rates tended to decline during the post-DOAC study 
period when compared to the pre-DOAC era, possibly driven by the increasing anticoagulation 
rates and the use of DOACs in preference to warfarin. Furthermore, the rate of major bleeding 
and ICH, in particular, was lower in DOAC- than warfarin-treated patients. We also identified 
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several factors associated with thromboembolic and bleeding events that could be targeted for 
future intervention, notably increasing age, comorbidities (prior stroke and bleeding), and 
warfarin, and multiple antithrombotic prescribing. Further studies are warranted to investigate 
barriers to OAC prescribing, primarily among the elderly patients, including those with a 
history of prior bleeding; comparative effectiveness of individual DOACs; and the 
appropriateness and clinical outcomes of multiple antithrombotic treatments in AF.   
The body of work presented in this thesis provides a number of real benefits to the various 
stakeholders involved in the management of AF. Policy makers will be able to better analyse 
impacts of the changing landscape of anticoagulation on the overall health service expenditure. 
Practitioners will have additional information for a more tailored approach in selecting the right 
treatment to the best benefit of individual patients. Our data could also be used as an input in 
the revision/development of local and national AF guidelines. Lastly, the findings reported in 
this research can be used in promoting the understanding of the various OAC options including 
associated risks and benefits. While the quality of stroke prevention and the outcomes of AF 
patients have improved in recent years, stroke prevention in AF is not yet optimal. The data 
presented in this thesis highlight these improvements and deficiencies in the Australian setting 
and can potentially be used to fully realise the benefits of OACs in the prevention of stroke 
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1.1 Definition and pathophysiology of atrial fibrillation  
Atrial fibrillation (AF) is the most common cardiac arrhythmia. It is characterised by high-
frequency dyssynchronous contraction of the upper cardiac chambers (atrial excitation) 
associated with irregular ventricular excitation [1]. It is well understood that a focus of rapid 
ectopic electrical activity, often located in the muscular sleeves that extend from the left atrium 
into the proximal parts of pulmonary veins, plays a critical role in the initiation and propagation 
of AF [2]. The abnormal electrical activity in the upper cardiac chambers undergoes irregular 
conduction across atrioventricular node, and subsequently to the lower cardiac chambers 
(ventricular excitation) causing a chaotic and quivering heartbeat [1-3].  
The pathophysiology of AF is thought to be multifactorial and involve a complex interaction 
of triggers, substrates, and autonomic influences [4].The various aetiological factors that cause 
a complex array of pathological changes in the atria of the heart resulting in AF include: 
hypertension, diabetes, heart failure, obesity, obstructive sleep apnoea, coronary artery disease , 
pulmonary embolism, increasing age, male sex, and genetic disorders [5,6]. Moreover, AF may 
be acutely associated with physiological stressors such as surgical procedures, hyperthyroidism, 
chronic respiratory diseases, and alcohol ingestion. All of these factors increase local ectopic 
electrical firing (rapid focal activity) or conduction disturbances (local re-entry) leading to AF 
[7].  
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AF can also occur in some patients without any overt structural heart diseases or identifiable 
risk factors, and such a condition is known as lone AF. The majority of patients with AF are 
asymptomatic while some patients have an awareness of rapid and irregular heartbeats, 
shortness of breath, fatigue, dizziness, and syncope [8].  
1.2  Classification of atrial fibrillation 
AF may be classified based on aetiology, i.e. depending upon whether it occurs without 
identifiable aetiology (lone AF), or whether it complicates other associated structural heart 
diseases [2]. A classification based on a temporal pattern of the arrhythmia has also been 
recommended by AF treatment guidelines [9,10]. According to presentation, duration, and 
spontaneous cardioversion or the success of pharmacological/electrical attempts to convert AF 
back to normal rhythm, five subtypes of AF are described (Table 1).  
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Table 1. Classification of atrial fibrillation subtypes.  
AF pattern  Definitions  
First diagnosed AF  AF that has not been diagnosed before, irrespective of the severity of 
symptoms or the duration of the arrhythmia. 
Paroxysmal AF  Arrhythmia self-terminates spontaneously and is defined by consensus as 
termination within 7 days, although most cases terminate within 48 hours 
of onset. AF episodes that are cardioverted within 7 days are categorised 
under paroxysmal. 
Persistent AF  Arrhythmia lasts more than 7 days, including those that are terminated by 
direct current or pharmacologic agents after 7 days.    
Long-standing 
persistent AF 
Continuous AF lasting for ≥ 1 year when it is decided to adopt rhythm 
control strategy.   
Permanent AF Continuous AF in which a consensus has been reached by the patient and 
the physician not to try to restore normal rhythm. Restoration of normal 
rhythm is impossible and consensus has been reached not to undertake 
procedures to restore sinus rhythm. 
 
Data are conflicting regarding the conversion rates of AF from one type to another and duration 
of the disease and underlying comorbidities can influence progression rates. In some patients, 
AF changes from paroxysmal to persistent, and subsequently to permanent forms because of 
atrial remodelling associated with the arrhythmia itself and other factors; permanent AF arises 
as the disease progresses and irreversible atrial structural changes occur over time [11,12]. A 
study by Proietti et al. [13] showed at one year of follow-up that 10-20% had progressed from 
paroxysmal to permanent AF, with higher progression rates observed in longer follow-up 
studies [14]. Conversely, AF may regress from persistent to paroxysmal AF, and asymptomatic 
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recurrences are common in patients with symptomatic AF [15]. Some observational data in 
patients with pacemakers also indicated that the majority of patients with paroxysmal AF 
remain paroxysmal [16,17]. 
Depending on the associated heart valve disorders, AF can also be classified into valvular AF 
or non-valvular AF (NVAF). Although various definitions are described in the literature, most 
guidelines define “valvular AF” as AF in patients with mitral stenosis or artificial heart valves 
(bioprosthetic or mechanical heart valves) [9,18,19]. Other valvular heart diseases such as 
mitral regurgitation, aortic stenosis, and aortic insufficiency in the presence of AF are all 
categorised as NVAF. Nevertheless, valvular AF represents a minor proportion of the overall 
AF population ranging from 4-30% of all patients with AF [20].   
1.3  Epidemiology of atrial fibrillation  
The clinical importance of AF gained greater attention in the 1990s when early population 
studies, including the Framingham Heart Study, revealed critical evidence regarding associated 
risk factors and patient outcomes [21,22]. AF is increasingly recognised as a major public 
health burden with the prevalence markedly increasing, particularly in the elderly population 
[23]. Aging is an important risk factor for AF and the incidence and prevalence of AF rise with 
increasing age. The prevalence of AF roughly doubles with each advancing decade of age, from 
0.5% at age 50 – 59 years to about 10% in those over 80 years of age [24-26]. Observational 
studies have also reported that the epidemiology of AF differs between sex categories with a 
higher age-adjusted prevalence in males than in females [26,27]. Likewise, data from the 
Framingham Heart and the Cardiovascular Health studies showed higher rates of AF in men 
compared to women (3.8 vs 1.9 per 1000 PY in men and women, respectively) [28,29].  
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AF is estimated to affect more than 30 million people worldwide including 1-4% of adults in 
Australia, Europe, and the United States [30-32]. Despite the increased awareness and 
enhanced detection of AF in recent years [28], about one-third of the total AF population is 
asymptomatic causing a significant underestimation of the burden of AF [33]. In Australia, the 
number of AF-related hospitalisations tripled between 1993 and 2007, with the rate of increase 
surpassing those for heart failure or myocardial infarction [34]. A similar study examining the 
trends of hospital admissions due to AF in the United States also reported a significant increase 
in AF-associated hospitalisations from 2000 through 2010 [35]. However, a declining rate of 
AF-related mortality was also observed in this study. Overall, the prevalence of AF is expected 
to double in the next 50 years attributed to several factors, including the aging population, the 
increasing prevalence of AF risk factors, a rise in chronic cardiovascular diseases, and 
improved patient survival rates [23].  
1.4  Mechanisms of thrombosis in atrial fibrillation 
AF primarily affects cardiac haemodynamics due to the loss of atrial contraction, and the 
rapidity and irregularity of ventricular rates. This leads to a significant increase in the risk of 
ischaemic stroke, transient ischaemic attack (TIA), other systemic embolic events (deep venous 
thrombosis, pulmonary embolism), and myocardial infarction [36]. Therefore, 
thromboembolism is the most important complication of AF causing a significant risk of 
morbidity and mortality. Population studies reveal that AF is associated with a 5-fold increased 
risk of stroke or systemic embolism with an absolute risk ranging from about 1-20% per year, 
depending on additional risk factors [37]. Furthermore, patients with AF have a 1.5 to 2-fold 
greater risk of mortality than patients without AF [38,39]. Contemporary data show 20-30% of 
patients with IS have AF diagnosed before, during, or after the thromboembolic event [40-42].    
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Thrombogenesis associated with AF is not fully described. Components of the Virchow triad 
for thrombosis [7], involving stasis and turbulence of blood flow, endothelial dysfunction, and 
hypercoagulability have been implicated in the development of thromboembolic complications 
in AF (Figure 1). The current hypothesis is that AF mainly causes stasis of blood in the left 
atrial appendage leading to local thrombus formation obstructing the flow of blood through the 
circulatory system. A thrombus that breaks free and circulates to another location is known as 
an embolus [43]. An embolus traveling through blood circulation to the brain causes ischaemic 
stroke or TIA [44]. Immunological studies that measured the markers of coagulability have 
also indicated that AF confers a hypercoagulable state and endothelial dysfunction increasing 
the risk of stroke and other systemic embolic events [45-47].  
Thrombi can form in the arterial or venous circulation with important implications on the 
clinical management and patient outcomes. The pathophysiology of arterial thrombi differs 
from that of venous thrombi, as reflected by the different ways in which they are treated. Unlike 
arterial thrombi which are triggered primarily by rapture of an atherosclerotic plaque that is 
platelet-rich, thrombi secondary to AF contain red blood cells – typical of venous thrombi that 
are rich in fibrin [48,49]. The abundance of fibrin relative to platelets in AF-related thrombi 
underlines the higher efficacy of OAC therapy that targets the coagulation cascade compared 
to antiplatelet (APT) agents that prevent platelet aggregation [50]. In summary, the 
mechanisms accounting for stroke, systemic embolic events, and myocardial infarction in AF 
are multiple and complex. Therefore, various factors need to be taken into account in designing 




Figure 1. The major components of Virchow’s triad for thrombosis in atrial fibrillation  
 (Source: Watson T, Shantsila E, Lip GY. Lancet. 2009; 373(9658):155-66. Reproduced with 
permission from Lancet.) 
Note: abnormalities in the cardiac vessel wall (atrial tissue changes, endothelial damage and 
dysfunction), in blood flow (stasis in left atrium), and hypercoagulability (coagulation cascade 
activation, inflammation) contribute to thrombus formation in AF. 
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1.5  The coagulation cascade and targets of oral anticoagulants 
The coagulation cascade is a sequence of biochemical reactions with the preceding reaction 
amplifying subsequent steps leading to the final stage - cross-linked fibrin strands. Coagulation 
proteins are the major components of the cascade involving a complex interplay of reactions 
leading to the conversion of soluble fibrinogen to insoluble fibrin. The fibrin strands together 
with the aggregation of active platelets yield stable thrombus [51,52]. Most of these proteins 
are inactive precursors of proteolytic enzymes known as zymogens. The activation of each 
component, depicted by suffix “a”, requires vitamin K dependent ϒ-carboxylation of glutamic 
acid residues enabling them to bind calcium and facilitate the clotting process [53].  
Various models of the coagulation cascade have been proposed. However, the most commonly 
described coagulation cascade model includes three pathways: i) the tissue factor pathway 
(previously called the extrinsic pathway) - is the primary activator of the cascade and involves 
tissue factor and factor VIIa, ii) the contact activation pathway (previously called the intrinsic 
pathway) - amplifies the cascade and involves factors XIIa, XIa, IXa and VIIIa, and iii) the 
common pathway- involves factor Xa and converts prothrombin to thrombin, which 
subsequently generates fibrin strands [43,51]. Figure 2 illustrates the coagulation cascade and 
targets of OAC agents. 
The extrinsic pathway is considered as the most critical part of the cascade that is essential for 
haemostasis compared to the downstream pathways. Coagulation is initiated by the extrinsic 
pathway when tissue factor exposed at sites of vascular injury binds and activates VII. The 
activated VII (VIIa) activates factor X in the common pathway and generates thrombin 
[54]. Conversely, data from experimental studies has shown that animal models survived 
without the components of the intrinsic pathway. Humans deficient in factors VIII, IX, or XI 
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have also been observed to experience mild haemostatic defects [55,56]. Accordingly, drugs 
that target the upstream proteins of the cascade such as tissue factor and factor VIIa are more 
potent than those that target the downstream targets such as thrombin. However, inhibition of 
tissue factor and factor VIIa can lead to severe bleeding and the intrinsic pathways are usually 
targeted for drug therapy [56].  
Most of the currently available OACs are designed based on targeting the downstream 
pathways. Whereas vitamin K antagonists (VKAs) indirectly block the syntheses of multiple 
components of the cascade (factors II, VII, IX, X, and anticoagulant proteins C and S), and the 
direct acting oral anticoagulants (DOACs) are selective inhibitors of Xa or thrombin (Figure 2) 
[57,58]. Emerging data also show that the contact system is essential for thrombus growth and 
stabilisation with factors XII and XI as potential targets for additional OACs that may be even 












Figure 2. The coagulation cascade and targets of oral anticoagulants  
(Source: Mekaj YH, et al. Therapeutics and clinical risk management. 2015;11:967-77. 
Reproduced with permission from Dovepress.) 
* VKAs do not inhibit, but prevent the synthesis of the coagulation factors VII, II, IX and X. 
Abbreviations: DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.  
1.6  Clinical management of atrial fibrillation  
The clinical management of AF is complex and aims to relieve symptoms, improve quality of 
life, and reduce the risk of thromboembolic complications and death. The overall management 
of patients with AF involves two major strategies: management of the arrhythmia (rate or 
rhythm control) and prevention of thromboembolism using antithrombotic agents (Figure 3). 
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The aims of a rate control strategy are to minimise AF-associated symptoms and prevent onset 
of heart failure (tachycardia-induced cardiomyopathy) [59]. Rate control in AF is typically 
achieved by pharmacological agents. Three major classes of pharmacological therapies for rate 
control in AF include beta-blockers, non-dihydropyridine calcium channel blockers, and 
digoxin. Moreover, non-pharmacological management methods such as cardiac ablation and 
pacemaker implantation are also used for rate control in selected groups of patients [60].  
Rhythm control restores normal sinus rhythm by means of direct current cardioversion, 
antiarrhythmic drugs, and catheter or surgical ablation. Pharmacological cardioversion restores 
sinus rhythm in about 50% of patients with recent onset AF [61-63]. Electrical cardioversion, 
on the other hand, restores sinus rhythm quicker and more effectively than pharmacological 
cardioversion [64,65]. However, antiarrhythmic agents are often used together with direct 
current cardioversion to help maintain sinus rhythm after the cardioversion. Various 
pharmacological agents are available for rhythm control in AF. The most commonly used 
antiarrhythmic agents in AF include Class IC antiarrhythmics (flecainide, moricizine, and 
propafenone), and Class III antiarrhythmic medications (amiodarone, dofetilide, dronedarone, 
ibutilide, and sotalol) [66].  
The choice of an antiarrhythmic agent needs to be individualised depending on the relative 
efficacy, side effect profile, contraindications, and the patient’s ventricular function. Moreover, 
the decision to use a rate or rhythm control strategy also requires consideration of several 
factors, including the degree of symptoms, the likelihood of successful cardioversion, and the 
presence or absence of concomitant comorbidities [67]. In patients with short paroxysms of 
AF, management generally focuses on controlling the arrhythmia (rhythm control). In patients 
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with persistent AF, however, consensus is lacking as to whether to try to restore sinus rhythm 
or accept the arrhythmia and control ventricular rate (rate control) [68]. 
Evidence shows that the risk of stroke persists in patients with additional risk factors, and the 
risk continues temporarily in those without additional risk factors for stroke, regardless of 
whether or not the arrhythmia is converted back to sinus rhythm  [69-71]. Furthermore, direct 
current electrical and pharmacological cardioversions in patients with AF are associated with 
an increased risk of stroke. Patients undergoing cardioversion of AF of more than 48 hours 
duration represent a particularly high-risk group compared to those with AF of less than 48 
hours duration. [72,73]. However, the risk of thromboembolism associated with cardioversion 
can be significantly reduced by using anticoagulant therapy [72,74]. Accordingly, in addition 
to rate and rhythm control strategies, anticoagulation is an essential component of AF 
management. Current AF treatment guidelines recommend that OAC therapy be commenced 
three weeks before cardioversion and continued for four weeks afterwards (in those without a 
need for long-term OAC) [9,10]. Conversely, OAC treatment should continue indefinitely in 









   
                       Figure 3. Therapeutic strategies in patients with atrial fibrillation. 
                       Abbreviations: TE, thromboembolism; SR, sinus rhythm.    
Therapeutic goals in patients with AF
Manage arrhythmia 
Control ventricular rate during AF 
(rate control)
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1.7 Antithrombotic therapies in atrial fibrillation 
The risk of stroke or other systemic embolic events in AF can be significantly reduced by 
optimal utilisation of antithrombotic medications. Various classes of antithrombotic agents 
have been approved for thromboprophylaxis in AF. The major groups of antithrombotic 
medications used in routine clinical practice include: anticoagulants (VKAs, DOACs, low 
molecular weight heparin and derivatives) – block the coagulation cascade and prolong clotting 
time thereby reducing fibrin formation and preventing clots from growing; and APT agents 
(e.g. aspirin and clopidogrel) – limit migration and aggregation of platelets thereby preventing 
them from clumping and also prevent clots from forming and growing [75]. Most of the current 
AF guidelines recommend OAC therapy for stroke prevention in eligible patients with AF 
while some guidelines also suggest APT agents in patients with contraindications to OACs or 
those at intermediate risk of stroke [10,19,76].    
1.7.1 Vitamin K antagonists 
VKAs are a class of OACs including warfarin (coumadin), dicumarol and acenocoumarol that 
decrease thrombosis indirectly by inhibiting the actions of vitamin K in the coagulation cascade. 
Vitamin K is essential for the synthesis of multiple factors in the coagulation cascade such as 
factors II (thrombin), VII, IX, X, and the anticoagulant proteins C and S. Vitamin K must be 
regenerated from a biologically inactive epoxide by vitamin K epoxide reductase for the 
continued synthesis of activated clotting factors. VKAs are structural analogues of vitamin K 
and act as competitive and irreversible inhibitors of vitamin K epoxide reductase, inhibiting 
the recycling of inactive vitamin K epoxide back to an active form (Figure 4) [77,78]. In 
addition, VKAs have the potential to be pro-coagulant, primarily at the initial stages of therapy, 
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as they inhibit the carboxylation of regulatory anticoagulant proteins, C and S [79]. However, 
the transient pro-coagulant effect decreases over time and the anticoagulant effect of VKAs 
becomes dominant at the later stages of treatment when the balanced decrease of clotting factor 
levels is achieved.  
 
Figure 4. Recycling of oxidised vitamin K (vitamin K epoxide) to reduced vitamin K and the 
effect of warfarin.  
(Source: Ansell J et al., Chest. 2008; 133 (6 Suppl):160s-98s. Reproduced with permission 
from ELSEVIER). 
Note: Vitamin K epoxide reductase is an important warfarin sensitive enzyme and serves as a 
major target for the S enantiomer of warfarin or other VKAs. S-warfarin is metabolised by the 




“What was good for a war hero and the President of the United States must be good 
for all, despite being a rat poison!” Duxbury and Poller, 2001 [80]. 
The pioneering discovery of VKAs dates back to the early 1920s when an epidemic of 
haemorrhagic diathesis of cattle was reported in North Dakota, the United States of America. 
Frank Schofield noticed that cattle bled only when they were fed mouldy sweet clover and 
named the ailment “sweet clover disease” [81]. The disease was reversed if the offending 
mouldy hay was removed or if fresh blood was transfused. In 1940, the active compound that 
caused “sweet clover disease”, coumarin, was identified and isolated by Karl Link [82]. 
Coumarin was metabolised by interacting with certain fungi in the mouldy hay and changed to 
dicoumarol. In 1945, Karl Link was funded by the Wisconsin Alumni Research Foundation 
(WARF) for his continued research on dicoumarol and suggested it as a rodenticide, the rodents 
dying of haemorrhage. However, dicoumarol proved to be slow-acting compound. Further 
research on several variations of coumarin led to the development of warfarin, named after the 
initials of the funding company, and marketed as a rat poison in 1948 [83]. In 1955, warfarin 
was given to Dwight Eisenhower, the then President of the United States, after he suffered an 
MI, marking a successful transition from a rat poison to clinical application [80].  
A number of randomised control trials conducted since the early 1960s established the safety 
and effectiveness of warfarin for the prevention of stroke in patients with AF [84,85]. Warfarin 
has been used as the gold standard and most widely prescribed OAC in AF and other embolic 
diseases; treatment with warfarin in AF can reduce the risk of stroke by about 60-70% versus 
placebo [86-88]. However, effective stroke prevention using warfarin therapy necessitates 
maintaining the international normalised ratio (INR) within the target range of 2-3. INRs above 
this range are associated with a significant bleeding risk (1-3% per patient-year (PY) and 3-8% 
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per PY reported in trial and observational data, respectively) [89-92]. The risk of bleeding in 
patients receiving warfarin is associated with several limitations of the therapy including its 
narrow therapeutic window, variabilities in dose-response relationship, requirement for strict 
INR control, and interactions with food and other medications [93,94]. These limitations have 
resulted in under-prescribing, poor treatment adherence, and suboptimal clinical outcomes. 
Observational studies have reported that a significant proportion of patients with AF did not 
receive optimal warfarin therapy or were given aspirin or no therapy [95]. A systematic review 
of 56 studies also showed the proportions of patients with AF receiving no antithrombotic 
therapy ranged from 4-48% and those who received APT therapy ranged from 10-56%. The  
rate of  warfarin prescribing in this study ranged from 9-86% (median 52%) [96]. Challenges 
of OAC use and under-prescribing of VKAs in AF are discussed in more depth in Chapter 2. 
1.7.2 Direct oral anticoagulants 
DOACs are antithrombotic agents that act by inhibiting a single component of the coagulation 
cascade thereby exerting their anticoagulant effects (Figure 2). These medications include the 
direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban, 
and edoxaban). Apart from stroke prevention in patients with NVAF, DOACs have also been 
approved for prophylaxis and treatment of deep venous thrombosis and pulmonary embolism. 
The discovery of DOACs represents a major breakthrough for stroke prevention in patients 
with NVAF and other embolic diseases. The new agents offer potential benefits over warfarin 
in that they have predictable pharmacokinetics eliminating the need for regular monitoring, 
convenient dosing, less drug-drug and drug-food interactions, and a reduced risk of bleeding, 
especially in terms of intracranial haemorrhage (ICH) [58,97]. Furthermore, while there are no 
antidotes to neutralise the effects of some DOACs such as factor Xa inhibitors, the rapid offset 
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of the anticoagulant effect due to their short half-lives may be sufficient to stop bleeding in a 
timely manner. 
Four innovative phase three clinical trials have established that the four DOACs were at least 
as effective as warfarin in reducing the risk of stroke or systemic embolism [98-100]. 
Dabigatran (110 or 150 mg twice daily) was compared against dose-adjusted warfarin in the 
Randomised Evaluation of Long-term anticoagulant therapY (RE-LY) study; this was a non-
inferiority trial involving 18,113 patients with AF having at least one additional risk factor for 
stroke [98]. The primary endpoint of stroke and systemic embolism was similar between 
warfarin and dabigatran 110 mg (relative risk 0.91 for dabigatran 110 mg; p<0.001 for non-
inferiority), and lower in patients receiving dabigatran 150 mg (0.66; p<0.001). Dabigatran 110 
mg showed lower rates of major bleeding than warfarin, but the rates were similar for the 150 
mg dose. However, a higher rate of gastrointestinal bleeding was observed in patients receiving 
both doses of dabigatran compared with warfarin. Based on these results, dabigatran was 
approved as the first DOAC for stroke prevention in NVAF in Europe and in the United States 
of America in 2010.     
In 2011, rivaroxaban became the first Xa inhibitor to be approved for the prevention of stroke 
and systemic embolism in NVAF. This OAC was evaluated in the ROCKET-AF trial 
(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) [99]. The 
ROCKET-AF trial randomised 14,264 patients with NVAF to dose-adjusted warfarin or 
rivaroxaban, 20 mg daily (15 mg for CrCl 30-49 mL/min). Enrolled patients were at moderate 
or high risk of stroke, and 55% of the participants had prior stroke or TIA. In the intention-
to-treat analysis, rivaroxaban was non-inferior to warfarin for the prevention of stroke and 
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systemic embolism. This trial also showed no significant differences in major and non-major 
bleeding between rivaroxaban and warfarin, although the rates of intracranial and fatal 
haemorrhage were lower with rivaroxaban (hazard ratio 0.67; p=0.02) 
The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation) non-inferiority trial compared apixaban with warfarin [100]. In this study, 
18,201 patients with NVAF were randomised to dose-adjusted warfarin or apixaban 5 mg 
twice daily; 2.5 mg twice daily dose was given to patients with two or more of the following 
criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5mg/dL. After a follow-
up of 1.8 years, apixaban was superior to warfarin in reducing stroke or systemic embolism, 
caused less bleeding, and resulted in lower mortality. In 2012, apixaban became the second 
factor Xa inhibitor to be approved for stroke prevention in patients with NVAF.  
Edoxaban, the third Xa inhibitor approved for stroke prevention in NVAF, was assessed in 
the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in 
Atrial Fibrillation–Thrombolysis in Myocardial Infarction) trial. This OAC was also non-
inferior to warfarin for the prevention of stroke, and was associated with lower rates of bleeding 
and mortality [101].   
In summary, these randomised controlled trials have shown DOACs to be at least as efficacious 
as warfarin, and associated with significantly lower rates of ICH, the most feared complication 
of OAC treatment. A meta-analysis of these trials also reported that the new OACs were 
associated with a reduced risk of stroke or other systemic embolic events as well as decreased 
rates of all-cause mortality [102]. It is likely that the reduced mortality rates in patients treated 
with DOACs is largely due to the significant reduction in ICH rates. These advantages make 
DOACs the treatment of choice in an increasing number of patients with NVAF and other 
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embolic diseases. The pharmacological features of the new OACs, and their advantages and 
disadvantages in real-world clinical practice are discussed further in Chapter 2. 
1.7.3 Antiplatelet agents  
APT agents are a class of antithrombotic medications that counteract thrombus formation by 
inhibiting platelet adhesion and aggregation. Low dose aspirin (75 to 325 mg) has been the 
most commonly prescribed agent for primary and secondary prevention of stroke in AF. APT 
therapies are shown to be most effective for arterial clots that are composed largely of platelets 
as opposed to AF-related embolic strokes; cardioembolic strokes related to AF are thought to 
be mainly due to thrombi originating from atrial appendages [103,104]. APT therapies are 
widely prescribed for preventing stroke in AF, although observational and trial data suggest 
that any potential protection is weaker compared to OAC therapy [86,105-107].  
The evidence supporting APT monotherapy for stroke prevention in AF is limited. Randomised 
trials have reported that treatment using aspirin and other APT agents provide only modest 
protection against stroke or other systemic embolic events due to AF compared to both warfarin 
and placebo [108-110]. Meta-analyses also show that aspirin was associated with a reduction 
of about 22% (95% CI: 2-39) in stroke, with a less consistent effect than OAC therapy [86,111]. 
Studies have shown that there appears to be a general misconception over the safety and 
efficacy of APT therapy in AF not only in the general public but also among health care 
professionals  [112-115]. Consequently, APT agents are commonly prescribed to a significant 
proportion of at-risk patients with AF with either real or perceived contraindications to OACs 
[86,116,117]. However, APT therapies are not any safer than OACs, primarily in elderly 
patients with AF [86,108]. Evidence suggests that the risk of bleeding associated with the use 
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of lone or dual-APT therapy is comparable to bleeding arising from using OAC therapy [108]. 
Accordingly, the 2016 European Society of Cardiology and the recently published Australian 
AF guidelines no longer recommend APT agents for stroke prevention in AF [9,118].  
1.7.4 Multiple antithrombotic prescribing in atrial fibrillation  
Prescribing of multiple antithrombotic agents in the form of dual-APT or OAC-APT therapy 
is common in clinical practice, mainly in AF patients with additional cardiovascular diseases 
[119,120]. Among other factors, the most common reason for dual-APT or OAC-APT 
combination therapy is the coexistence of indications for both drugs, usually coronary artery 
disease for APT and AF for OAC therapy. The majority of patients with AF require OAC 
treatment and coronary heart disease coexists in 20-30% of them [20,121]. However, the 
efficacy and safety of dual-APT or OAC-APT combination therapy in patients having more 
than one indication for antithrombotic treatment is unresolved. Given the different mechanism 
of actions, OAC-APT combination treatment increases the risk of clinically significant 
bleeding. Observational data show adding a single APT drug to an OAC therapy (warfarin or 
DOAC) increases the risk of major bleeding by 60-80% [122]. Moreover, adding dual-APT 
drugs to an OAC agent increases the risk of major bleeding by about 130% compared to lone 
OAC therapy [123].  
1.8  Stroke and bleeding risk assessment 
Prescribing antithrombotic treatment for stroke prevention in AF involves a trade-off between 
stroke and bleeding risk. The risk of thromboembolism and bleeding in patients with AF is not 
homogeneous; each patient’s risk depends largely on the combination of specific comorbidities. 
Thus, the decision to use antithrombotic therapy in AF should be based upon the net clinical 
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benefit for a given patient. Hence, the management of patients with AF requires assessment of 
stroke and bleeding risk scores and appropriate use of thromboprophylaxis.  
Development of stroke risk-prediction tools in AF emerged in the 1990s involving small cohort 
studies; these have since been refined in larger populations. Several stroke risk-scoring 
methods have been developed and validated to guide treatment decisions in AF. The most 
commonly used risk scoring methods include: CHADS2 (congestive heart failure, hypertension, 
age >75 years, diabetes, stroke (doubled)) [124], and the more recent and refined version of 
CHADS2 i.e. CHA2DS2-VASc, which assigns 1 point each for congestive heart failure, 
hypertension, diabetes, vascular disease, age 65 to 74 years, and sex category (females), and 2 
points for age ≥75 years, and prior ischaemic stroke/ TIA [125]. The CHA2-DS2-VASc score 
was first incorporated in the European Society of Cardiology guideline in 2010 [126]. Currently, 
treatment guidelines in various countries recommend using the CHA2DS2-VASc scoring 
method for OAC prescribing in AF and it has been widely accepted in clinical practice.   
Similarly, a number of bleeding risk scoring methods have been proposed, primarily in patients 
taking VKAs. The relatively simple HAS-BLED (hypertension, abnormal renal/liver function 
(1 point each), stroke, bleeding history or predisposition, labile INR, elderly (> 65 years), 
drugs/alcohol concomitantly (1 point each)) score has been demonstrated to have better 
predictive value than other risk prediction tools [127-129]. The HAS-BLED scoring method 
has also been validated in patients receiving non-warfarin anticoagulant therapy such as 
DOACs, as well as in AF and non-AF populations [130-132]. Stroke and bleeding scoring 
methods, risk stratification, and AF guideline recommendations for antithrombotic therapy are 
discussed further in section 2.4.    
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The first Australian guideline for the management of AF was recently published [118]. In this 
guideline, a refined stroke risk scoring method, abbreviated as CHA2DS2-VA, was 
recommended by removing female sex from the CHA2DS2-VASc risk score. The rationale 
behind this modification was that female sex alone or in the presence of one additional risk 
factor does not confer a sufficient or consistent increase in the risk of stroke. Furthermore, the 
different CHA2DS2-VASc threshold values for males and females when recommending an 
OAC could be avoided by using the new CHA2DS2-VA score. For high-risk patients with AF, 
however, the Australian recommendations for OAC prescribing are in line with 2016 European 
AF guidelines. During the timeframe of our study, however, there was no Australian guideline 
for the management of AF; clinicians used a mix of European and American guidelines from 
various sources which were sometimes inconsistent or unclear, mainly in terms of 
recommendations for the moderate risk groups. Additionally, at the commencement of this 
study, there was a transition from use of the CHADS2 to CHA2DS2-VASc method. Hence, we 
followed current European and American AF guidelines, and the CH2ADS2-VASc stroke risk 








1.9  Rationale of the current study 
AF represents an increasing public health burden in Australia. Recent population studies have 
shown that more than 300,000 Australians have AF and this number has been projected to 
increase to 600,000 by 2034 [32]. The prevalence of AF in the Australian population aged 55 
years or more is estimated to be 5.4% [26,32]. In 2015, the National Heart Foundation of 
Australia conducted a survey of emerging issues in cardiovascular diseases to prioritise clinical 
conditions and develop contemporary local guidelines [133]. The major criteria for comparison 
include the burden of disease, existence of treatment gaps, evolving therapeutic landscape, 
evidence of inequity and existence of treatment guidelines. AF was identified to have highest 
scores in the assessment standards, and recognised as a burdensome condition with increasing 
prevalence, mainly in elderly individuals, and in the Aboriginal and Torres Islander population.  
The Commonwealth Review of Anticoagulation Therapies in AF in 2012 reported that stroke 
prevention in AF required improvement [134]. This review identified a number of focus areas 
to be addressed in relation to assessment of patients for stroke and bleeding risk, appropriate 
choice of antithrombotic agents, monitoring of patients, and the need for local studies on which 
to base the recommendations regarding the management of AF. Furthermore, DOACs were 
introduced into Australian clinical practice with the market authorisation of dabigatran in 2011. 
Little was known about the adoption patterns and safety and effectiveness of DOACs outside 
the clinical trial settings. Hence, we established that there was a need for contemporary data 
regarding the integration of DOACs, their impacts on OAC prescribing practices, and clinical 
outcomes in patients with AF. Thus, the Tasmanian AF study (TAFs) was initiated in three 
public hospitals (the Royal Hobart Hospital (RHH), Launceston General Hospital and North 
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West Regional Hospital) to generate current data regarding the utilisation and outcomes of 
antithrombotic therapy in Tasmanian patients with AF.  
AF is considered the leading cause of preventable strokes in Australia. It has also been well 
established that AF-related strokes can be significantly reduced by optimal use of OAC therapy. 
However, data from real-world clinical settings show a significant discordance between AF 
treatment guideline recommendations and anticoagulation practices, characterised mainly by 
under-prescribing and sometimes over-prescribing of OACs in AF. One nationwide study, 
evaluating Australian general practice, reported warfarin prescriptions in only 44% of a random 
sample of general practice encounters in which AF was managed [135]. Another study from 
the RHH reported that approximately half of the high stroke-risk patients admitted with AF 
and without contraindications to warfarin were receiving the therapy [136]. Moreover, despite 
guideline recommendation, studies have also reported that significant proportions of patients 
with AF receive APT agents [137-139]. Various factors have been implicated in the suboptimal 
anticoagulation of patients with AF. The most frequently reported barriers to OAC prescribing 
in AF include adverse drug reactions, drug-drug interactions, the need for monitoring and dose 
adjustment, advanced age, and fear of bleeding complications [140-142]. 
After about six decades of VKA dominance as the only OAC for stroke prevention in AF, the 
therapeutic spectrum for thromboprophylaxis in patients with NVAF is changing significantly. 
Since 2010, four DOACs, namely dabigatran, apixaban, rivaroxaban, and edoxaban, have been 
approved for the prevention of NVAF-related embolic events. The seminal development and 
approval of the new antithrombotic agents have changed stroke prevention in AF.  
DOACs have been approved for stroke prevention in patients with NVAF in many regions 
throughout the world. In Australia, three DOACs (dabigatran, rivaroxaban and apixaban) 
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received marketing authorisation by the Therapeutic Goods Administration (TGA) for stroke 
prophylaxis in NVAF. Dabigatran was the first DOAC to be approved by the TGA in April 
2011 followed by rivaroxaban in May 2012, and apixaban in April 2012. Subsequently, the 
new therapies were listed on the Pharmaceutical Benefits Scheme (PBS) for subsidisation by 
the Australian government in mid-2013 [143]. Rivaroxaban was the first DOAC to be listed on 
the PBS in August 2013 while both dabigatran and apixaban were listed in September 2013. 
Warfarin has been listed on the PBS since 1964 whereas edoxaban was not approved in 
Australia during our study period [143].  
The major clinical trials that compared the efficacy and safety of DOACs with warfarin showed 
that the new OACs have comparable efficacy and superior safety [98-100]. As a group, DOACs 
have a rapid onset of action with more predictable pharmacokinetics than warfarin and routine 
monitoring is not required [144]. Given their greater convenience and improved safety, DOACs 
have been anticipated to address the widespread challenges of optimal anticoagulation practices 
in patients with NVAF and improve overall patient outcomes. At the start of this study, there 
was limited Australian data pertaining the integration of DOACs into clinical practice, their 
impact on anticoagulation practices and clinical outcomes in contemporary patients with AF.  
As new treatments for patients with NVAF have already been approved, assessing shifts in 
prescribing patterns, investigating the impacts of the new therapies on anticoagulation practice, 
and evaluating treatment outcomes are deemed to be top research priorities. Early practice level 
studies are essential for timely interventions, including refining the use of DOACs, guideline 
development, professional training and awareness creation about the new OAC therapies. Our 
review of local observational data and large AF registry studies undertaken in various countries 
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has been summarised in Chapter 2. In this review, we have identified ongoing issues regarding 
under- and over-prescribing of OACs in AF despite the availability of DOACs. 
This research was part of the TAFs involving patients admitted to the RHH and undertaken to 
generate current evidence regarding: overall antithrombotic prescribing practices, and adoption 
of DOACs, and treatment outcomes in Tasmanian patients with AF. The RHH is the largest 
referral centre in Tasmania; patients with major health conditions are typically admitted to this 
hospital, and longer-term follow-up data were most readily available for these patients. As a 
result, these patients’ data largely reflects anticoagulation practices and patient outcomes in the 
state of Tasmania. It was envisaged that findings from this research could help in mapping 
changes in antithrombotic prescribing, enhance our understanding of anticoagulation practices, 
identify factors associated with OAC prescribing, investigate patient outcomes in the real-
world clinical settings, and inform the need for additional intervention to improve patient 
outcomes. 
We hypothesised that the general availability of new OACs in Australia would improve 
anticoagulation practices and clinical outcomes in patients with AF. Given the lack of prior 
Australian studies regarding adoption of DOACs, their impact on OAC prescribing and 
treatment outcomes in AF, this thesis focussed on two research questions, each having two 
specific objectives (Figure 5). The first question focused on assessing changes in the overall 
antithrombotic prescribing in AF over time, detailing temporal patterns of antithrombotic 
prescribing, clinical integration of DOACs, and the impact of the availability of DOACs on 
OAC prescribing practices in AF in relation to current guideline recommendations. The second 
question focused on evaluating efficacy and safety outcomes of antithrombotic therapy in 
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patients with AF, primarily comparing thromboembolism and bleeding-related readmissions of 











Figure 5. Major components of the Tasmanian Atrial Fibrillation study (TAFs).   
Abbreviations: DOAC, direct oral anticoagulant; OAC, oral anticoagulant. 
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2 Suboptimal use of oral anticoagulant in atrial fibrillation: has the 
introduction of direct oral anticoagulants improved prescribing practices?  
Overview  
This chapter summarises observational data from various countries regarding suboptimal OAC 
prescribing, pharmacologic features and clinical integration of DOACs, and impacts of DOAC 
availability on OAC prescribing in AF. The results showed that the introduction of DOACs led 
to the revision of AF treatment guidelines and changed OAC prescribing patterns. Early 
evidence suggested slow integration of DOACs in most countries with limited impact on 
anticoagulation of patients with AF. This review was published in the American Journal of 










Background and objectives: Atrial fibrillation (AF) and the associated risk of stroke are 
emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for stroke 
prevention has been widely reported from observational studies. In recent years, direct oral 
anticoagulants (DOACs) have been introduced for thromboprophylaxis. We conducted a 
literature review to evaluate current practices of anticoagulation in AF, pharmacologic features 
and adoption patterns of DOACs, their impacts on proportion of eligible patients with AF who 
receive OACs, persisting challenges and future prospects for optimal anticoagulation.  
Literature source and selection criteria: In conducting this review, we considered the results 
of relevant prospective and retrospective observational studies from real world practice settings. 
PubMed (MEDLINE), Scopus (RIS), Google Scholar, EMBASE and Web of Science were 
used to source relevant literature. There were no date limitations while language was limited 
to English. Selection was limited to articles from peer reviewed journals and related to our 
topic. 
Results: Most studies identified in this review indicated suboptimal use of anticoagulants is a 
persisting challenge despite the availability of DOACs. Underuse of oral anticoagulants is 
apparent particularly in patients with high risk of stroke. DOAC adoption trends are quite 
variable with slow integration into clinical practice reported in most countries, while there has 
been limited impact to date on prescribing practice.  
Conclusions: Available data from clinical practice suggest that suboptimal OAC use in 
patients with AF and poor compliance with guidelines still remains commonplace despite 




• The introduction of direct oral anticoagulants (DOACs) into clinical practice and updates 
in atrial fibrillation (AF) management guidelines have changed OAC prescribing patterns.  
• Early evidence suggests slow adoption of DOACs in most countries and persisting 
suboptimal use of OACs in eligible patients after the introduction of DOACs into clinical 
practice. 
• Additional DOACs and reversal agents are in the pipeline, and with ongoing efforts, 
















2.2  Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, 
mainly in the aged population. The incidence and prevalence of AF have been rising over recent 
decades and are expected to double by 2050, partly because of the aging population and 
associated comorbid conditions [23,145,146]. Epidemiological studies have shown that AF 
affects 8-9% of people aged 80 years or more; 35% of patients with AF are > 80 years age 
[23,147]. The Global Burden of Diseases study reported the estimated number of individuals 
with AF in 2010 was 35 million. Findings from this study indicated a progressive increase in 
incidence, prevalence and AF-associated mortality between 1900 and 2010, with significant 
public health implications [148]. The overall prevalence of AF is in the range of 1-2% in 
developed counties, with a higher prevalence (2.5-4%) when only the adult population is 
considered [23,30,32]. A substantial proportion of people in developing countries are also 
affected by this emerging epidemic [148,149].   
AF adversely impacts cardiac haemodynamics because of uncoordinated (or loss of) atrial 
contraction and the rapidity and irregularity of the ventricular rate [76,150]. This leads to the 
formation of emboli that can flow to the systemic circulation increasing the risk of ischaemic 
stroke. The clinical significance of AF lies in its association with a 5-fold increase in the risk 
of stroke. Additionally, stroke due to AF is known to be more severe and disabling than non-
cardioembolic stroke and the likelihood of recurrence is higher [151-153]. AF accounts for 15 
to 20% of all strokes and 36% of strokes in individuals aged > 80, of which >20% are fatal 
[38,154]. Hence, stroke prevention using oral anticoagulants (OACs) is considered to be a 
critical component of AF management in patients with additional risk factors.  
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Discovered in the 1920s and approved for clinical use in the 1950s, warfarin has long been the 
standard of care and most widely prescribed OAC throughout the world [81]. APT agents, 
mainly low dose aspirin, are also used widely for stroke prevention in patients who are not 
candidates for OACs [108,155,156]. However, APT agents are less efficacious and no safer 
than warfarin, primarily in the elderly. While adjusted dose warfarin reduces the risk of stroke 
by 64% (95% CI 49 % to 74%) and all-cause mortality by 26% compared to placebo, stroke 
risk reduction using APT agents is estimated to be 22% with no impact on mortality 
[86,151,157]. Nonetheless, optimal anticoagulation using warfarin has remained challenging 
due to a range of limitations including multiple interactions with drugs and food, genetic 
variability in metabolism and unpredictable effects [158]. Of particular concern is warfarin’s 
narrow therapeutic index that necessitates regular monitoring and dose adjustments to maintain 
the INR in the range of 2-3. INR results out of this range pose significant risk. Low intensity 
anticoagulation (INR < 2.0) increases the risk of thrombosis while high intensity 
anticoagulation (INR > 3.0) increases the risk of bleeding [159,160]. Warfarin is known for 
common and severe adverse drug reactions. A national review of medication incidents in the 
United Kingdom indicated warfarin caused about 5.6% of fatal and severe drug related 
incidents, most of which needed hospitalisation [161].   
Recently four direct oral anticoagulants (DOACs), namely dabigatran, rivaroxaban, apixaban 
and edoxaban, have been approved for stroke prevention in NVAF, with others in late-stage 
clinical development. Among other benefits, DOACs offer comparable or better efficacy and 
safety, more predictable effects and fewer interactions with drugs and food than warfarin [162-
164]. Considering their unique features and ease of use, DOACs are anticipated to address 
existing challenges with regard to stroke prevention in AF. However, the absence of reversal 
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agents for most of the new agents, issues related to cost, and lack of data and limitations to 
their use in certain groups of patients are considered as major challenges for their effective 
utilisation. This review was undertaken to evaluate the impact of DOACs on the proportion of 
eligible patients who receive OACs and early adoption patterns in clinical practice. Further, we 
discuss current practices of anticoagulation, pharmacologic features of the new agents, and 
persisting challenges and future prospects of optimal anticoagulation in patients with AF. 
2.3  Literature source and selection criteria  
This review was conducted following the PRISMA guidelines for systematic reviews. We 
considered the results of relevant prospective and retrospective observational studies conducted 
in clinical settings to assess current practices of anticoagulation in AF and adoption patterns of 
DOACs. Updated guidelines from different countries, randomised clinical trials, meta-analyses 
and review articles were reviewed to evaluate and compare clinical practice and guideline 
recommendations. A literature search was undertaken using PubMed (MEDLINE), Scopus 
(RIS), Google Scholar, EMBASE and Web of Science. There were no date limitations while 
language was limited to English. Selection was limited to articles from peer reviewed journals 
and related to our topic. Recent studies conducted on anticoagulant utilisation patterns, DOAC 
use in clinical practice and impacts on prescribing OACs for patients with AF were included 
for analysis or summary. Data reported from the reviewed articles were summarised in graphs 
or tables. Search terms include atrial fibrillation, prevalence, epidemiology, stroke, 
anticoagulation, DOACs, TSOACs, NOACs, dabigatran, rivaroxaban, apixaban, edoxaban, 
clinical studies, prescribing practice and warfarin. MeSH terms were included where applicable. 




Table 2. Summary of literature source and selection for the review. 
Total abstracts identified from PubMed using MeSH term and filters 
(Observational study, Meta-analysis, practice guide, randomised controlled trial: 
("Anticoagulants"[Mesh]) AND "Atrial  Fibrillation"[Mesh]) 
485 




Contained information not related to the objectives of this review or not published 
in English language 
  
448 
Articles included in this review 140            
Full text articles 117 
Abstracts   23 
Prospective and retrospective observational studies            67 
Review articles              48 
Meta-analyses              8 
Randomised controlled trials                 9 
Experimental (in vivo and in vitro studies)               2 
Published AF treatment guidelines                6 
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2.4  Stroke risk stratification and guideline recommendations   
The risk of stroke among patients with AF is heterogeneous and depends on the presence of 
various risk factors. Combinations of these factors have been used to formulate stroke 
prediction tools. The most common in use are CHADS2 (Congestive heart failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, prior Stroke/TIA - double score) and 
CHA2DS2-VASc (Congestive heart failure, Hypertension, Age > 74 - double score, Diabetes, 
prior Stroke, TIA or thromboembolism - double score, Vascular diseases, Age 65-74, Sex 
category - females single score). Recent guidelines recommend CHA2DS2-VASc as the 
preferred scoring method for it has a particular advantage in identifying low risk patients who 
do not need antithrombotic therapy [165,166]. Most patients categorised as moderate risk (1 
point) using CHADS2 score would move to 2 points in the new CHA2DS2 -VASc score. This 
enables classification of patients truly at low risk and identification of more patients as eligible 
for anticoagulation. Treatment guidelines strongly recommend that OACs should be offered to 
patients with AF and stroke risk scores >2 [167-169]. While guidance currently differs on the 
preferred option for stroke prevention when CHA2DS2-VASc = 1 (for males), European 
guidelines recommend an OAC over single or multiple APT therapy [9].   
Observational studies have shown widespread discordance between guidelines and real world 
practice where OACs are underused in high risk patients, and sometimes overused in low risk 
patients [170-172]. Since 2001, several national and international multi-centre registries have 
been launched to generate valuable data and assess patient characteristics, treatment patterns, 
implementation of guideline recommendations and treatment outcomes. The most recent 
registries include Global Anticoagulant Registry in the FIELD (GARFIELD) [173], Global 
Registry on Long-term Oral Antithrombotic Treatment in Patients with AF (GLORIA-AF) 
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[174], Outcomes Registry for Better Informed Treatment of AF in the United States (ORBIT-
AF) [175], Acute Decompensated Heart Failure Registry (ADHERE), and PREvention oF 
thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF) [176]. 
Useful data regarding utilisation patterns, impacts of DOACs on rates of oral anticoagulation 
and outcomes in clinical practice are being generated from these registries and some have been 
summarised in Table 5. Preferred stroke and bleeding risk scoring approaches in patients with 
AF and antithrombotic recommendations of major treatment guidelines based on the scored 
values are summarised in Table 3. 
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Table 3. Stroke and bleeding risk scoring approaches and stroke prophylaxis recommendations in patients with atrial fibrillation [10,18,76,177]. 
Stroke risk scoring methods   Bleeding risk scoring method (HAS-BLED) 
Clinical parameter CHA2DS2VASc (Points) CHADS2 
(Points) 
Clinical parameter    
Points 
Congestive heart failure 1 1 Hypertension or uncontrolled BPb 1 
Hypertension (including well 
controlled hypertension) 
1 1 Renal/liver function (one point each)c 1-2 
Age ≥ 75 2 1 Stroke 1 
Diabetes mellitus 1 1 Bleeding tendency or predisposition 1 
Stroke/TIA/thromboembolism# 2 2 Labile INRd 1 
Vascular diseasesa 1 NA Elderly (>65 years) 1 
Age 65–74 1 NA Drugs (antiplatelet agents/NSAIDs) or harmful 
alcohol use (one point each)e 
1-2 
Sex category, female gender 1 NA   





Guideline recommendations for stroke prophylaxis based on stroke risk scores 





0 No antithrombotic therapy 
1 No therapy, or treatment with OAC or aspirin may be 
considered.   




CHA2DS2VASc 0 No antithrombotic therapy 
1 Consider OAC for men, assess HAS-BLED score 
≥ 2 Offer OAC, assess HAS-BLED score 
NICE 2014 CHA2DS2VASc 0 (men) or  
1 (women) 
No antithrombotic therapy 
 
1 (men) Consider OAC, discuss options with patients 
 




Guideline  Preferred scoring method Value Recommendation  
CCS 2014 CHADS2  (age ≥ 65 & vascular 
diseases are considered) 
0  No therapy, but aspirin is suggested for patients aged < 65 
years and with vascular disease. Female sex and vascular 
disease are not considered as sufficient reasons for OAC use 
≥ 1 
 
OAC should be used including patients aged ≥ 65 years and 
without other risk factors. 
 
• Interpretations: CHADS2: Historically, aspirin was recommended when score = 0; aspirin or an anticoagulant could be used when score = 1, 
although anticoagulation was recommended; anticoagulation recommended when score was ≥ 2. Currently, anticoagulation is recommended 
when score is 1 or greater. 
• CHA2DS2-VASc: People with a score = 0 (i.e. lone AF and no risk factors) do not require treatment; people with a score ≥2 should be 
prescribed an anticoagulant if anticoagulant therapy is not contraindicated. Recommendations differ for patients with a score = 1, and include 
no therapy, aspirin, dual antiplatelet therapy or an anticoagulant, depending on the risk of bleeding and patient preference. 
• HAS-BLED: Score ≥3 indicates need for caution and regular review, and efforts to correct reversible risk factors for bleeding.  
a Prior myocardial infarction, peripheral artery disease, aortic plaque. b Hypertension or uncontrolled BP refers to SBP >160 mmHg. c Abnormal 
renal function defined as CrCl < 50/mL/min, Scr ≥ 200 µmol/L , chronic dialysis or renal transplantation; abnormal hepatic function defined as 
chronic hepatic disease or evidence of significant hepatic derangement (bilirubin 2 to 3 times the upper limit of normal, AST/ALT 3 times the 
upper limit normal). d < 60% TTR (an approximation of < 6 in the previous 10 INR results in the therapeutic range can be used). e Harmful 
alcohol use refers to ≥ 8 units of alcohol per week.  #Thromboembolism included in CHA2DS2-VASc only. 
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2.5  Suboptimal oral anticoagulant use in atrial fibrillation: challenges in 
clinical practice  
Effective stroke prevention for patients with AF requires proper utilisation of OAC therapy in 
eligible patients. Optimal anticoagulation is considered as a missed opportunity to impact on 
an important cause of stroke. Studies from clinical settings have shown underuse of OACs in 
eligible and overuse in ineligible patients. Underuse of OACs is noticeable, primarily in 
patients with high stroke risk, despite the evidence that benefit of stroke prevention outweighs 
bleeding risk in these populations [20,178]. Most studies conducted on utilisation of 
anticoagulants in AF from many countries and different practice settings have revealed one-
third to one-half of eligible patients (i.e. with no contraindications) do not receive OACs.  
A study on 2,578 long-term care residents (mean age, 87.0 + 7.1 years) in 21 facilities in the 
state of Connecticut, United States of America, reported 53% OAC use among all  ideal patients 
with AF identified [179]. Findings from the PINNACLE registry program in the USA (2008-
2009) also reported widespread underuse of warfarin in patients with high risk of stroke. 
Among the 18,393 patients with non-valvular AF (NVAF) and high risk of stroke, the rate of 
anticoagulation using warfarin was 55.1% [180]. Preliminary results from GARFIELD 
indicated a disparity in risk scoring and OAC use. Data from 10,614 patents with AF in one 
cohort revealed 38.0% of patients from the high risk group (CHADS2 > 2) did not receive 
anticoagulant therapy [173]. The Fushimi AF registry, a community based prospective study 
in Japan, also reported underuse of warfarin in patients with a high risk of stroke. Among the 
2,914 AF patients included in this registry, only 60% with a stroke risk score of > 2 and no 
contraindication were given an OAC [181]. A similar study from the Chinese national stroke 
registry reported significant underuse of warfarin in patients with AF having a high risk of 
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stroke and without contraindications. Of the 11,080 patients with a first ever TIA, 592 had a 
history of AF and only 16.2% were taking warfarin [182].  
A systematic review using literature from 1997 to 2008 was undertaken to compare treatment 
practices of stroke prevention in AF with published guidelines. In this review, under treatment 
was defined as treatment of < 70 % of high-risk patients. The majority of the studies showed 
underutilisation of OACs in patients with high risk of stroke. Of the 29 studies involving 
patients with prior stroke or transient ischaemic attack (stroke risk score of > 2), 21 of them 
reported OAC treatment levels below 60% [95].   
OACs are not always underused. A number of studies found overuse of OACs in patients with 
low risk of stroke contrary to guideline recommendations. This is associated with more 
potential harm than benefit in patients that do not have additional risk factors for stroke. 
According to current guideline recommendations, patients with a CHA2DS2-VASc score of 0 
are regarded as “truly low-risk” with a stroke/thromboembolic rate of 0.84% (95% CI, 0.65-
1.08) per 100 person-years [183]. The risk of bleeding in low risk patients initiated on OAC 
has been shown to be higher than the risk of stroke. For example, a study in Denmark revealed 
that the risk of bleeding among low risk patients initiated on OAC was higher (1.08 per 100 
persons at one year) than stroke rates in the untreated group (0.49 per 100 person-years) [184].  
A study from the Michigan Anticoagulation Quality Improvement Initiative, (MAQI) indicated 
overutilisation of warfarin in patients with low risk of stroke. Among patients participating in 
this study, 10.4% receiving warfarin were identified as having the lowest risk of stroke (score 
= 0) according to their CHADS2 score [185]. A prospective registry study of 3,049 AF patients 
presenting to cardiologists in nine European countries also revealed overutilisation of OACs in 
the low risk groups. Based on CHA2DS2-VASc, 56.4% of low risk patients were on OACs in 
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contrast to current European guideline recommendations [186]. The GARFIELD registry study 
also reported overuse of OAC; 42.5% patients with AF from the low-risk category (CHADS2 
= 0) received OACs. Similarly, the ADHERE international registry in Asia evaluated OAC use 
in 3,032 patients with AF in 10 countries. There was a significant risk-treatment mismatch 
between low-risk (CHADS2 = 1) and high-risk (CHADS2 > 2) groups. Warfarin use was 50.6% 
among patients with heart failure as the only risk factor (CHADS2 = 1) while aspirin was used 
widely among patients with higher stroke risk [187]. 
A study from 430 general practices in the UK reported overuse of warfarin in different stroke 
risk groups. Thirty-seven percent of the low risk patients based on the CHADS2 score, or 26.6% 
using CHA2DS2-VASc, were on warfarin. Similar evaluations from the USA Market Scan and 
Medicare Supplemental database found that warfarin was used in 40.1% of low risk patients 
[171,188].  
2.6  Poor adherence to warfarin 
Suboptimal adherence to warfarin places patients with AF at risk for stroke or bleeding 
complications. Poor patient adherence to warfarin therapy is one significant factor impacting 
on the quality of INR control [189]. Guidelines suggest that patients can be considered well-
managed on VKA therapy if they spend at least 70% of their time in the desired INR range of 
2-3 [126,190]. However, most patients receiving warfarin spend only 50% to 65% or less of 
their time in the range [191-193]. Success in maintaining the desired INR values can vary from 
country to country and treatment settings where patients are managed. Findings from the RE-
LY registry in 46 countries showed a large global variation in treatment of AF and poor INR 
control in all regions. Mean time in therapeutic range (TTR) in this study was 62.4% in Western 
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Europe, and 50.9% in North America, but only between 32% and 40% in India, China, 
Southeast Asia and Africa [194].  
Studies have shown that a considerable proportion of patients with AF interrupt therapy at least 
once during a mean follow-up time of about two years. These therapy gaps are shown to be 
significantly associated with increased risk of stroke [195-197]. A prospective study from a 
large contemporary cohort (2004-2011) of 71,644 patients with AF in Israel revealed low rate 
of persistent warfarin use based on dispensing for three months or more. The TTR among those 
treated with warfarin in this cohort was 42% and only 41% of the patients had a TTR >50%. 
On the other hand, 43% of the time was spent with an INR < 2 while 16% of time was spent 
with supratherapeutic INR [198]. Another study from the Fushimi AF Registry in Japan 
showed similar practices of warfarin under dosing and poor INR control. Among the 2,914 
participants, only 54.4% maintained the optimal TTR [181]. These findings showed existing 
challenges with the use of warfarin and the need to improve the quality of OAC treatment. 
Although some practice improvements have been observed in recent years, overall 
anticoagulation rates and INR control still remain suboptimal. Moreover, most observational 
studies have revealed that guideline recommendations regarding anticoagulant prescribing in 
accordance with stroke risk level are not routinely followed in clinical practice. Figure 6 
summarises observational studies on anticoagulation rates in different risk groups of patients 




Figure 6. Summary of oral anticoagulant utilisation studies showing underuse in high risk and overuse in low risk patients with AF. 
 [170-172,176,182,187,188,190,199-204].  AF, atrial fibrillation; CHA2DS2-VASc Congestive heart failure, Hypertension, Age [74— double 
score, Diabetes, prior Stroke, TIA or thromboembolism—double score, Vascular diseases, Age 65–74, Sex category—females single score, 
CHADS2 Congestive heart failure, Hypertension, Age C75 years, Diabetes mellitus, prior Stroke or TIA—double score, OAC oral anticoagulant, 





















Studies Risk score ≥ 2 Risk score = 1 Risk score= 0
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2.7  Direct oral anticoagulants: pharmacologic features and advantages 
The challenges of optimal anticoagulation in AF and other thromboembolic diseases prompted 
the search for “ideal anticoagulants” that offer the advantages of being effective, safe and more 
convenient to use. Progress has been achieved focusing on the two important target serine 
proteases in the coagulation cascade, namely thrombin (factor-II) and activated factor X 
(factor-Xa) [205,206].The first thrombin inhibitor to be discovered and licensed was 
ximelagatran. However, this agent was withdrawn from clinical practice in 2006 because of 
hepatic toxicity. More recently, DOACs such as dabigatran that target thrombin, and apixaban, 
rivaroxaban and edoxaban all targeting factor Xa have been licensed (2010, 2011, 2012 and 
2015, respectively) for stroke prevention in patients with AF in the USA, Europe  and other 
countries throughout the world [207,208].  
DOACs have some unique pharmacologic features that enable easier use in patients with AF. 
Such features include fixed dosing, fewer drug-drug interactions and a relatively wide 
therapeutic window. While VKAs inhibit production of several clotting factors in the clotting 
cascade, the newer agents reversibly block single steps and have predictable anticoagulation 
effects [206]. All the four DOACs have consistent and predictable dose-response curves and 
time to reach steady state. Hence, haematological monitoring and dose adjustment are 
unnecessary. Anticoagulant effects of DOACs are determined by plasma concentration, unlike 
VKAs that act by blocking clotting factor synthesis. Hence, DOACs have rapid onset and offset 
of action making initiation and interruption considerably easier [209,210]. Although the lack 
of a requirement for INR monitoring is considered as an advantage, ongoing renal function 
tests and dose adjustments are recommended in patients with chronic kidney disease. 
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Accordingly, patients should be offered different dosages after assessment of renal function, 
age and weight.  
Data from randomised clinical trials and meta-analyses have indicated that DOACs have a 
favourable risk-benefit profile compared to warfarin. Four pivotal clinical trials ( RE-LY [98], 
ROCKET-AF [99], ARISTOTLE [100] and ENGAGE-AF [101]) evaluated efficacy and safety 
of dabigatran, rivaroxaban, apixaban and edoxaban, respectively. In these trials, DOACs were 
demonstrated to have equivalent or better efficacy and safety profiles compared to warfarin. 
Dabigatran 150 mg twice daily, apixaban 5 mg twice daily and edoxaban 60 mg once daily 
were more effective than warfarin. In the intention-to-treat analysis from the ENGAGE-AF 
trial, there was a trend favouring high-dose edoxaban in preventing stroke or systemic 
embolism compared to warfarin. Similarly, results from the ARISTOTLE trial showed fixed 
dose once daily rivaroxaban (20 mg or 15 mg daily in patients with CrCl of 30-59 ml/min) was 
non-inferior to warfarin in preventing stroke or systemic embolism based on analysis of the 
intention-to-treat trial population. Further, dabigatran 110 mg, apixaban and edoxaban were 
demonstrated to have better safety in terms of major bleeding rates compared to warfarin. More 
importantly, ICH were less with all DOACs compared to warfarin [100,105,211,212].  
Insights from a meta-analysis of approved dosage forms from 50 randomised trials indicated 
DOACs caused significantly less major bleeding compared to VKAs (odds ratio 0.77, 95% CI, 
0.64-0.91) while there was no significant difference in the rate of bleeding among the DOACs 
[213]. A Bayesian meta-analysis, on the other hand, revealed safety and efficacy differences 
among the DOACs, although all agents reduced the risk of ICH compared to warfarin. Warfarin 
was ranked the worst in all-cause mortality and ICH leading to the suggestion that DOACs 
were preferable to warfarin for patients with NVAF. Dabigatran 150 mg was the best for stroke 
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and systemic embolism prevention while edoxaban 30 mg was the best in terms of  major and 
gastrointestinal (GI) bleeding events [214]. Retrospective studies also reported similar results 
with respect to safety and efficacy endpoint evaluations. The Danish national prescription and 
patient registry study indicated that VKA naïve patients initiated on warfarin therapy had a 
higher rate of overall bleeding compared to dabigatran group [215]. Some DOACs, however, 
are reported to be associated with increased GI bleeding, dyspepsia, diarrhoea and vomiting. 
Both meta-analysis and observational studies indicated high dose dabigatran was associated 
with increased GI bleeding and dyspepsia compared to warfarin [102,216]. However, such 
complaints are considered as minor compared to VKAs with a higher risk of drug-drug 
interactions and serious adverse drug reactions. These features of DOACs are anticipated to 
revolutionise stroke prophylaxis in patients with AF and offer significant opportunities to 
improve anticoagulant underuse. Pharmacodynamic and pharmacokinetic profiles of the 
DOACs approved for stroke prophylaxis in patients with NVAF and comparisons with warfarin 




            
50 
 
Table 4. Comparison of key pharmacological features of direct oral anticoagulants and warfarin for stroke prevention in atrial fibrillation 
 [163,206,207,217-226].  
 Warfarin Dabigatran  Apixaban Rivaroxaban Edoxaban 
Target site and 
mechanism 
action 
Vitamin-K epoxide reductase  
Inhibit production of II, VII, IX, 
X and Proteins C and S   
Factor IIa - reversible 
inhibition of free and 
clot-bound thrombin 
Factor Xa, Selective and reversible inhibition 
Bioavailability > 95% 6-7% 60% 63-79% 62% 
Dosage form Tablet Capsule Tablet  Tablet Tablet 
Dose and dosing 
frequency 
Variable, target INR 2-3 150mg and 110mg, 
(75mg for CrCl 15-
30mL/min) BID 
5mg (2.5mg for age > 
80 years, weight 
<60kg, CrCl 15-
30mL/min) BID 
20mg (15mg for 
CrCl 15-50 
mL/min) OD 
60 mg (30 mg for 
CrCl 15-50 mL/min) 
OD 
Time to C-max 4-5 days 1-3 hours 3-4 hours 2-4 hours 1-2 hours 
Half life About 40 hours 12-15 hours 8-13 hours 5-9 hours 10-12 hours 
Renal clearance None ∼80%  ∼25% ∼66% ∼49% 
INR monitoring Yes  No No No No 
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 Warfarin  Dabigatran  Apixaban  Rivaroxaban Edoxaban  
Prominent drug 
interactions 
Multiple and clinically 
significant interactions 
Interaction with strong 
P-gp inhibitors and 
inducers 









Category X, CI CI, not established CI, not established CI, not established CI, not established 
Antidote Fast reversal using PCC or FFP, 
slow reversal with vitamin K 
Fast, complete reversal 
using idarucizumab 






Evaluated in all groups of 
patients, long experience  
Long half-life, once daily 
dosing, lower GI bleeding rates 
Reversible using antidotes 
Affordable 
Rapid onset and off set of action  
Predictable pharmacodynamics and pharmacokinetics 
Lower risk of overall and ICH 
Minimal food and drug interactions 
No need of regular blood monitoring  
Short half-life (easier to interrupt and avoid the need of bridging during procedures) 
Abbreviations: C-max, maximum plasma concentration; CrCl, Creatinine Clearance; P-gp, P-glycoprotein; CI-Contraindicated; BID-twice daily; 
OD, Once daily; INR, international normalised ratio; PCC, prothrombin complex concentrate; FFP, Fresh Frozen Plasma. a Reversal agents in late-
stage clinical development [e.g., andexanet alfa and ciraparantag (aripazine/PER977)]  
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2.8   Direct oral anticoagulants in clinical practice 
2.8.1 Adoption patterns  
DOAC approval for use in NVAF is quite recent. These agents are included in guidelines as 
preferred agents or alternatives to VKAs for stroke prevention in AF and are widely available 
in the developed world. In developing countries, however, availability of DOACs is considered 
to be limited [227]. Accordingly, OAC utilisation patterns in patients with AF are changing 
with variable proportions of DOAC use reported from different countries. Most studies 
reported slow integration of the new agents into clinical practice, while some revealed fast 
adoption patterns. Among other factors, differences in time trends of regulatory approval of 
countries, acceptability by patients and health care professionals and costs of DOACs are 
considered to be responsible for these differences.  
A prospective survey of 3,049 patients with AF in the PREFER-AF registry illustrated an 
increasing trend of DOAC adoption in nine European Society of Cardiology member countries. 
Substantial inter-country differences were noted, with higher adoption of DOACs in France, 
Austria, Germany, Spain and Switzerland than in the United Kingdom and Italy. A high rate 
of OAC use was reported, 80% of patients overall, most often VKAs (71.6%), with DOACs 
accounting for 8.4%. Of note, the study was conducted while the new agents were not 
extensively available in all countries. APT therapy was still used in one-third of the patients 
and no antithrombotic treatment in only 4.8% [186]. This survey concluded that uptake of oral 
anticoagulation, mostly VKA therapy, had improved compared to prescribing a decade ago. 
However, APT therapy was still commonly prescribed and elderly patients continued to be 
commonly under-treated. Similarly, recent data from the GLORIA-AF global registry showed 
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a high proportion of OAC use (80% overall) in patients with AF. Unlike the PREFER-AF study, 
remarkable uptake of DOACs (47.7% DOACs and 32.3% VKAs) has been reported, 
particularly in North America and Europe [228]. A population-based descriptive analysis in 
Canada also reported rapid uptake of DOACs within two years of approval. The study was 
conducted from October 2010 to September 2012 for all OACs. Over the 24-months, 
prescriptions for DOACs rose more than 20-fold, to represent 21.1% of all prescriptions by the 
end of the period. Conversely, the rate of prescription of warfarin declined from 1,526 to 1,316 
per 100,000 people (p = 0.007) [229].  
The utilisation pattern of dabigatran was evaluated from June 2010 to August 2011 in the USA 
in patients enrolled in the ORBIT-AF registry. Results revealed that 12% of the 9,974 
participants were treated with dabigatran and 8% had dabigatran initiated during follow-up. In 
contrast to the findings of the Canadian study, patients receiving dabigatran were younger 
(median age 72 versus 75 years, p<0.0001) and less likely to have prior cardiovascular diseases 
(4% versus 33%, p<0.0001). More than half of the patients with severe kidney disease were 
not prescribed a reduced dose, while 10% with preserved renal function received lower dosing, 
showing disparity with guideline recommendations [230]. Similarly, a prospective survey in 
Europe (EORP-AF) revealed that the rate of OAC use has increased recently, although the 
proportion of patients taking DOACs was found to be lower than expected. Findings from this 
study indicated compliance with treatment guidelines in patients from low and high-risk groups 
remained suboptimal. Of the 3,119 patients enrolled, the majority received VKA therapy 
(71.6%) whilst DOACs were used in a minority (8.4%). OACs were more often prescribed in 
females, and less often associated with valvular heart disease, heart failure and diabetes. DOAC 
use was more often associated with previous TIA and a rhythm control strategy [186]. 
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Another study using prescription claims data from a large American medical insurance 
company revealed rapid adoption of DOACs into clinical practice. Conducted from 2010- 2013 
on a cohort of 6,893 patients with AF initiated on OACs, DOACs accounted for 62% of new 
prescriptions, higher than reports from the ORBIT-AF study. DOAC initiators tended to be 
younger and healthier with significantly lower CHADS2, CHA2DS2-VASc and HAS-BLED 
scores compared to those on warfarin [231]. Some studies, however, showed greater benefits 
of DOACs in patients at high baseline stroke risk. The Danish National Patient Registry data 
revealed dabigatran, rivaroxaban and apixaban appeared superior for net clinical benefit than 
warfarin in warfarin in patients with CHA2DS2-VASc > 2 regardless of risk of bleeding[232].  
A higher rate of overall OAC use and higher DOAC adoption was also reported from a study 
in France. Among the 293 elderly patients aged over 75 years included in this study, 74.7% 
received OACs with DOACs accounting for 14.3% of the overall use. The rate of 
anticoagulation (VKA or DOACs) decreased moderately with age: 81.5% in the 75-79 year 
age group, 75% among those aged 80-84 years and 67% after 85 years [233].   
2.8.2 Impacts of direct oral anticoagulants on prescribing practice  
The availability of DOACs, coupled with improved stroke and bleeding risk assessment in 
recent treatment guidelines, is anticipated to increase the proportion of eligible patients with 
AF who receive thromboprophylaxis. Accordingly, studies with contrasting results on 
prescribing patterns of OACs and impacts of DOACs in clinical practice are emerging. Most 
of these studies, however, revealed under treatment of patients with AF continued to be a 
persisting challenge despite a transition to a new era of anticoagulation featuring DOACs.  
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The overall rate of anticoagulation remained unchanged, at approximately 40% after approval 
of dabigatran in 2010 according to a study on patterns of OAC use in the USA. This was despite 
rapid adoption of dabigatran during the study period. APT use as mono-therapy remained 
constant at roughly 4.6% of AF treatment visits. Dabigatran use increased from 0.062 million 
quarterly visits (2010Q4) to 0.363 million visits (2011Q4), reflecting an increased share of 
OAC visits [234]. A similar retrospective cohort study conducted on 183,450 patients with AF 
in the USA also showed a limited impact of DOACs on anticoagulation practice. The study 
was conducted from January 2006 to July 2012 to evaluate trends in OAC use after the 
introduction of DOACs. Results indicated that the proportion of patients prescribed OAC 
slightly increased in the post-DOAC period compared to the pre-DOAC period (33.7% versus 
31.7%). However, the overall rate of anticoagulant use still remained low [235]. Similarly, 
findings from the PINNACLE-AF registry showed no significant change in the overall rate of 
anticoagulant prescribing (p=0.43) following approval of the DOACs. Nonetheless, there was 
a significant trend towards using DOACs, while the rate of warfarin use decreased over time 
(p < 0.001) [236] . 
Preliminary data from Cohort 1 GARFIELD-AF registry also showed the proportion of patients 
receiving any anticoagulant to be suboptimal despite availability of the DOACs. One-year 
results from 351 Australian participants in this registry revealed suboptimal use of OAC in 
patients with high risk of stroke. While the average CHA2DS2-VASc score was 3.4, VKA and 
DOAC use was 59% and 4%, respectively. On the other hand, APT therapy was used in 24% 
of high risk patients implying continued under-anticoagulation and discordance with guideline 
recommendations [237]. Utilisation pattern evaluation of 19,730 incident patients with NVAF 
in the USA also revealed a low rate of anticoagulation since the introduction of the DOACs. 
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Data from medical records in this assessment showed that over 60% of newly diagnosed cases 
did not receive OACs despite being at high risk of stroke (CHADS2 > 2) [238]. 
Physician or patients’ hesitance to change treatment, preference for warfarin given extensive 
experience with its use, and medication costs have been shown as potential reasons for the slow 
uptake rate of DOACs in clinical practice and limited impacts on practice [231,239]. Moreover, 
DOACs require careful patient selection when considering switching from warfarin. Patients 
with severe renal insufficiency will have limited potential to use the new agents due to their 
renal excretion. Fear of bleeding and absence of reversal agents for most DOACs are also 
considered to be factors associated with their slow adoption into clinical practice. Additionally, 
there is insufficient knowledge regarding the long-term effects these agents could have on 
patients [240]. Accordingly, most guidelines recommend that patients on dose adjusted 
warfarin and with stable INR values be maintained on this therapy [9,10,18].   
Overall, early evidence has suggested that integration of DOACs into clinical practice has been 
variable with low rates of use in most countries. Moreover, impacts of the new agents on the 
proportion of eligible patients with AF receiving OAC has been relatively minor in many 
countries. However, change is expected with time considering the fact that these agents have 
only been approved recently and new DOACs with improved profiles as well as reversal agents 
are in the pipeline. Recent observational studies on overall OAC utilisation patterns in patients 
with AF, DOAC adoption trends and impacts on clinical practice are summarised in Table 5. 
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Table 5.  Summary of oral anticoagulant utilisation patterns in patients with atrial fibrillation, direct oral anticoagulant adoption trends and impacts 
on prescribing practice. 
Research group, year and study description  DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Huisman MV, et al  [228], Am J Med. 2015 
Baseline data from GLORIA-AF Phase II Registry,  
10,000 patients with AF from around the world 
47.7% 32.3% Overall DOAC use was higher than VKA use 
High proportion of OAC use in Europe and North America 
Impact of DOACs on practice was not assessed   
Lauffenburger JC, et al [241], Am J Cardiol. 2015 
USA database of commercial Medicare claims 
October 2010 to December 2012. 
70, 498 patients initiated on OAC for AF 
37.8 % 62.2 % High proportion of patients initiated on DOACs  
Patients with CHA2DS2-VASc score ≥2 were less likely to be on 
DOACs 
Impact on practice was not evaluated 
Olesen JB, et al [242]; Europace 2015 
Danish nationwide descriptive study (2011-2013) 
18 611 OAC-naive AF patients 
46.8% 
 
53.2% Rapid adoption of DOACs for NVAF 
DOACs were used according to guidelines 
Impact on overall prescribing was not evaluated  
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Research group, year and study description DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Desai NR, et al [231]; Am J Med.2014  
Medical prescription claims data, USA, 2010 2013.  
6,893 patients newly initiated on OACs 
42.2% 57.7% Rapid adoption of DOACs in low stroke risk groups 
Significant decline of warfarin prescribing over the study period 
Impact of DOACs on practice was not explicitly stated 
Shah N, et al [236]; J Am Coll Cardiol.2014. 
PINNACLE-AF outpatient registry, 2009-2012, USA 
Quarter 2, 2012 results 
12.9% 44.8% Rapid adoption of DOACs, decreased use of VKAs 
55.7% overall OAC prescribing for eligible patients  
The new agents had no significant impact on OAC prescribing  
Hamilton M, et al [238]; Circulation.2012 
 Incident cases of NVAF from medical records, USA 
19,730 patients, November 2010 to August 2011 
5.5% 31.0% Only 36.5% patients with AF initiated on OAC therapy 
Over 60% of newly diagnosed patients did not receive OAC 
DOAC approval has shown no impact on prescribing practice 
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Research group, year and study description  DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Lip GY, et al [186] ; Europace 2014 
EORP-AF Pilot Survey 
Prospective survey in 9 European countries,    
February 2012 to March 2013, 3,049 AF patients 
8.4% 71.6% OAC use improved compared to previous reports 
Based on CHA2DS2-VASc score 80.5% received OACs 
Adoption of DOACs was found to be low 
Compliance with guidelines was suboptimal in low risk patients 
J Steinberg BA, et al [230]; J Am Heart Assoc. 2013 
ORBIT-AF registry in the USA   
June 2010-August 2011, 9,974 AF patients  
12%,  --- Dabigatran was initiated in 8% during follow-up 
Patient education resulted in significant switching to DOACs  
Study suggested cautious early uptake of dabigatran 
Kakkar AK, et al, [243]; PLoS One 2013. 
Perspectives from the GARFIELD registry 
Findings from 19 countries, 10,614 AF patients 
4%,  58% 67% of all AF patients eligible for DOACs were prescribed therapy 
Higher OAC use in patients with high stroke risk 
No apparent improvement in adherence with guidelines 
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Research group, year and study description  DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Xu Y et al [229]; CAMJ Open. 2013. 
Data from province-wide prescription volumes, 
Ontario, October 2010 to September 2012 
21.2%  78.9% Impact on overall practice was not assessed  
Dabigatran uptake was rapid 
Prescription of DOACs increased by 20 fold  
Sorensen R, et al [244]; BMJ Open 2013. 
Danish nationwide register study 
Prescription claims, August 22-Deember 31, 2011. 
5.2%  94.8% Overall impact was not evaluated 
Dabigatran uptake was rapid during the initial 4 months 
Most DOACs users were new initiators, good guideline compliance 
Kirley K, et al [234]; Circ Cardiovasc Qual Outcomes 
2012. 
National Trends in OAC Use in USA, 2007 – 2011 





------ Rate of anticoagulation remained at 40% 
Dabigatran rapidly adopted mainly for AF and for off-label use 
No impact on overall anticoagulation rates 
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Research group, year and study description  DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Sorea C, et al [233]; Archives of Cardiovascular 
Diseases Supplements 2014. 
Retrospective study,  293 patients aged over 75 years  
14.3%  60.4% Overall rate of anticoagulation was 74.7% 
High proportion of anticoagulation was reported 
Impact of DOACs on prescribing practice was not evaluated  
Kirchhof P, et al [176]; Europace 2014. 
PREFER AF registry in 7 European countries 
January 2012 to January 2013 
7,243 patients with AF enrolled in the registry 
6.1% 66.3% Majority of patients (>80%) were given OACs 
Guidelines were followed and treatment patterns changed 
Percentage of patients on DOACs doubled from 6.1% to 12.6% 
Use of VKAs and APTs reduced in the same period. 
Gorczyca-Michta, et al [245]; Kardiol Pol. 2015 
Prospective study on 550 patients with NVAF 
September2012-August 2013  
19.4%  80.6% Rate of OAC utilisation was high (84.2%) 
Impact of DOACs on OAC prescribing rate was not evaluated 
Patients treated with DOACs were older than patients on VKAs 
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Research group, year and study description  DOACs VKAs Summary of findings, impacts of DOACs on prescribing practice 
Lauffenburger JC, et al [246]; Am J Cardiol, 2015.  
Us database of commercial and Medicare claims 
70,498 NVAF patients initiated on anticoagulation  
29.9% 
7.9%  
62.2% Impact on practice was not evaluated  
Patients with high stroke and bleeding risk were less likely to be 
initiated on DOACs 
 
Akao M, et al [181]; Circ J 2014. 
The Fushimi AF Registry, Japan 
2,914 AF patients enrolled by October 2012  
6.3%  48.4% Overall OAC use was 54.6% 
Status of OAC use at one year follow-up did not change substantially 
despite DOACs availability  
Abbreviations:  NVAF, non-valvular AF; OAC, oral anticoagulant; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist; APT, antiplatelet; 
TIA, transient ischaemic attack 
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2.9  Persisting challenges and future prospects 
While DOACs present an opportunity to improve stroke prevention in AF, there are still several 
limitations that affect their wider acceptance. To be considered as first choice in AF, DOACs 
must not only be more convenient but also need to result in better clinical outcomes, at an 
acceptable cost, with consistency in all groups of patients. Major uncertainties related to 
DOACs include medication adherence and persistence, absence of specific antidote for most 
of the DOACs, higher cost, and lack of data in some groups of patients in which they have not 
been adequately studied. These patients include those with mechanical heart valves, pregnancy 
or disease states in which there is potential for toxicity, such as renal insufficiency [247,248]. 
Clinical experience with DOACs is relatively short-lived and there is a lack of data from real 
world practice settings regarding long-term adherence and persistence with these agents. 
However, there are some concerns that patients may have difficulty in remembering to take 
DOACs without the requirement of blood monitoring [249]. Consequently, if DOACs are not 
taken regularly, the risk of embolic stroke may be higher as these agents have short half-lives 
compared to warfarin. The safety of DOACs has been challenged as there is no reversal agent 
for the Xa inhibitors currently approved in clinical practice. Lack of a specific reversal agent 
has been a major concern among prescribers and patients, ultimately affecting adoption into 
clinical practice [250]. Nonetheless, withholding the drug and providing supportive care 
indirectly achieve DOAC reversal. Compared to warfarin, the shorter half-lives of DOACs 
result in rapid waning of anticoagulant effect upon cessation of treatment [251,252]. Moreover, 
there are ongoing efforts to develop specific antidotes for DOACs.   Recently, a breakthrough 
has been achieved with the development of a reversal agent for dabigatran. The monoclonal 
antibody idarucizumab binds dabigatran with a stronger affinity, 350 times higher than 
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thrombin. It has been tested in clinical trials and granted approval for dabigatran reversal by 
the FDA [253-255]. Further, a recombinant protein acting as a universal antidote for factor Xa 
inhibitors (andexanet alfa) is under development [256]. Approval of these agents is expected 
to increase the acceptance rate of DOACs and subsequently improve the practice of stroke 
prevention in AF. 
Cost is the other challenge hindering adoption of DOACs. The direct medication cost of the 
new agents is much higher than warfarin. A quality and cost implications study conducted in 
6893 patients with AF in the USA indicated higher patient and insurer spending for DOACs 
compared to warfarin users, indicating a high health care cost burden for the new agents [231]. 
Moreover, DOACs are taken chronically in NVAF, the disease is highly prevalent, and hence 
there could be a significant financial burden both on the patient and the health care 
system [257,258]. However, studies applying different economic models in real world practice 
settings have revealed dabigatran to be as, or more cost effective than warfarin. Event specific 
cost analysis based on efficacy and safety endpoints has showed an overall cost reduction for 
DOACs compared to warfarin [259-261]. Overall, issues associated with cost are considered 
to be transitory as more DOACs are licensed increasing the generic options.  
A lack of data in some patient groups and disease states are other factors impeding adoption of 
DOACs into clinical practice. Clinical trials are usually performed in selected patient cohorts 
due to strict regulatory controls. Typically excluded in the evaluation of DOACs are those 
patients with advanced renal and liver dysfunctions, children, patients at extremes of body 
weight and with complex disease and multiple morbidities [240]. Moreover, the efficacy of 
DOACs, particularly dabigatran, is shown to be inferior compared to warfarin in patients with 
mechanical heart valves or hemodynamically significant valvular heart disease [262]. DOACs 
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are also not suitable in patients with history of GI bleeding while warfarin may be used with 
caution in these patients [225,263]. Hence, more information is needed regarding the use of 
DOACs in these comorbidities and special populations.  
On the other hand, the new agents are approved for venous thromboembolism in some countries 
including Europe, USA, Canada and Japan [206]. Moreover, clinical trials are being undertaken 
to evaluate the safety and efficacy of DOACs for valvular AF, acute coronary syndrome and 
in patients with prosthetic heart valves [262,264]. Research is also currently ongoing to develop 
additional DOACs targeting specific steps in the coagulation process with improved 
pharmacological profiles [265]. Accordingly, it is likely that the options and the range of 
indications for DOACs will increase over time. All of these efforts are paving the way and in 
the future, it seems that optimal anticoagulation and stroke prevention in AF are attainable 
goals. However, much effort will be required in real world practice settings to refine their use 
and ultimately gain wider acceptance with a subsequent impact on clinical practice.   
2.10 Conclusions 
Current research indicates that introduction of DOACs with some pharmacological advantages 
has led to a revision of previous guidelines and changed prescribing patterns. Adoption trends 
are quite variable with slow integration of DOACs into clinical practice reported in most 
countries, while there has been limited impact to date on prescribing practices. Accordingly, 
suboptimal OAC use and poor compliance with guidelines still remains commonplace despite 
a transition to a new era of anticoagulation using DOACs.   
Hence, it is imperative that more work is done on effective implementation of evidence-based 
best practice, including the selection of suitable patients for anticoagulation and their optimal 
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management in line with current treatment guidelines. Interventions should focus on education 
about recent developments regarding DOACs and reversal agents, including updates on AF 
treatment guidelines. Treatment guideline recommendations should be communicated 



















3 The Tasmanian atrial fibrillation study: transition to direct oral 
anticoagulants, 2011-2015. 
Overview  
This study was undertaken to address the first objective of the thesis. It describes temporal 
patterns of overall antithrombotic prescribing and adoption of DOACs for stroke prevention in 
AF. Antithrombotic prescribing patterns were assessed by organising admissions into quarterly 
periods. The proportions of patients receiving warfarin, DOACs, and APT agents in the 
corresponding quarters were determined. The results showed that DOACs became the most 
commonly prescribed class of antithrombotic agents in AF shortly after they were listed on the 
PBS. Warfarin and APT prescribing declined significantly, although a substantial proportion 
of patients with AF continued to be prescribed APT therapy. This study was published in the 










Introduction: Contemporary Australian data regarding antithrombotic prescribing patterns 
following approval of direct oral anticoagulants (DOACs) in patients with atrial fibrillation 
(AF) are limited.  
Aim: The aim of the present study was to assess antithrombotic prescribing patterns before, 
during, and after the clinical introduction of DOACs. 
Methods: Using digital medical records, this retrospective cohort study included all patients 
with AF as a primary or secondary diagnosis who were admitted to the Royal Hobart Hospital, 
Tasmania, Australia, between January 2011 and July 2015.  
Results: Antithrombotic agents were prescribed for 2078 (91.9%) of 2261 patients without 
documented contraindication to therapy. Higher rates of OAC prescribing were observed 
following Government subsidisation of DOACs in Quarter 3 (Q3) 2013 than anticoagulation 
rates in the prior quarters, (54.4% in Q3, 2013 to 68.1% in Q2, 2015, p < 0.001), with the 
prescribing of warfarin and APT agents declining. DOACs, as a class, accounted for 18.4% of 
patients on antithrombotic therapy in 2011-2015; the proportion of patients receiving a DOAC 
steadily increased from 3.9% among OAC users in Q3, 2011 to 67.6% in Q2, 2015 (p < 0.001). 
In a sub-set of patients with newly diagnosed AF, patients commenced on DOACs were 
younger (70.4 vs. 73.8 years, p = 0.04) and had lower stroke and bleeding risk scores 
(CHA2DS2-VASc 2.8 vs. 3.3, p = 0.03, HAS-BLED 2 vs. 3, p = 0.04) than patients who were 
newly prescribed warfarin. 
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Conclusions: DOACs rapidly became the most commonly prescribed class of antithrombotic 
medications in patients with AF, soon after they became widely available. Warfarin and APT 
prescribing declined significantly, although a substantial proportion of patients continued to be 
prescribed APT therapy. Patients who were initiated on DOACs were typically younger with 
fewer comorbid conditions compared to those initiated on warfarin therapy. 
Keywords 
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3.2  Introduction 
Atrial fibrillation (AF) is a common cardiac arrhythmia, mainly affecting the aged population 
[147]. AF is associated with a 5-fold increase in the risk of stroke across all age groups and 
accounts for more than 36% of all strokes in individuals aged 80 years and over [38]. Thus, 
stroke prevention is central to the management of patients with AF. Treatment decisions 
involving antithrombotic therapy should be made based on stroke risk assessment results by 
using the contemporary risk stratification method: CHA2DS2-VASc (1 point assigned for 
Congestive heart failure (CHF), Hypertension (HTN), Diabetes mellitus (DM), Vascular 
disease, Age 65-74 years, female gender and 2 points for age ≥ 75 years and prior stroke/TIA 
or thromboembolism) or the previous scoring method CHADS2 (1 point each for CHF, HTN, 
Age ≥ 75 years, DM and 2 points for prior stroke or TIA [124,125]. The majority of patients 
with AF in clinical practice are at high risk of stroke (CHA2DS2-VASc >2) and high 
proportions of patients are in need of thromboprophylaxis [95].  
Current AF treatment guidelines recommend oral anticoagulants (OACs) over APT agents in 
patients with moderate to high risk of stroke [18,76]. Despite controversy regarding its efficacy 
and safety, some guidelines continue to suggest low-dose aspirin in patients with low to 
moderate risk of stroke (CHA2DS2-VASc score = 0–1) as an alternative to OAC therapy 
[10,177]. Observational studies have typically demonstrated under-use of anticoagulants in 
patients who are eligible to receive them, and that APT agents are commonly used among 
patients with AF including those at higher risk of stroke (CHADS2 or CHA2DS2-VASc > 2) 
[138,266,267].  
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Since the 1950s, vitamin K antagonists (VKAs) were the only available OACs and most widely 
used antithrombotic agents for stroke prophylaxis in patients with AF [81,83]. In recent years, 
four direct oral anticoagulants (DOACs), namely dabigatran, rivaroxaban, apixaban and 
edoxaban, have been approved for the prevention of stroke associated with non-valvular AF 
(NVAF). The introduction of the DOACs has resulted in significant changes in the therapeutic 
landscape of stroke prevention in AF and other cardio-embolic diseases [268,269]. Studies 
regarding recent antithrombotic prescribing practices in general and the integration of DOACs 
into clinical practice, in particular, are emerging from different countries [242,270]. These 
studies have shown some improvement in OAC prescribing, with DOACs increasingly being 
prescribed in preference to warfarin. However, a considerable percentage of high-risk patients 
continue to be treated with APT agents or remain untreated.  
DOACs were approved for use in Australians with NVAF by the Australian Therapeutic Goods 
Administration (TGA) in 2011 [271], but their listing  on the Australian Pharmaceutical 
Benefits Scheme (PBS) for subsidy by the Government was more recent; rivaroxaban was 
Government subsidised in August 2013, while apixaban and dabigatran were listed on the PBS 
in September 2013 [272]. The Tasmanian AF (TAF) study was established in 2012 with the 
aim of observing the use of anticoagulants, and the outcomes of treatment with anticoagulants, 
in Tasmanian patients with AF. The aim of this analysis was to investigate the utilisation 
patterns of antithrombotic therapies for stroke prevention in AF between 2011 and 2015, and 
observe changes in anticoagulant prescribing prior to, during, and following the introduction 
of DOACs in Australia.  
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3.3  Methods 
3.3.1 Study design   
We conducted a hospital-based, retrospective cohort study of patients aged ≥ 18 years admitted 
to the Royal Hobart Hospital (RHH) with a primary or secondary diagnosis of AF. The RHH 
is the largest referral hospital in the state of Tasmania, Australia, and provides clinical services 
for a population of approximately 240,000 people in Southern Tasmania. Electronic medical 
records of all patients with AF admitted from January 2011 to July 2015 were used as the data 
source. Patients’ electronic medical record contained information including date of birth, 
gender, primary and secondary diagnosis, associated comorbidities, medication history, and 
laboratory data. Patients were identified by the Medical Record Department using Australian 
Refined Diagnosis Related Groups (AR-DRG) codes. AR-DRG code I48 was used for 
screening atrial fibrillation or flutter. Study subjects were excluded if they: (i) developed AF 
due to a complication of an acute illness, (ii) were diagnosed with AF due to a coding error, or 
(iii) had a single episode of AF that reverted spontaneously upon cardioversion without any 
documented recurrence. Because our aim was to assess antithrombotic prescribing patterns in 
the study population (as opposed to a focus only on DOACs), we included patients with 
valvular and non-valvular AF. 
Patient demographics (gender, admission and discharge dates, alcohol use including estimated 
amount per week, smoking status), primary and secondary admission diagnosis, medical 
history, admission and discharge medications and laboratory data were entered in an online 
study database. The Charlson Comorbidity Index (CCI),[273] CHA2DS2-VASc,[125] and 
CHADS2 [124] were calculated based on patient-specific comorbidities. The HAS-BLED score 
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(1 point each for HTN, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile International Normalised Ratio, (INR, as documented in the medical 
record), Elderly age ≥ 65 years, Drugs (APT agents or non-steroidal anti-inflammatory drugs 
or alcohol use > 8 units/week) [127] was also calculated. All antithrombotic therapies 
prescribed at hospital discharge were recorded. 
To enable review of temporal trends in antithrombotic prescribing, antithrombotic users were 
defined as patients prescribed OACs (warfarin, apixaban, rivaroxaban, dabigatran) or APT 
medications. We categorised antithrombotic users into three cohorts based on the 
antithrombotic medication prescribed at discharge of their index admission (episode-1 during 
the study period): i) warfarin - patients with AF discharged on lone warfarin or warfarin-APT 
combination therapy, ii) DOAC - patients with AF discharged on lone dabigatran, rivaroxaban 
or apixaban, or DOAC-APT combination therapy, iii) APT agents - patients with AF prescribed 
lone APT or combination APT therapy. Temporal trends of antithrombotic prescribing were 
assessed by organising the admissions into quarterly (Q) periods. The proportions of patients 
prescribed warfarin, DOACs or APT agents (in the absence of an OAC) in each quarter were 
determined by dividing the number of patients prescribed each agent by total patients 
prescribed an antithrombotic within the respective period.  
Persistence to antithrombotic therapy (antithrombotic survival analysis) was limited to patients 
admitted after PBS listing of DOACs (August 1, 2013). The analysis was conducted by 
following each patient discharged with the respective antithrombotic until a switch to another 
antithrombotic or cessation due to adverse effects or an emergence of a contraindication(s) 
(CI(s)). CIs to antithrombotic therapy were defined as documented evidence of recent bleeding 
while on antithrombotic therapy, severe anaemia, bleeding diathesis, clotting factor 
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deficiencies, dementia, and psychosis; additional contraindications for specific agents or 
classes included valvular AF for all DOACs, renal impairment (GFR< 30 mL/min for 
dabigatran, GFR<15 mL/min for rivaroxaban and apixaban), and pregnancy for all OACs. 
Subjects were censored at death or end of the study period (July 30, 2015). For each cohort, a 
Kaplan-Meier drug-survival plot was produced for the proportion of patients still being treated 
during follow-up. Comparison of patient characteristics among cohorts was limited to patients 
newly diagnosed with AF and initiated on antithrombotic therapy.  
3.3.2 Statistical analysis  
Continuous variables were described using mean + standard deviation (SD) or median and 
interquartile range (IQR) as appropriate. Categorical variables were reported as frequency 
counts and percentages. Temporal trends in antithrombotic prescribing patterns per quarter 
were calculated as proportions and presented graphically. Quarterly proportions, including the 
linearity for increasing or decreasing trend, were tested based on the null hypothesis of no trend 
in the utilisation patterns for each antithrombotic therapy. Antithrombotic survival analyses 
were based on the time to the first event (drug discontinuation or change to an alternative 
agent), and a Kaplan-Meier antithrombotic-survival plot was produced for each cohort of 
antithrombotic users. Comparisons of patient characteristics were performed using the 
independent sample Student’s t-test or Mann-Whitney U-test for continuous variables and the 
chi-square test for categorical variables. Data was analysed using R, version 3.2.3 (R 
Foundation for statistical computing, Vienna, Austria). A p-value of < 0.05 was considered 
statistically significant for all analyses.  
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3.4  Results 
A total of 3265 patient records were reviewed. Of these, 2390 (73.2%) fulfilled our inclusion 
criteria and 875 (26.8%) were excluded. Three hundred and sixteen patients were excluded 
because AF was due to a complication of an acute illness, 341 because they had one episode 
of AF that reverted spontaneously upon cardioversion and without documented recurrence, and 
218 because they were diagnosed to have AF due to a coding error. Eighty patients died during 
their index admission, leaving 2310 patients available for follow-up. 
3.4.1 Study population characteristics  
Patient demographics, comorbidities, and baseline stroke and bleeding risk scores are 
summarised in Table 6. The mean age of the study subjects was 74.8 years (standard deviation 
[SD] = 11.5), 44.6% were females, and hypertension was the most frequent comorbidity 
(61.5%). Mean (SD) CHADS2 and CHA2DS2-VASc scores were 1.7 (1.1) and 3.2 (1.5), 
respectively. Only 96 (4.2%) patients were at low predicted risk of stroke (CHA2DS2-VASc = 
0), while most (85.7%) patients were at high risk of stroke (CHA2DS2-VASc > 2) during the 
index admission. Seven hundred and thirty-four (31.8%) patients had high bleeding risk scores 
(HAS-BLED > 3).  
3.4.2 Antithrombotic prescribing  
Antithrombotic prescribing at the discharge of their index admission (episode-1) for our study 
population is summarised in Table 6. Of the 2261 (97.9%) study participants without a 
documented CI to any available antithrombotic therapy, 2078 (91.9%) were prescribed 
antithrombotic agents. One thousand three hundred and three (57.6%) patients received lone 
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OAC or OAC-APT combination therapy; 920 (40.7%) received warfarin alone or combined 
with APT therapy and 383 (16.9%) were prescribed DOACs (lone or combined with APT 
agents). APT therapy was prescribed for 745 (33.0%) and heparins or derivatives were 
prescribed for 30 (1.3%) patients. Forty-nine patients had a documented CI to all available 
antithrombotic therapies. The majority of these patients had their antithrombotic ceased prior 
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Table 6. Baseline characteristics of patients with atrial fibrillation (January 2011 to July 2015). 
Characteristics  All patients (n = 2310) 
Age , mean (SD) 74.8 ± 11.5 
Sex, (F), n (%) 1029 (44.6) 
Alcohol use (>8 units /week), n (%) 159 (6.9) 
Hospital stay in days, median (IQR) 5 (8) 
CCI, mean (SD) 4.4 (2.2) 








Hypertension 1420 (61.5) 
Ischaemic heart diseases 701 (30.3) 
Diabetes mellitus 500 (21.6) 
Chronic respiratory disease 477 (20.6) 
Congestive heart failure 429 (18.6) 
Myocardial infarction  249 (10.8) 
Valvular heart disease 216 (9.4) 
Renal disease 213 (9.2) 
History of stroke 156 (6.7) 
Peptic ulcer disease 119 (5.1) 
Other embolic events a  109 (4.7) 
Cerebrovascular disease  85 (3.7) 
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Characteristics  All patients (n = 2310) 
 Prior bleeding 45 (1.9) 
AF history, n (%) 
 
First detected 812 (35.2) 
Pre-existing  1498 (64.8) 
CHA2DS2-VASc  Mean, (SD) 3.2 (1.5) 
CHA2DS2-VASc = 0, n (%) 96 (4.2) 
CHA2DS2-VASc =1, n (%) 234 (10.1) 
CHA2DS2-VASc > 2, n (%) 1980 (85.7) 
CHADS2 Mean, (SD) 1.7 (1.1) 
CHADS2 = 0, n (%) 329 (14.2) 
CHADS2 = 1, n (%) 676 (29.3) 
CHADS2  > 2, n (%) 1305 (56.5) 
HAS-BLED score   Median (IQR)  2 (1) 
HAS-BLED > 3, n (%) 734 (31.8) 
Patients with documented CI to antithrombotic, n (%) 49 (2.1) 
Patients without CI to antithrombotic therapy, n (%)  2261 (97.9) 
Overall antithrombotic prescribing 
 
Antithrombotic prescribed 
 at discharge, n (%)* 
2078 (91.9) 
 No therapy, n (%) 183 (8.1) 
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Characteristics  All patients (n = 2310) 
Antithrombotic group prescribed 
at discharge, n (%) 
Warfarin (lone and with 
APT) 
920 (40.7) 
DOAC (lone and with APT) 383 (16.9) 
APT (lone and combination) 745 (33.0) 
Heparin or derivatives 30 (1.3) 
Abbreviations: AF, atrial fibrillation; OAC, oral anticoagulant; APT, antiplatelet agent; CCI, 
Charlson comorbidity index; SD, standard deviation; IQR, interquartile range; CI, 
contraindication. a Other embolic events include patients with history of deep venous 
thrombosis and pulmonary embolism. *The percentages of patients receiving various 
antithrombotic medications at discharge were calculated using the number of patients without 
a documented contraindication to antithrombotic therapy (n=2261).  
 
3.4.3 Temporal antithrombotic utilisation patterns  
The temporal utilisation patterns of OACs and APT agents are illustrated in Figure 7. The 
utilisation of warfarin and individual DOACs are presented in Figure 8. A consistently higher 
proportion of patients were prescribed OACs during the later quarters (Q), (Q4, 2013 to Q2, 
2015), largely explained by the introduction of DOACs. In earlier Qs of our study (Q1, 2011 
to Q2, 2014), warfarin was the most commonly prescribed antithrombotic.  
DOACs were available for patients with NVAF from Q3, 2011, although they did not become 
Government-subsidised until mid-late 2013. Prescribing of DOACs among patients discharged 
on OAC therapy steadily increased from 3.9% in Q3, 2011 to 67.6% in Q2, 2015 (p < 0.001). 
Uptake of the DOACs was rapid following the availability of Government subsidisation and, 
as a class, they became the most commonly prescribed agents from Q3, 2014 to the end of our 
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study period. In contrast, the prescribing of warfarin significantly declined from Q3, 2013 to 
Q2, 2015 (38.1% vs. 22.1%, p < 0.001). Further, a significant decline in the prescribing of APT 
agents alone (in the absence of an OAC) was observed when proportions across all quarters 
were compared (39.8% in Q1, 2011 to 31.9% in Q2, 2015, p < 0.001). 
Analysis of the utilisation patterns of individual OACs showed that warfarin prescribing 
dropped steadily (p <0.001 for decreasing trend) while dabigatran prescribing remained stable 
at low proportions (p = 0.07) over the follow-up period. Rivaroxaban and apixaban prescribing 
increased rapidly, mainly later in the study period. A rapid decline in warfarin prescribing was 
noticeable from Q2, 2013 to Q2, 2015 (94.2% to 32.4%, p < 0.001), with a corresponding 
increase in the uptake of DOACs in the same period (5.8% to 67.6%, p < 0.001). In the final 
quarter of the study period (Q2, 2015), apixaban was the most commonly prescribed OAC 
(33.8%), followed by warfarin (32.4%) and rivaroxaban (24.7%) while dabigatran was 













Figure 7. Temporal antithrombotic utilisation patterns, January 2011 to July 2015.  
Abbreviations: NVAF, Non-valvular atrial fibrillation; OAC, oral anticoagulant; DOAC, direct 
oral anticoagulant; APT, antiplatelet agents; Q, quarter. *Groups consisted of lone agents or 
OAC-APT combination therapy. Percentages are rounded to the nearest integer.  
Note: Each quarter (Q) includes all patients with AF discharged within that three-month period 
and prescribed antithrombotic therapy at discharge of their index admission. Q1 = January-
March, Q2 = April-June, Q3 = July-September, Q4 = October-December. DOACs were 
approved by the Therapeutic Goods Administration (TGA) for use in the Australian patients 
with NVAF in April 2011, and subsequently listed on the Pharmaceutical Benefits Scheme 






































Warfarin* 60% 54% 61% 51% 46% 61% 47% 65% 65% 58% 38% 42% 38% 37% 30% 29% 24% 22%
DOACs* 0% 0% 2% 3% 3% 2% 5% 4% 8% 7% 16% 25% 31% 36% 38% 44% 44% 46%
OAC (Overall)* 60% 54% 63% 54% 49% 63% 52% 69% 73% 65% 54% 67% 69% 73% 66% 73% 68% 68%
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Figure 8. Temporal oral anticoagulant utilisation patterns, January 2011-July 2015.  
Abbreviations: NVAF, non-valvular atrial fibrillation; OAC, oral anticoagulant; DOAC, direct 
oral anticoagulant; Q, quarter. *Groups consisted of lone agents or combined OAC and 
antiplatelet agents. Percentages are rounded to the nearest integer.  
3.4.4 Antithrombotic survival   
A Kaplan-Meier plot of antithrombotic survival is presented in Figure 9. The plot shows the 
probability of drug survival at the given time intervals (months) and rates of switching to an 
alternative agent, drug discontinuation due to ADR, or emergence of a CI to antithrombotic 





































Warfarin* 100%100% 96% 95% 95% 96% 95% 95% 93% 94% 73% 63% 55% 51% 45% 39% 35% 32%
All DOACs* 0% 0% 4% 5% 7% 4% 5% 5% 7% 6% 27% 37% 45% 49% 55% 61% 63% 68%
Dabigatran* 0% 0% 4% 5% 7% 4% 5% 5% 4% 3% 4% 8% 7% 13% 11% 8% 8% 9%
Rivaroxaban* 0% 0% 0% 0% 0% 0% 0% 0% 3% 3% 23% 25% 36% 17% 29% 23% 32% 25%
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agents (warfarin = 309, DOACs = 360, and APT agents = 304) at discharge of their index 
admission. The mean (95% CI) survival time in months for the three groups were: 22.4 (20.3-
22.0) for DOACs, 21.9 (21.2-23.1) for warfarin and 21.1 (20.3-22.0) for APT agents. The Log-
rank, Breslow, and Tarone-Ware test of survival distribution showed a significant difference 
between the cohorts (p = 0.04, 0.009 and 0.016, respectively). 
 
Figure 9. Kaplan-Meier plot of drug survival among antithrombotic users in atrial fibrillation.  
Abbreviations: APT, antiplatelet; DOAC, direct oral anticoagulant; WARF, warfarin. 
3.4.5 Warfarin versus DOAC prescribing in newly diagnosed AF 
We conducted a sub-analysis of 364 patients with newly diagnosed AF who were admitted to 
the RHH from August 1, 2013, to compare the characteristics of subjects prescribed APT 
agents, warfarin, and DOACs. Seven patients died during the index admission, three patients 
had a documented contraindication to antithrombotic therapy, and 51 were discharged without 
antithrombotic therapy. Antithrombotics were prescribed for 303 patients; warfarin was 
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prescribed for 56 patients, DOACs for 140 patients, and APT therapy (in the absence of an 
OAC) for 107 patients. Table 7 summarises the baseline characteristics of these cohort. Patients 
treated with DOACs were younger (mean age 70.4 vs. 73.8 years, p = 0.04) and had a lower 
comorbidity (mean CCI 3.5 vs. 4.7, p < 0.001) than patients treated with warfarin. Patients 
prescribed DOACs had a significantly lower predicted stroke risk (mean CHA2DS2-VASc 2.8 
vs. 3.3, p = 0.03), and bleeding risk scores (median HAS-BLED 2 vs. 3, p = 0.04) compared to 
warfarin users. There were no significant differences in the characteristics of patients 
prescribed OACs compared to patients prescribed APT agents.  
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Table 7. Baseline characteristics of patients newly diagnosed with atrial fibrillation according to prescribed antithrombotic agents.  
Variable  DOAC (n = 140) a vs. 
Warfarin (n = 56) b  
p-value   OAC (n = 196) c vs. 
 Antiplatelet (n = 107) d 
p-value 
Gender (F), n (%) 65 (46.4) 22 (39.3) 0.450  87 (44.4) 49 (45.8) 0.910 
Age (years),  Mean (SD)                        70.4 (11.1) 73.8 (8.6) 0.040  71.3 (10.6) 73.8 (13.0) 0.080 
CHADS2 , Mean (SD)        1.5 (1.1) 1.7 (1.2) 0.210  1.5 (1.2) 1.4 (1.1) 0.720 
CHA2DS2-VASc,  Mean (SD)                    2.8 (1.5) 3.3 (1.4) 0.030  2.9 (1.4) 2.8 (1.5) 0.880 
HAS-BLED score,  Median (IQR) 2 (0.3) 3 (1) 0.040  2 (1) 2 (1) 0.080 
Hospital stay, Median (IQR) 3 (6) 6 (9) 0.002  3 (8) 4 (10) 0.070 
CCI, Mean  ( SD ) 3.5 (2.3) 4.8 (2.0) <0.001  3.8 (2.3) 3.9 (2.5) 0.960 
Abbreviations: DOAC, direct oral anticoagulant; OAC; oral anticoagulant; CCI, Charlson comorbidity index; SD, standard deviation; IQR, 
interquartile range. a Included patients discharged with lone dabigatran, rivaroxaban, apixaban or these therapies combined with antiplatelet agents. 
b Included patients discharged with lone warfarin or warfarin-antiplatelet combination therapy. c Included patients discharged with warfarin, one 
of the DOACs alone or combined with antiplatelet therapy.  d Included patients discharged with aspirin, clopidogrel or dipyridamole, either alone 
or in combination
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3.5  Discussion 
This study assessed contemporary utilisation patterns of antithrombotic therapy in patients 
admitted to the Royal Hobart Hospital in Tasmania, Australia with AF. It is among the first 
Australian studies to provide detailed information from a real-world clinical setting on 
antithrombotic prescribing patterns before, during and after the introduction of DOACs.  
DOACs have clearly become the agents of choice for stroke prevention in NVAF. We observed 
a slight and steady increase in the number of patients receiving DOACs from Q3, 2011 to Q2, 
2013. Uptake of the new agents, however, became rapid from Q3, 2013 onwards. Analysis of 
admissions from the later quarters of our study (Q3, 2014 onwards) showed that the majority 
of patients receiving an OAC were prescribed a DOAC, accounting for 54.7%, 60.8%, 64.7% 
and 67.5% of OAC prescribing during the last four quarters of the study period. Conversely, 
the proportion of patients discharged on warfarin declined rapidly in the same period. Moreover, 
a statistically significant reduction in APT prescribing was observed during the study period. 
This corresponded with the commencement of Government subsidy of the new agents. 
Nonetheless, APT agents accounted for a quarter to a third of all antithrombotic prescribing 
after Q3, 2013 to the end of our study period.  
Overall, a consistently higher OAC prescribing was observed during the last seven quarters 
whereas there was a significant decline in warfarin prescribing in the same period. This 
suggested the growth in OAC prescribing was due to an increase in DOACs initiation. While 
this can be considered as an essential step towards addressing suboptimal OAC use in eligible 
patients with AF as observed in multiple observational studies [95,269], there remains a 
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significant proportion of patients at moderate-high risk of stroke receiving APT medications 
who may benefit from the prescribing of an anticoagulant medication. 
In line with our results, a study on the uptake of the new agents using the administrative claims 
data from the Australian Government Veterans’ Affairs (including all indications for OACs) 
showed an overall increase in OAC and a sharp increase in DOAC use; warfarin prescribing 
declined after the new agents were listed on PBS [274]. A small study from Manning Base 
Hospital, New South Wales, Australia, also observed rapid growth in the prescribing of 
DOACs; more patients were reported to have been anticoagulated for AF compared to earlier 
practices. However, warfarin prescribing remained stable and the increase in DOAC use was 
not attributed to a reduction in warfarin prescribing [275]. 
Over the study period, we observed that rivaroxaban was the most (49.2%) prescribed DOAC 
followed by apixaban (29.6%) and dabigatran (21.2%). A modest increase in dabigatran 
prescribing was observed in the later quarters of 2014, followed by a slight decline in the last 
two study quarters. Analogous to our finding, a study of patients receiving long-term 
anticoagulation in the USA reported rivaroxaban (55.3%) as the most prescribed DOAC 
followed by apixaban (22.5%) and dabigatran (22.2%) [276]. Other studies on trends of OAC 
use from European countries and Canada showed a growing share of DOACs among OAC 
prescriptions and decreasing trend of warfarin prescribing in recent years [277,278]. Increased 
prescribing of DOACs in eligible patients with AF was an anticipated phenomenon as the new 
agents offer comparable efficacy, better safety, and fewer interactions with drugs and food than 
warfarin [276]. In the last quarter of the study period, apixaban was the most commonly 
prescribed OAC. 
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In the antithrombotic survival analysis (Figure 9), patients discharged on DOACs had a higher 
persistence to treatment than warfarin or APT agents; and this was mainly explained by a higher 
rate of switch from warfarin or APT agents to DOACs. Moreover, further analysis on 
readmitted patients revealed a higher proportion of drug discontinuation due to ADRs and 
emergent contraindications among warfarin and APT users compared to DOAC users. This 
finding, however, should be interpreted with caution, as DOACs were prescribed for younger 
patients with less comorbidity, who may therefore be less likely to experience ADRs as a result. 
Contrasting reports are emerging in regards to persistence to therapy among patients on OAC 
therapy. Analogous to our findings, a study measuring 6-, 9-, and 12-month persistence from 
the United States Department of Defence administrative claims data showed significantly 
higher rates of persistence among dabigatran compared to warfarin users. A similar study on 
27,514 OAC-naïve patients from primary care Clinical Practice Research Datalink in the 
United Kingdom indicated persistence with OACs declined within 12 months to 63.6% for 
VKAs and 79.2% for DOACs (p<0.001) [279,280]. In contrast, observational studies from 
Japan and Denmark reported lower persistence rates among DOAC compared to warfarin users 
with a large proportion of DOAC users switched to a VKA within six months of follow-up 
[281,282]. The reasons for early discontinuation of DOACs in the Japanese patients were 
ADRs, worsening renal dysfunction, and patient choice; while the reason for early switching 
in the Denmark study was not explained.      
Comparative analysis of patients with newly diagnosed AF who were initiated on OACs 
showed that DOACs were prescribed to younger patients with fewer comorbidities than their 
warfarin counterparts. Moreover, the DOACs were prescribed to patients with lower predicted 
risk of stroke and bleeding than those prescribed warfarin. This might reflect a more 
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conservative approach to prescribing the new agents among elderly patients with more 
comorbid conditions, or in patients with diminished renal function.  
Similar to our findings, a registry study in the ORBIT-AF reported patients receiving 
dabigatran were younger and had lower stroke and bleeding risk scores than patients who did 
not receive dabigatran [230]. Another study on factors driving OAC selection in patients with 
AF in the USA also showed higher bleeding and stroke risk scores associated with warfarin 
initiation compared to DOAC initiation [246]. Randomised controlled trials established that 
DOACs had comparable efficacy in preventing stroke and systemic embolism, but were 
significantly safer than warfarin, primarily when ICH was considered [99,105,276]. It follows 
that initiating DOACs in elderly patients with more comorbid conditions may lead to improved 
clinical outcomes.  
3.6  Conclusion 
DOACs rapidly became the most commonly prescribed class of antithrombotic medications in 
patients with AF soon after they became widely available. Warfarin and APT prescribing 
declined significantly, although a substantial proportion of patients continued to be prescribed 
APT therapy in preference to an anticoagulant. Patients who were initiated on DOACs were 
typically younger with fewer comorbid conditions compared to those initiated on warfarin 
therapy. Patients who were prescribed DOACs tended to persist on therapy longer than patients 
prescribed warfarin or APT agents.  
 




4. Changes in oral anticoagulant prescribing for stroke prevention in 
patients with atrial fibrillation. 
 
Overview  
This study was undertaken to address the second objective of the thesis, i.e. to evaluate the 
impact of the availability of DOACs on OAC prescribing practices in patients with NVAF. We 
hypothesised that there would be a net increase in OAC prescribing over time, driven primarily 
by a greater use of DOACs. In this analysis, we compared anticoagulation practices before and 
after DOACs became widely available in Australia, and investigated OAC prescribing by 
stroke risk stratification, using current AF guidelines. We also identified factors independently 
associated with OAC prescribing in AF. This paper was published in the American Journal of 
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4.1  Abstract  
Suboptimal guideline adherence and underuse of anticoagulants in patients with atrial 
fibrillation (AF) have been reported worldwide. This study aimed to compare anticoagulation 
practice in Australia during the pre- and post-direct oral anticoagulant (DOAC) eras. Between 
January 2011 and July 2015, patients with non-valvular AF (NVAF) admitted to the Royal 
Hobart Hospital, Tasmania, Australia, were retrospectively reviewed. The pre- and post-DOAC 
era cohorts included admissions from January 2011 to July 2013 and August 2013 to July 2015, 
respectively. Anticoagulation practices were compared in the two eras using contemporary 
guideline recommendations for oral anticoagulant (OAC) use in AF. Overall, 2118 patients 
(1089 from the pre-DOAC and 1029 from the post-DOAC era) met our inclusion criteria. The 
overall rate of anticoagulation increased from 52.5% in the pre-DOAC era to 60.7% in the post-
DOAC era (p < 0.001). Moreover, prescribing of OACs among high-risk patients improved 
significantly (63.1% vs 55.2%, p = 0.001). OAC over-prescribing in low-risk patients did not 
change significantly between the two cohorts (35.0% vs 42.9% in the pre- and post-DOAC eras, 
respectively, p = 0.59). In multivariate analysis, DOAC era (odds ratio [OR], 1.40, 95% CI 
1.17–1.68) and CHA2DS2-VASc > 2 (OR 1.95, 95% CI 1.36–2.80) were independent 
predictors of OAC prescribing in both eras and the whole study period. Conversely, aging and 
prior bleeding were inversely associated with OAC prescribing. In conclusion, there has been 
a significant increase in OAC prescribing in the post-DOAC era, potentially driven by the 
widespread availability of DOACs. However, OAC underuse in high-risk and overuse in low-
risk patients was apparent throughout our study.  These findings highlight the need to identify 
the drivers of anticoagulant under- and over-use and address them accordingly. 
Keywords: atrial fibrillation; stroke; oral anticoagulant; warfarin; direct oral anticoagulant.   
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4.2  Introduction  
Effective utilisation of oral OACs is essential in the management of patients with atrial 
fibrillation (AF) [283]. For many decades, vitamin K antagonists (VKAs) were the most 
effective treatment in AF, reducing stroke and systemic embolism by 60% to 70% compared 
to placebo [86,111]. However, suboptimal use of VKAs, such as under-prescribing in high 
stroke risk, and over-prescribing in low-risk patients, was frequently reported in observational 
studies [95,269]. Since 2010, four direct-acting oral anticoagulants (DOACs), including 
dabigatran, rivaroxaban, apixaban and edoxaban, have been approved for stroke prevention in 
patients with non-valvular AF (NVAF). Post-marketing AF-registry studies and local data from 
clinical settings show significant uptake of DOACs for stroke prevention in NVAF [284-286]. 
Nonetheless, data is conflicting as to whether DOACs are being used as therapeutic substitutes 
for VKAs, or there is an overall increase in OAC prescribing following the approval of the new 
agents [287]. The focus of the present analysis was to examine anticoagulation practices before 
and after DOACs became widely available in Australia, and to investigate whether DOAC 
availability was an independent predictor of OAC prescribing in NVAF. 
4.3  Methods 
Between January 2011 and July 2015, patients with NVAF admitted to the Royal Hobart 
Hospital (RHH), Tasmania, Australia, were assessed retrospectively using digital medical 
records as a data source. The Tasmanian Health and Medical Research Ethics Committee 
approved this study. Patients were identified using the Australian Refined Diagnosis Related 
Groups (AR-DRG) code I48 to screen for atrial fibrillation or flutter. Based on the definitions 
in current AF guidelines [9,10], patients with valvular AF (i.e. those with a documented history 
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of mitral stenosis and artificial heart valves) were excluded. However, we included patients 
with AF and other types of valvular heart disease (VHD) including mitral regurgitation, aortic 
regurgitation, aortic stenosis and mitral valve prolapse. 
Demographic data including sex, age, smoking status and alcohol use as listed in the medical 
record were entered into an online study database. Further, admission diagnoses, comorbidities, 
admission and discharge medications, and laboratory data were reviewed and entered into the 
database. For the assessment of stroke or bleeding risk, CHA2DS2-VASc [125] and HAS-
BLED [127] scoring methods were used respectively. Eligibility and OAC prescribing 
practices were assessed based on contemporary AF treatment guideline recommendations. For 
this purpose, we used European Society of Cardiology and the joint American Heart 
Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) AF 
guidelines [10,76]. Each patient’s stroke risk score was calculated and categorised into three 
groups with anticoagulation recommendations as follows: i) low stroke risk (CHA2DS2-VASc 
= 0) - no antithrombotic therapy recommended, ii) intermediate stroke risk (CHA2DS2-VASc 
= 1) - guideline recommendations differ in this group; whereas the AHA/ACC/HRS guidelines 
recommend aspirin, OAC or no therapy, European guidelines recommend OAC for men,  iii) 
high stroke risk (CHA2DS2-VASc ≥ 2) – all guidelines recommend OAC in this group.  
To compare anticoagulation practices before and after government subsidy of DOACs, we 
grouped the study population into two cohorts based on index admission dates: i) pre-DOAC 
era (January 2011 to July 2013), and ii) post-DOAC era (August 2013 to July 2015). 
Rivaroxaban was first listed on the Pharmaceutical Benefits Scheme (PBS) for subsidy by the 
Australian Government, on 1 August 2013, followed by dabigatran and apixaban in September 
2013 [272]. Thus pre-DOAC era, in this study, was defined as the time period at which DOACs 
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were at the early stages of clinical familiarisation in the Australian settings (between early 2011 
and mid-2013). Post-DOAC era was defined as the time period after the new therapies were 
listed on the PBS until the end of our study period (mid-2013 to mid-2015).  
Patients were considered anticoagulated if warfarin, dabigatran, rivaroxaban or apixaban was 
prescribed at discharge of their first (index) admission unless contraindicated (edoxaban has 
yet to be approved in Australia). Contraindications to OAC therapy included the following: 
recent bleeding while on an antithrombotic therapy, severe anaemia, bleeding disorders 
(bleeding diathesis, clotting factor deficiencies), dementia, psychosis, and pregnancy or 
breastfeeding. Patients without documented contraindication and discharged without any 
antithrombotic therapy were categorised as “no therapy”. In patients not receiving an OAC, we 
reviewed the medical records for documented reasons for not prescribing an OAC.  
Continuous variables were expressed as means and standard deviations (SD) and categorical 
variables as frequencies and percentages. Independent-sample Student’s t-tests were used to 
compare continuous variables in two groups, and Chi-square and Fisher’s exact tests were used 
for comparing categorical variables. Multivariate logistic regression modelling was used to 
identify factors associated with OAC prescribing in the pre-DOAC, post-DOAC, and overall 
study period. The threshold for entry into the multivariate model was set at p < 0.25. Multi-
collinearity among predictor variables was checked using the variance inflation factor (VIF); 
VIF ≤ 3 was taken for stable estimation of regression coefficients. All statistical analyses were 
conducted using R, version 3.2.5. A p-value < 0.05 was considered statistically significant.  
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4.4  Results  
4.4.1 Baseline characteristics comparison  
A total of 2,118 patients with NVAF, 1,089 from the pre-DOAC, and 1,029 from the post-
DOAC eras, were included for assessment. Baseline patient characteristics are shown in Table 
8. There were no statistically significant differences in the mean age, sex, stroke and bleeding 
risk scores, and most comorbidities between the two cohorts. According to contemporary risk 
score stratification methods and AF treatment guideline recommendations, most of our study 
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Table 8. Comparison of baseline characteristics of the study population 
Variables  Pre-DOAC 





Age (years), mean (±SD)  74.7 ±11.6 74.9 ±11.6 0.605 
Women 471(43.2%) 476 (46.3%) 0.178 
Hospital stay (days), mean (±SD) 9.8 ±14.5 8.1 ±13.1 0.005 
CCI, mean (±SD) 4.5 ± 2.2 4.3 ± 2.2 0.109 
Hypertension  715 (65.6%) 607 (59.0%) 0.002 
Ischaemic heart disease 365 (33.5%) 273 (26.5%) < 0.001 
Chronic respiratory disease  249 (22.9%) 189 (18.4%) 0.012 
Diabetes mellitus  230 (21.1%) 229 (22.2%) 0.561 
Congestive heart failure 181 (16.6%) 203 (19.7%) 0.072 
Myocardial infarction  125 (11.5%) 101 (9.8%)  0.243 
Renal disease 89 (8.2%) 112 (10.9%) 0.040 
Past or current stroke 54 (4.9%) 96 (9.3%) < 0.001 
Other embolic events *  51 (4.7%) 50 (4.9%) 0.930 
Valvular heart disease ¥ 50 (4.6%) 51 (4.9%) 0.770 
Peripheral vascular disease  44 (4.0%) 33 (3.2%) 0.911 
Cerebrovascular disease  44 (4.0%) 35 (3.4%) 0.509 
Prior bleeding history  25 (2.3%) 12 (1.2%) 0.069 
Alcohol use (> 8 units /week) 83 (7.6%) 63 (6.1%) 0.202 
CHA2DS2-VASc score, mean (±SD) 3.2 ±1.6 3.3 ±1.1 0.635 
CHA2DS2-VASc = 0  43 (3.9%) 49 (4.8%)  
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Variables  Pre-DOAC Post-DOAC p-value 
CHA2DS2-VASc =1 116 (10.6%) 92 (8.9%)  
CHA2DS2-VASc ≥ 2 930 (85.4%) 888 (86.3%)  
HAS-BLED score, mean (±SD) 2.3 ± 0.77 2.2 ± 0.72 0.075 
HAS-BLED = 0-1 112 (10.3%) 142 (13.8%)  
HAS-BLED = 2 625 (57.4%) 579 (56.3%)  
HAS-BLED ≥ 3 352 (32.3%) 308 (29.9%)  
Abbreviations: CCI, Charlson comorbidity index; DOAC, direct oral anticoagulant; SD, 
standard deviation.  * Include patients with history of deep venous thrombosis and pulmonary 
embolism. ¥ Include patients with a history of mitral or aortic regurgitation, aortic stenosis, and 
mitral valve prolapse.  
4.4.2 Antithrombotic prescribing at discharge  
Overall prescribing of any antithrombotic (OAC or APT therapy) was significantly higher in 
the pre-DOAC era compared to the post-DOAC era (93.1% vs. 90.0%, p = 0.012). There was 
an absolute increase in the overall anticoagulant prescribing over time, from 52.5% in the pre-
DOAC to 60.7% in the post-DOAC era (relative increase of 15.6%, p < 0.001) (Table 9). 
Prescribing of lone warfarin, lone APT agent, warfarin-APT, and combination APT therapy 
(without OAC) was higher in the pre-DOAC cohort.  
When anticoagulation was analysed by the CHA2DS2-VASc score strata, OAC prescribing 
increased with increased stroke risk score in the two study populations (Figure 10). Comparing 
anticoagulation practices by stroke risk groups between the two eras, OAC prescribing was 
higher across all stroke risk groups in the post-DOAC era than OAC prescribing in the pre-
DOAC era. OAC prescribing in high-risk patients improved in the post-DOAC era compared 
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to the pre-DOAC era (an absolute increase from 55.2% to 63.1%, relative increase of 14.3%, 
p = 0.001). There was no statistically significant change in OAC over-prescribing in the low-
risk patients between the two periods. APT prescribing declined in the post-DOAC era across 
all stroke risk strata compared to the pre-DOAC era. However, a substantial proportion of high-
risk patients were treated using APT therapy in both eras-38.9% in the pre-DOAC and 28.2% 
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Table 9. Antithrombotic prescribing in the pre- and post-direct oral anticoagulant eras.  
Prescribing at discharge, n (%) Pre-DOAC (n =1089) Post-DOAC (n= 1029) p-value 
All OACs a 572 (52.5%) 625 (60.7%) < 0.001 
All DOACs b 22 (2.0%) 348 (33.8%) < 0.001 
All APT agents c 421 (37.5%) 295 (28.7%) < 0.001 
Warfarin  380 (38.7%) 206 (20.0%) < 0.001 
Dabigatran 15 (1.4%) 52 (5.1%) < 0.001 
Rivaroxaban 4 (0.4%) 139 (13.5%) < 0.001 
Apixaban  0 (0.0%) 85 (8.3%) < 0.001 
Aspirin 336 (30.8%) 249 (24.2%) < 0.001 
Clopidogrel 33 (3.0%) 16 (1.5%) 0.035 
Warfarin-APT combination 170 (15.6%) 71 (6.9%) < 0.001 
DOAC-APT combination 3 (0.3%) 72 (7.0%) < 0.001 
OAC-APT combination d 173 (16.9%) 143 (13.9%) 0.221 
APT combination e 52 (4.8%) 30 (2.9%) 0.035 
Heparin and derivatives 21 (1.9%) 6 (0.6%) 0.010 
No therapy  75 (6.9%) 103 (10.0%) 0.012 
Abbreviations: APT, antiplatelet; DOAC, direct oral anticoagulant; OAC, oral anticoagulant. a 
Includes all OACs (warfarin and DOACs) with or without antiplatelet therapy. b Includes lone 
apixaban, dabigatran, rivaroxaban, and DOAC-antiplatelet combination therapy. c Includes 
lone or dual-APT combination therapy. d Includes warfarin or a DOAC with antiplatelet 
combination therapy. e Includes APT combination without OAC therapy. 




Figure 10. Antithrombotic prescribing stratified by stroke risk scores in the pre- and post-direct 
oral anticoagulant era.   
*** P ≤ 0.001. Abbreviations: OAC, oral anticoagulant (with or without antiplatelet therapy); 
APT, antiplatelet (lone- or dual-APT without OAC therapy); DOAC, direct oral anticoagulant. 
 
4.4.3 Factors associated with oral anticoagulant prescribing 
Table 10 shows the results of the multivariate logistic regression analysis for factors associated 
with OAC prescribing in the pre-DOAC, post-DOAC, and overall study periods. Patients in 
the post-DOAC era were more likely to receive OAC therapy compared to patients in the pre-
DOAC era (odds ratio [OR] 1.40, 95% CI 1.17 – 1.68, p < 0.001). Age was inversely associated 
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positively associated with OAC prescribing in the pre-DOAC era and overall study period. 
Higher stroke risk score (CHA2DS2-VASc ≥ 2) was significantly associated with OAC 
prescribing in both eras and for the entire study period. A history of prior bleeding, on the other 
hand, was inversely associated with OAC prescribing in both eras and the whole study period. 
Reasons for not prescribing an OAC were documented for 154 patients (Table 11). Falls risk, 
refusing OAC therapy, and adverse drug reactions, mainly recent bleeding from antithrombotic 
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Table 10. Factors associated with oral anticoagulant prescribing.  
 
Variable 
Pre-DOAC era Post-DOAC era Overall Period 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Age 0.98 (0.97 – 0.99) 0.025 0.98 (0.96 – 0.99) 0.048 0.98 (0.97 – 0.99) < 0.001 
Sex (reference = women) 1.34 (1.02 – 1.76) 0.031 1.19 (0.91 – 1.58) 0.198 1.28 (1.05 – 1.54) 0.012 
Alcohol use 0.84 (0.51– 1.39) 0.491 0.79 ( 0.45 – 1.39) 0.411 0.82 (0.57 – 1.19) 0.299 
Hypertension  1.43 (1.07 – 1.89) 0.013 1.17 (0.88 – 1.55) 0.276 1.21 (0.95 – 1.56) 0.114 
Myocardial infarction  0.87 (0.58 – 1.30) 0.497 1.25 (0.80 – 1.99) 0.328 1.03 (0.77 – 1.39) 0.843 
Congestive heart failure 1.83 (1.29 – 2.63) 0.001 1.14 (0.82 – 1.61) 0.432 1.36 (1.01 – 1.83) 0.042 
Cerebrovascular diseases 1.62 (0.83 – 3.25) 0.161 0.86 (0.43 – 1.77) 0.631 1.16 (0.72 – 1.91) 0.540 
Valvular heart diseases 2.25 (1.20 – 4.44)  0.014 1.33 (0.73 – 2.52) 0.362 1.71 (1.11 – 2.70)  0.017 
Other embolic events * 1.58 (0.87 – 2.95) 0.139 1.25 (0.68 – 2.39) 0.477 1.42 (0.93 – 2.22) 0.108 
Renal diseases  1.17 ( 0.71 – 1.96) 0.549 0.61 (0.36 – 1.02) 0.059 0.86 (0.60 – 1.23) 0.407 





Pre-DOAC era Post-DOAC Overall Period 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Diabetes mellitus 1.19 (0.87 – 1.65) 0.279 1.24 ( 0.89 – 1.73) 0.202 1.16 (0.90 – 1.49) 0.245 
Ischaemic heart diseases 1.10 ( 0.83 – 1.46) 0.499 0.91 (0.68 – 1.24) 0.559 1.02 (0.83 – 1.25) 0.875 
Stroke  1.52 ( 0.82 – 2.86) 0.188 1.20 ( 0.69 – 2.14) 0.520 1.34 (0.88 – 2.06) 0.167 
Prior bleeding  0.15 (0.04 – 0.41)  < 0.001 0.17 (0.03 – 0.60) 0.015 0.14 (0.06 – 0.29) < 0.001 
CHA2DS2-VASc ≥ 2 vs. 0-1 1.72 (1.06  – 2.81)  0.030  2.16 (1.29 – 3.62) 0.004 1.95 (1.36 – 2.80) < 0.001 
HAS-BLED ≥ 3 vs. 0-2 1.06 ( 0.76 – 1.47) 0.747 1.63 ( 1.08 – 2.49) 0.022 1.23 (0.96 – 1.59) 0.107 
DOAC era  – – – – 1.40 (1.17 – 1.68) < 0.001 
Abbreviations: CI, confidence interval; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; OR, odds ratio.  
* Include patients with history of deep venous thrombosis and pulmonary embolism.        
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Table 11. Summary of documented reasons for not prescribing an oral anticoagulant.   
 







Falls risk  36 (42%) 20 (29%) 0.154 
Refusal  18 (21%) 14 (21%) 1.000 
ADR (current bleeding)  14 (16%) 9 (13%) 0.765 
Anaemia, thrombocytopaenia, clotting 
factor deficiencies, leukaemia 
5 (6%) 6 (9%) 0.54 
Non-compliance, labile INR  7 (8%) 8 (12%) 0.631 
Aging, bipolar disorder, psychosis,  
dementia, renal failure, palliative care 
4 (5%) 7 (10%) 0.216 
Fear of bleeding, high bleeding risk, 
history of prior bleeding 
2 (2%)  4 (6%)  0.406 
ADR = adverse drug reaction; DOAC = direct oral anticoagulant; INR = international 
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4.5  Discussion 
 In this analysis, we noted a significant increase in OAC prescribing in the post-DOAC era. 
Most importantly, anticoagulation of high-risk patients significantly improved after DOACs 
began being subsidised by the Australian government. Widespread availability of DOACs after 
subsidisation (post-DOAC era) was an independent predictor of OAC prescribing, resulting in 
a 40% increase in the odds of a patient being prescribed an OAC after accounting for other 
factors. This increase was observed while the majority of our patients in both eras had high 
stroke risk scores requiring OAC therapy. Of note, baseline patient characteristics were broadly 
similar across the cohorts, particularly when comparing CHA2DS2-VASc and HAS-BLED 
scores that guide OAC prescribing.  
There are two possible explanations for our findings. First, the availability of DOACs coupled 
with the relative efficacy, safety, and convenience associated with the use of the new agents 
compared to VKAs [288] could be the major driving factor for the increased OAC prescribing. 
Second, recent updates in AF guidelines including changes in the stroke risk scoring methods 
[9,19], increased awareness about AF, physicians becoming more familiar with stroke risk 
scoring methods [28], and promotion of DOACs by pharmaceutical companies in the 
Australian market are possible contributing factors for the overall increase in OAC prescribing.  
One limitation of this study is that it involved hospitalised AF patients who could be relatively 
more comorbid than AF patients managed in primary care. Hence, our results may not reflect 
OAC prescribing rates in AF in the community setting. Moreover, this study was conducted in 
one referral hospital in the Southern Tasmania. However, the relatively large number of 
participants over an extended study period, and the study centre being the largest referral 
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hospital in the region can improve the robustness and representativeness of our study. Missing 
values and incomplete documentations inherent to observational studies were additional 
limitations. Nonetheless, our data clearly highlighted a fundamental improvement in OAC 
prescribing in the post-DOAC era, and that DOAC subsidisation was an independent predictor 
of OAC prescribing. This improvement could be considered as an essential step towards 
addressing the commonly reported issue of OAC underuse in patients with AF [95,269].  
Overall OAC prescribing (56.5%) and anticoagulation of high-risk patients in the post-DOAC 
era was higher than an earlier study in Tasmania, which reported warfarin prescribing in 34% 
of AF patients with a high risk of stroke [289]. A more recent study from three Tasmanian 
hospitals indicated 52.5% OAC prescribing in high-risk patients with AF, lower than OAC 
prescribing rate in the post-DOAC era in our study [290]. The post-DOAC era anticoagulation 
rate in this study was comparable to a large observational data in the USA that showed 61.8% 
OAC prescribing among high-risk patients with AF [291]. However, our result was lower than 
two European registry studies: 70.9% OAC prescribing in high-risk patients in EORP-AF [278] 
and 85.6% in PREFER-AF [176]. 
Although anticoagulation of AF patients had improved in the post-DOAC era, OAC underuse 
in the high-risk and overuse in the low-risk groups was apparent in both eras. Furthermore, 
APT therapy was widely used among high-risk patients in both eras (38.9% and 28.2% in the 
pre- and post-DOAC eras, respectively). APT agents were prescribed more commonly in this 
study than in the PREFER-AF (12.2%) [176] and GLORIA-AF (10.0%) [270] registry studies. 
This is despite observational studies having demonstrated APT therapy in AF is less effective 
and no safer than OAC therapy [292]. A potential reason for the lower OAC and higher APT 
prescribing rates in this study compared to the European studies is the impact of guidelines. 
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Recently updated European AF guidelines no longer recommend APT agents in AF [76], 
however a current national guideline for the management of AF is lacking in Australia.  
We also identified factors associated with OAC prescribing in the pre-DOAC, post-DOAC, 
and overall study period. Patients admitted in the post-DOAC era vs those admitted in the pre-
DOAC era were more likely to receive an OAC. Conversely, our study confirmed the findings 
of prior studies that older age and perceived risk of bleeding were potent negative predictors 
of OAC prescribing in patients with AF [20]. In line with guideline recommendations, 
CHA2DS2-VASc ≥ 2 was a significant predictor of OAC prescribing in all the study periods. 
Despite studies demonstrating an increased stroke risk in females [125,293], males in the pre-
DOAC era and overall study period had greater odds of being prescribed OACs than females. 
Nonetheless, women in our study population were older and at higher stroke risk than men 
(data not shown). Previous data from large observational studies also revealed lower odds of 
OAC prescribing in female patients with AF [291,294]. This may reflect under appreciation of 
gender as a risk factor for stroke in the practice settings despite guideline recommendations.   
When documented reasons for not prescribing an anticoagulant were analysed, there was no 
significant difference in the frequency of stated reasons between the two eras. This suggests 
that the availability of DOACs has yet to change the way prescribers and patients think about 
OAC in AF. Our results were consistent with other studies that indicated aging, falls risk, 
physicians’ fear of bleeding, and patients’ abilities to comply with treatment as major barriers 
to OAC prescribing [295-297]. However, observational studies showed bleeding risk in aging 
and falling risk are overestimated and should not deter OAC prescribing in AF [298].  
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The present study provides empirical data regarding contemporary OAC prescribing in patients 
with AF now that the DOACs are feasible options in Australian clinical practice. This 
information is important given the limited studies regarding the impact of DOACs on 
Australian anticoagulation practices. Although there was an improvement in OAC prescribing, 
driven perhaps by the widespread availability of DOACs, the anticoagulation rate among high-
risk patients in our study was lower than the rates reported in recent European studies 
[176,278]. While OAC underuse in high-risk patients persisted in the post-DOAC era, there 
was an apparent increase in OAC overuse in low-risk patients. Despite the widespread 
availability of DOACs, more than a third of high-risk patients without a contraindication to 
OAC therapy did not receive the therapy. Conversely, 42.9% of low-risk patients in the post-
DOAC era received OAC therapy showing suboptimal use of risk stratification methods to 
determine OAC prescribing in AF. This suggests the need for further improvement towards 
optimal OAC prescribing for better stroke prevention in AF. Recent European AF guidelines 
recommend OAC for all patients with AF at moderate or high risk of stroke [76]. Widespread 
availability of DOACs [294,299], and increased awareness regarding AF [294,300] have 
improved OAC prescribing rates in Europe. Similar initiatives including national guideline 
development with a clear recommendation regarding OAC and APT prescribing in moderate-
risk patients, interventions to strengthen adherence to guidelines, and education focusing on 
the importance of tailoring OAC to patients’ stroke risk may have a role in optimising 
prescribing practices in Australia.  
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4.6  Conclusion 
A significant increase in OAC prescribing was observed in the post-DOAC era, and the 
increment appeared to be largely driven by the availability of DOACs. However, OAC 
underuse in high-risk and overuse in low-risk patients was apparent throughout our study. 
These findings highlight the need to identify the drivers of anticoagulant under- and over-use 

















5. Thromboembolism and mortality in the Tasmanian atrial fibrillation 
study. 
Overview  
This study aimed to address the third objective of the thesis. Results from the prior analyses 
(Chapters 3 and 4) indicated a progressive shift towards prescribing of DOACs and an overall 
increase in the prescribing of anticoagulants to patients with AF. The present analysis was built 
on the previous findings by focusing on investigating the impact of the general availability of 
DOACs on clinical outcomes (thromboembolism and all-cause mortality rates). It also 
compared outcomes between antithrombotic groups and identified factors that influenced the 
risk of incident thromboembolism and all-cause mortality in patients with AF. The results 
suggested a significant reduction in the incidence rates of embolic events and all-cause 
mortality in AF following general availability of DOACs. This study was published in 









Background: While utilisation of anticoagulation in patients with atrial fibrillation (AF) has 
increased in recent years, contemporary data regarding thromboembolism and mortality 
incidence rates are limited outside of clinical trials. This study aimed to investigate the impact 
of direct oral anticoagulants (DOACs) on clinical outcomes of patients with AF included in the 
Tasmanian Atrial Fibrillation Study (TAFs). 
Methods: The medical records of all patients with a primary or secondary diagnosis of AF who 
presented to public hospitals in Tasmania, Australia, between 2011 and 2015 were 
retrospectively reviewed. We investigated overall thromboembolic events (TEs), ischaemic 
stroke/transient ischaemic attack (IS/TIA), and mortality incidence rates in patients admitted 
to the Royal Hobart Hospital, the main teaching hospital in the state. We compared outcomes 
in two-time periods; prior to the availability of DOACs (pre-DOAC; 2011 to mid-2013), and 
following their general availability after Government subsidisation (post-DOAC; mid-2013 to 
2015). 
Results: Of the 2,390 patients with AF admitted during the overall study period, 942 patients 
newly prescribed an antithrombotic medication (465 and 477 from the pre-DOAC and post-
DOAC time periods, respectively) were followed. We observed a significant decrease in the 
incidence rates of overall TE (3.2 vs 1.7 per 100 PY, p < 0.001) and IS/TIA (2.1 vs 1.3 per 100 
PY, p = 0.022) in the post-DOAC compared to the pre-DOAC period. All-cause mortality was 
significantly lower in the post-DOAC period (2.9 vs 2.2 per 100 PY, p = 0.028). Increasing 
age, prior stroke, and admission in the pre-DOAC era were all risk factors for TE, IS/TIA, and 
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mortality in this study population. The risk of IS/TIA was more than doubled (HR 2.54, 95% 
CI 1.17-5.52) in current compared to ex- and non-smokers. 
Conclusion: TE and all-cause mortality rates were lower following the widespread availability 
of DOACs in this population.  
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5.2 Introduction  
Atrial fibrillation (AF) increases the risk of thromboembolic events including ischaemic stroke, 
transient ischaemic attack (TIA), pulmonary embolism (PE), and myocardial infarction (MI), 
and significantly increases the risk of morbidity and mortality [154]. The association between 
AF and stroke is well-established. Population studies demonstrate that patients with AF have a 
5-fold increase in their risk of stroke, and up to 25% of all patients with stroke have AF as their 
admission diagnosis [153,301]. Compared to AF-related stroke, less is known regarding the 
relationship between AF and other systemic embolic events (PE or deep venous thrombosis 
(DVT)) and MI. Observational data, however, show AF to be an important risk factor for these 
events [302,303]. A prospective cohort study by Soliman et al. involving 23,928 participants 
reported that AF was independently associated with a 2-fold increased risk of incident MI [304].  
Epidemiological research shows that the prevalence of AF is rising globally [3,28]. This is 
likely to result in a substantial increase in hospital admissions and mortality due to AF-related 
cardiovascular complications in the future. Encouragingly, observational data from clinical 
practice and large AF registry studies have suggested that the proportion of patients with AF 
receiving OACs for stroke prevention is also increasing [176,305]. The major reasons for the 
growing rates of anticoagulation include the recent availability of DOACs [305], updated AF 
guidelines [9,177], and improved awareness about the importance of stroke prevention in AF 
[28,36].  
DOACs were subsidised for stroke prevention in non-valvular AF in Australia in August 2013 
in the hope that they would improve the clinical outcomes of patients and reduce the burden of 
AF-related stroke in the community. DOACs were rapidly adopted by prescribers, and by mid-
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2015 almost 70% of anticoagulated patients with AF presenting to the Royal Hobart Hospital 
(RHH) received a DOAC [269,274]. The Tasmanian AF study (TAFs) was established in 2012 
to monitor prescribing trends and patient outcomes in Tasmania, Australia, over time. Our 
previous analyses have focused on assessing the patterns of antithrombotic prescribing and the 
quality of anticoagulation practices in AF [284,305]. In this analysis, we aimed to investigate 
the impact of the availability of DOACs on the thromboembolic event (TE)-related 
readmissions of patients with AF. Our specific objectives were to: 1) compare thromboembolic 
and mortality rates in patients commenced on antithrombotic therapy prior to and following 
the availability of DOACs, and 2) identify factors that influenced the risk of incident 
thromboembolism and all-cause mortality in patients with AF. 
5.3 Methods 
5.3.1 Study design and participants 
This was a retrospective observational study involving consecutive patients with AF admitted 
between 2011 and 2015 to the RHH, Tasmania, Australia. Patients were identified using the 
Australian Refined Diagnosis Related Groups, AR-DRG code-I48 for AF or flutter (referred to 
as AF hereafter). The Tasmanian Health and Medical Human Research Ethics Committee 
approved this study and informed consent was waived as the study was retrospective in nature 
and considered low risk. Patients’ baseline demographics, comorbidities, and prescribed 
medications were obtained by reviewing digital medical records. Baseline stroke and bleeding 
risk scores were calculated using the CHA2DS2-VASc (Cardiac failure, Hypertension, Age ≥ 
75, Diabetes mellitus, Stroke, Vascular disease, Age 65–74 and Sex category-female) and 
HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
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predisposition, Labile international normalised ratio (INR) - if documented in medical records, 
Elderly, Drugs or alcohol use > 8 drinks/week) scoring methods, respectively [125,127]. Labile 
INR was defined as an unstable or high INR (INR > 3) as recorded in the medical records. The 
Charlson Comorbidity Index (CCI) was used to quantify and compare comorbid conditions 
among groups [273]. The CCI, CHA2DS2-VASc, and HAS-BLED scores were estimated based 
on demographic variables and comorbidities diagnosed before or during index admissions. An 
index admission was defined as the participants’ first hospitalisation to our study setting with 
AF as a primary or secondary diagnosis. Readmissions were subsequent hospitalisations after 
the index admission during the study period.    
5.3.2 Follow-up and outcomes 
To compare baseline characteristics, identify risk factors, and quantify incidence rates, patients 
were grouped according to the presence or absence of thromboembolism diagnosed at index 
admission or readmissions during follow-up. A TE was defined as a composite outcome 
including IS/TIA, other systemic embolic events (PE or DVT), and MI (ST-segment or non-
ST elevation MI). Hospitalisations due to TEs were ascertained by reviewing the medical 
records where these comorbidities were documented as a primary or secondary diagnosis 
during the study period. Only the first TE was used in the analyses.   
Analysis of TE and mortality incidence rates involved patients with AF newly initiated on an 
antithrombotic therapy at their index admissions. Exposure to an antithrombotic therapy at the 
discharge of index admissions was stratified according to the prescription of warfarin, DOACs, 
and APT agents (prescribed without an anticoagulant). For each patient, follow-up began 
immediately after treatment initiation and continued to the first TE, treatment change, treatment 
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discontinuation, in-hospital mortality, or end of the study period, whichever came first. For 
comparative purposes, we grouped study participants based on their index admission dates as 
follows: 1) pre-DOAC period - admissions between January 2011 and July 2013, and 2) post-
DOAC period - admissions between August 2013 and July 2015. Finally, TE and all-cause in-
hospital mortality incidence rates were also compared by treatment category initiated at the 
discharge of index hospitalisations. 
5.3.3 Definitions of antithrombotic exposure, switch or discontinuation   
Exposure to an antithrombotic (new initiation) was defined as discharge with an antithrombotic 
medication in patients with AF who did not have a documented history of being prescribed an 
antithrombotic prior to their index hospitalisation. We considered treatment to be discontinued 
when patients previously receiving thromboprophylaxis were discharged without any 
antithrombotic at subsequent readmissions, because of an emergence of contraindications, or 
without documented reasons, for an unspecified period. An antithrombotic switch was defined 
as a change from one type of antithrombotic to another that occurred during a readmission.  
5.3.4 Statistical analysis  
All statistical analyses were executed using R, version 3.2.5 (R Foundation for Statistical 
Computing, Vienna, Austria, https://www.r-project.org/). Baseline patient characteristics were 
presented using descriptive statistics. Continuous variables were summarised as means and 
standard deviations (SD), and group differences were compared using Analysis of variance or 
independent samples Student’s t-tests. Categorical variables were summarised as frequencies 
and proportions, and differences were tested using Chi-square or Fisher exact-tests, as 
appropriate. 
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We pooled IS/TIA, other systemic embolic events, and MI into a composite end point as overall 
TEs. Further, we pooled IS/TIA, and other systemic embolic events as another composite end 
point, and also completed an additional analysis for IS/TIA events only. The all-cause mortality 
incidence rate was estimated by following patients from the date of index hospitalisation to 
death or the end of the study period. For all outcomes, the first event after AF diagnosis was 
included regardless of whether the patient had a prior history of thromboembolism. However, 
all TEs occurring on the same day as AF diagnosis were excluded from the incidence analysis. 
Incidence rates and corresponding 95% confidence intervals (CIs) were calculated as the 
number of the first event in each category divided by the total patient-years (PY) at risk for a 
particular outcome within the observation period. All of the events were expressed as rates/100 
PY of follow-up.  
Cox proportional hazards regression analyses adjusted for baseline covariates were performed 
to identify risk factors for overall TE, IS/TIA, and all-cause mortality. The proportional hazards 
assumption was tested using scaled Schoenfeld residuals and was found appropriate for all the 
models. Risk relationships were presented as hazard ratios (HRs) and 95% CIs. P < 0.05 was 
considered statistically significant for all analyses. 
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5.4 Results  
5.4.1 Patient demographics and clinical characteristics  
During the study period (January 2011 to July 2015), we identified 2,390 patients with AF as 
a primary or secondary diagnosis. In total, 384 (16.1%) patients experienced thromboembolic 
complications during their index hospitalisation or at readmissions during follow-up; 264 
(68.8%) had IS/TIA, 90 (23.4%) had MI, and 30 (7.8%) had other systemic embolic events 
including PE and DVT. Baseline characteristics of the overall study population and those 
admitted with thromboembolism are detailed in Table 12. Current smoking, hypertension, 
ischaemic heart disease, and a history of prior stroke were significantly more frequent in 
patients admitted with thromboembolic complications than those admitted due to other causes. 
Moreover, patients who experienced TEs were older (mean age 77.6 vs 74.2 years, p < 0.001), 
had higher stroke and bleeding risk scores (mean CHA2DS2VASc score 3.7 vs 3.1, and mean 
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Table 12. Baseline characteristics (overall and by thromboembolic events).   





All patients  
(n = 2390) 
Yes€ 
(n = 384) 
No  
(n = 2006) 
Age 75.1 (11.5) 77.6 (9.8) 74.2 (11.7) < 0.001 
Female  1068 (44.7) 166 (43.2) 902 (45.0) 0.568 
Smoking history* 897 (38.1) 153 (39.9) 744 (37.1) 0.339 
Current smoking 195  (8.2) 43 (11.2) 152 (7.6) 0.023 
Alcohol (>8 units/week) 160 (6.7) 27 (7.0) 133 (6.6) 0.859 
CCI, mean (SD) 4.4 (2.2) 4.6 (1.8) 4.4 (2.2) 0.193 
Hypertension  1469 (61.5) 273 (71.1) 1196 (59.6) < 0.001 
Ischaemic heart disease  721 (23.9) 136 (35.4) 585 (29.2) 0.017 
Diabetes mellitus 518 (21.7) 79 (20.6) 439 (21.9) 0.614 
Chronic respiratory disease 495 (20.7) 64 (16.7) 431 (21.5) 0.039 
Congestive heart failure 454 (19.0) 52 (13.5) 402 (20.0) 0.004 
Chronic renal diseases 232 (9.7) 32 (8.3) 200 (10.0) 0.369 
Valvular heart diseases 224 (9.4) 42 (10.9) 182 (9.1) 0.292 
History of stroke  166 (6.9) 74 (19.3) 92 (4.9) < 0.001 
Previous embolic diseases¥ 113 (4.7) 20 (5.2) 93 (4.6) 0.724 
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  TE-related admission  
p-value  
Characteristics  
All patients  
(n = 2390) 
Yes€ 
(n = 384) 
No  
(n = 2006) 
CHA2DS2-VASc, mean (SD) 3.2 (1.5) 3.7 (1.4) 3.1 (1.2) < 0.001 
CHA2DS2-VASc = 0 97 (4.1) 6 (1.6) 91 (4.5)  
CHA2DS2-VASc = 1 236 (9.9) 26 (6.8) 210 (10.5)  
CHA2DS2-VASc ≥ 2 2057 (86.1) 352 (91.7) 1705 (85.0)  
HAS-BLED, mean (SD) 2.2 (0.7) 2.5 (0.8) 2.2 (0.7) < 0.001 
Abbreviations: CCI, Charlson comorbidity index; SD, standard deviation; TE, 
thromboembolic event. *Includes current and ex-smokers. € Includes thromboembolic event 
(stroke/transient ischaemic attack, systemic embolism and myocardial infarction) diagnosed at 
index admission or readmissions.  ¥Includes patients with history of deep venous thrombosis 
and pulmonary embolism. 
5.4.2 Thromboembolic and mortality incidence rates 
Thromboembolic and mortality incidence rates categorised by admission eras and treatment 
groups are presented in Tables 13 and 14, respectively. A total of 942 patients (465 from the 
pre-DOAC and 477 from the post-DOAC era) newly initiated on antithrombotic therapy at 
their index admission were included for this analysis. The mean follow-up duration for the pre- 
and post-DOAC cohorts were 1,204 and 863 PY, respectively. Overall, 54 patients (39 from 
the pre-DOAC and 15 from the post-DOAC time periods) experienced TE during follow-up.  
A significant reduction was observed in the incidence rates of overall TEs, TE/TIA or systemic 
embolic events, IS/TIA events, and all-cause mortality in the post-DOAC compared to the pre-
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DOAC era. During follow-up, TE occurred in 39 patients in the pre-DOAC and 15 patients in 
the post-DOAC group (3.2 vs 1.7 per 100 PY, p <0.001). Combined IS/TIA or other systemic 
embolic events occurred in 29 patients in the former and 13 patients in the later period (2.4 vs 
1.5 per 100 PY, P = 0.014). Similarly, IS/TIA events occurred in 25 and 11 patients in the pre- 
and post-DOAC groups, respectively (2.1 vs 1.3 per 100 PY, p = 0.022). Furthermore, the 
incidence rate of all-cause mortality was significantly lower in the post-DOAC era than in the 
pre-DOAC era (2.9 vs 2.2 per 100 PY, p = 0.028).  
When TE incidence rates were analysed by antithrombotic prescribing at the discharge of the 
index hospitalisations, lower rates of overall TE and combined IS/TIA or other systemic 
embolic events were observed in patients initiated on DOACs than in the warfarin and APT 
only cohorts. Mean follow-up durations by treatment category were: 894 PY for warfarin, 208 
PY for DOACs, and 488 PY for APT agents. The overall TE incidence rates per 100 PY were: 
3.2 in the warfarin, 1.9 in the DOAC, and 4.3 in the APT agent groups (p = 0.002 for the group 
comparison). Moreover, IS/TIA or other systemic embolism incidence rates per 100 PY were: 
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Table 13.  Thromboembolism and all-cause mortality incidence rates in patients with atrial fibrillation by admission era. 
 Pre-DOAC era (n = 465)  Post-DOAC era (n = 477)   
p value  Event  Rate per 100 PY (95% CI) Event  Rate per 100 PY (95% CI) 
Overall TEs¥ 39 3.2 (2.3 – 4.4)  15 1.7  (1.0 – 2.9) < 0.001 
IS/TIA or SE 29 2.4 (1.6 – 3.5)  13 1.5 (0.8 – 2.6) 0.014 
IS/TIA 25  2.1 (1.4 – 3.1)  11 1.3 (0.7 – 2.3) 0.022 
MI  10 0.8 (0.4 – 1.6)  2 0.2 (0.0 – 0.9) 0.038 
SE* 4 0.3 (0.1 – 0.9)  2 0.2 (0.0 – 0.9) 0.446 
Fatal stroke/TIA  5 0.4 (0.1 – 1.0)  4 0.5 (0.2 – 1.4) 0.750 
All-cause morality 35 2.9 (2.1 – 4.1)  19 2.2 (1.4 – 3.5) 0.028 
Abbreviations: TEs, thromboembolic events; IS, ischaemic stroke; TIA, transient ischaemic attack; SE, systemic embolic event; MI, myocardial 
infarction; DOAC, direct oral anticoagulant; PY, patient-years; CI, confidence interval. * Includes other systemic embolic diseases such as deep 
venous thrombosis and pulmonary embolism. ¥ Includes ischaemic stroke/transient ischaemic attack, systemic embolism and myocardial infarction.  
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Warfarin (N=431)   
 
DOAC (N=258)  
 




p value  
 
Events 
Rate per 100 
PY (95% CI) 
 
Events  
Rate per 100  
PY (95% CI) 
 
Events 
Rate per 100  
PY (95% CI) 
Overall TE¥  29 3.2 (2.2 – 4.7)  4 1.9 (0.6 – 5.2)  21 4.3 (2.7 – 6.6)  0.002 
IS/TIA or SE 23 2.6 (1.7 – 3.9)  4 1.9 (0.6 – 5.2)  15 3.1 (1.8 – 5.1)  0.027 
IS/TIA 20 2.2 (1.4 – 3.5)  4 1.9 (0.6 – 5.2)  12 2.5 (1.3 – 4.4)  0.082 
MI  6 0.7 (0.3 – 1.5)  0 0.0   6 1.2 (0.5 – 2.8)  0.060 
SE* 3 0.3 (0.1 – 1.1)  0 0.0   3 0.6 (0.2 – 1.9)  0.217 
Fatal stroke  5 0.5 (0.2 – 1.4)  0 0.0   4 0.8 (0.3 – 2.2)  0.114 
Abbreviations: DOAC, direct oral anticoagulant; TE, thromboembolic event; IS, ischaemic stroke; TIA, transient ischaemic attack; MI, myocardial 
infarction; SE, systemic embolism; PY, patient-years; CI, confidence interval. * Includes other systemic embolic diseases such as deep venous 
thrombosis and pulmonary embolism. ¥ Includes ischaemic stroke/transient ischaemic attack, systemic embolism and myocardial infarction. 
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5.4.3 Factors that influenced the risk of thromboembolism and mortality 
Table 15 summarises Cox regression analysis results for the risk factors associated with overall 
TEs (IS/TIA, other systemic embolic events, MI), IS/TIA, and all-cause mortality. After 
adjusting for baseline covariates, independent risk factors associated with the incidence of 
overall TEs were: increasing age (HR 1.03, 95% CI 1.01–1.05), hypertension (HR 1.81, 95% 
CI 1.08 – 3.46), history of prior stroke (HR 2.56, 95% CI 1.08 – 5.22), and MI (HR 1.17, 95% 
CI 1.05 – 1.68). Furthermore, admission in the pre-DOAC era (relative to admission in the 
post-DOAC era) was also significantly associated with an incident risk of TE (HR 1.21, 95% 
CI 1.02 –1.84).  
Independent risk factors for incident IS/TIA included increasing age (HR 1.04, 95% CI 1.01 – 
1.07), current smoking (HR 2.54, 95% CI 1.17 – 5.52), hypertension (HR 2.63, 95% CI 1.42 – 
4.26), prior stroke (HR 3.57, 95% CI 1.57 – 5.12), and hospitalisation in the pre-DOAC era 
(HR 1.42, 95% CI 1.02 – 2.37). Finally, risk factors independently associated with the 
incidence of all-cause mortality included: increasing age (HR 1.06, 95% CI 1.03 – 1.09), 
chronic renal diseases (HR 2.51, 95% CI 1.18 – 5.34), prior stroke (HR 2.47, 95% CI 1.11 – 
5.48), MI (HR 2.62, 95% CI 1.38 – 4.98), and admission in the pre-DOAC era (HR 1.30, 95% 
CI 1.07 – 2.36). Sex category, alcohol use (> 8 units /week, as documented on the patients’ 
medical records), a history of congestive heart failure, diabetes mellitus, chronic respiratory 
disease, ischaemic heart disease, valvular heart diseases, and other systemic embolic events 
were not significantly associated with the risk of overall TEs, IS/TIA, and all-cause mortality 
in this study population. 
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Table 15. Factors that influenced the risk of thromboembolism and all-cause mortality.   
 
Characteristics  
Overall TEs   IS/TIA   All-cause mortality  
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age 1.03 (1.01 – 1.05) 0.026  1.04 (1.01 – 1.07) 0.023  1.06 (1.03 – 1.09) < 0.001 
Women  0.83 (0.42 – 1.42) 0.493  0.64 (0.35 – 1.20) 0.167  1.23 (0.71 – 2.14) 0.463 
Smoking history* 1.41 (0.82 – 2.40) 0.211  1.51 (0.81 – 2.82) 0.191  2.54 (0.97 – 2.82) 0.066 
Current smoking 2.04 (0.99 – 4.17) 0.051  2.54 (1.17 – 5.52) 0.018  1.03 (0.41 – 2.59) 0.146 
Alcohol 0.99 (0.36 – 2.75) 0.988  0.32 (0.04 – 2.34) 0.262  0.99 (0.36 – 2.77) 0.298 
Hypertension   1.81 (1.08 – 3.46) 0.035  2.63 (1.42 – 4.26) 0.007  1.05 (0.60 – 1.86) 0.854 
Ischaemic heart disease 1.33 (0.76 – 2.32) 0.318  0.91 (0.46 – 2.86) 0.836  1.14 (0.64 – 1.81) 0.663 
Diabetes mellitus 0.61 (0.28 – 1.36) 0.228  0.46 (0.16 – 1.30) 0.143  1.42 (0.77 – 2.61) 0.261 
Chronic respiratory disease 0.84 (0.41 – 1.72) 0.637  1.06 (0.49 – 2.29) 0.890  1.44 (0.78 – 2.64) 0.244 
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 Overall TEs  IS/TIA  All-cause mortality  
 HR (95% CI) p-value  HR (95% CI) p-value  HR (95% CI) p-value 
Congestive heart failure 1.60 (0.82 – 3.11) 0.164  1.32 (0.58 – 2.99) 0.503  1.75 (0.92 – 3.33) 0.087 
Chronic renal diseases  0.57 (0.14 – 2.37) 0.445  0.79 (0.19 – 3.29) 0.749  2.51 (1.18 – 5.34) 0.016 
Valvular heart disease 1.18 (0.47 – 2.98) 0.718  1.28 (0.45 – 3.61) 0.641  0.97 (0.35 – 2.69) 0.152 
History of stroke/TIA  2.56 (1.08 – 5.22) 0.021  3.57 (1.57 – 5.12) 0.002  2.47 (1.11 – 5.48) 0.026 
Myocardial infarction 1.17 (1.05 – 1.68) 0.043  1.31 (0.51 – 3.36) 0.567  2.62 (1.38 – 4.98) 0.003 
Previous embolic disease¥ 1.48 (0.46 – 4.75) 0.509  0.65 (0.09 – 4.72) 0.668  1.46 (0.56 – 4.68) 0.524 
Pre-DOAC era 1.21 (1.02 – 1.84) 0.025  1.42 (1.02 – 2.37) 0.017  1.30 (1.07 – 2.36) 0.039 
Abbreviations: TEs, thromboembolic events; IS, ischaemic stroke; TIA, transient ischaemic attack; HR, hazard ratio; CI, confidence interval; 
*Includes current and ex-smokers. ¥ Pulmonary embolism, deep venous thrombosis. 
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5.5 Discussion  
This study provides a comprehensive description of patients with AF admitted with TEs, 
identifies risk factors, and compares TE and all-cause mortality incidence rates prior to and 
following the introduction of DOACs into clinical practice. We observed a significant 
reduction in the incidence rates of TEs and all-cause mortality in patients with AF following 
the Government subsidisation of DOACs. TE incidence rates were also lower in patients 
initiated on DOACs compared to those initiated on warfarin and APT agents at index 
admissions. Furthermore, hospitalisation post-DOAC availability was associated with a 
decreased risk of overall TEs, IS/TIA, and all-cause mortality. This was despite the similarity 
in the baseline characteristics of the study participants newly initiated on antithrombotic 
therapies, particularly when we compared baseline stroke risk scores between the two time-
periods (Supplementary Table 16). The declining rates of TEs, IS/TIA, and total mortality in 
this analysis were consistent with findings that showed a declining trend of stroke and mortality 
incidence rates in AF reported from other countries [306-308].  
The explanations for these findings are likely multifactorial. First, changes in clinical practice 
such as increasing rates of OAC prescribing in recent years, driven mainly by the availability 
of DOACs, and updates in AF management guidelines, could have improved patient outcomes. 
A recent analysis of OAC prescribing in AF in the same population showed the proportion of 
patients with AF receiving OACs increased significantly over the study period [284,290]. 
Second, DOACs are increasingly used in patients with non-valvular AF in preference to 
warfarin [305,309]. Comparative analysis involving warfarin-treated patients in this study also 
indicated no significant difference in the overall TE, IS/TIA, and all-cause mortality incidence 
rates between the two eras (data not shown). This suggests the observed improvements in 
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clinical outcomes were potentially due to the increasing utilisation of DOACs in patients with 
AF rather than improvements in warfarin management. Based on trial results, this is expected 
to result in fewer complications such as ICH or other major bleeding events. Clinical trials 
demonstrated lower rates of major bleeding and mortality in patients treated using DOACs 
compared to those receiving warfarin [99,100]. In addition, observational data has shown that 
all DOACs reduced intracerebral bleeds, the most feared complication of OAC therapy in 
patients with AF, by at least 50% [310]. Meta-analysis studies also reported a significant 
decline in IS/systemic embolism and total mortality that appeared to be driven by a reduction 
in fatal bleeding in DOAC- compared to warfarin-treated patients [311-313].  
Although randomised clinical trials and the majority of observational data showed comparable 
efficacy between DOACs and warfarin in terms of stroke prevention, few studies indicated 
lower rates of thromboembolism in patients treated with DOACs than those treated with 
warfarin [314]. A real-world practice study among Asians with non-valvular AF reported a 
lower risk of IS/systemic embolism and all-cause mortality in patients with AF receiving 
dabigatran and rivaroxaban compared with patients receiving warfarin [315]. Moreover, other 
factors such as improved management of chronic diseases including hypertension, congestive 
heart failure, and diabetes mellitus could also play significant roles in the reduction of TE and 
mortality incidence rates in AF.  
AF-related TE rates in cohort studies are highly heterogeneous and have ranged from 0.45 to 
9.28 per 100 PY owing to variabilities in the study design, study setting, and the data source 
[316]. While low overall TE and IS/TIA incidence rates were observed in patients initiated on 
DOACs in this study, IS/TIA incidence rates in patients initiated on warfarin in this study were 
broadly similar to rates reported from large observational studies in Europe and Japan [317-
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319]. Our analysis showed comparable rates of IS/TIA and other systemic embolic events, but 
a lower rate of all-cause mortality than rates reported from a large nationwide observational 
study in Denmark [317]. Furthermore, no MI were observed in patients initiated on DOACs 
while the incidence rate of MI in patients initiated on warfarin in this analysis corresponded 
with a 0.7 per 100 PY MI rate in AF patients who received warfarin in the United Kingdom 
[318].  
The risk of stroke in patients with AF is high and increases in the presence of other risk factors, 
particularly those described in the validated CHA2DS2-VASc stroke risk score [125]. However, 
the contribution of some of these factors may underestimate the true risk of stroke in the real-
world patient management. For instance, a history of prior stroke is the most prominent risk 
factor for IS/TIA in AF, and the contribution of prior stroke in predicting IS/TIA recurrence is 
considered to be higher than that described in the CHA2DS2-VASc score [320,321]. Although 
existing evidence is not robust, other comorbidities and demographic factors not included in 
the CHA2DS2VASc score such as chronic renal diseases and smoking could be important risk 
factors for thromboembolism in AF. Our study builds on the available data by comparing 
previously reported risk factors and identifying concomitant comorbidities as additional risk 
factors for TE and mortality in contemporary patients with AF.      
The strongest risk factors for the overall TE and IS/TIA outcome used in this study were a 
history of stroke, followed by hypertension, admission in the pre-DOAC era, and increasing 
age. Patients with a history of prior IS/TIA had a more than 2-fold increase in the risk of overall 
TE and all-cause mortality, and more than 3-fold increase in the risk of recurrent IS/TIA than 
patients without a history of prior IS/TIA. Previous studies also showed a history of prior stroke 
as the most powerful and consistent risk factor for recurring cerebrovascular events in AF 
            
130 
 
[321,322]. Current smoking was also identified as an important risk factor for IS/TIA in our 
analysis; the risk of suffering an IS/TIA was more than doubled (HR 2.54, 95% CI 1.17 – 5.52) 
in current smokers over non-smokers and former smokers. Similarly, an observational study 
involving optimally anticoagulated patients with AF found an independent association between 
smoking and IS/TIA [320].  
The Framingham Heart Study also showed the risk of stroke in heavy smokers (> 40 
cigarettes/day) was twice that of light smokers (< 10 cigarettes/day), whereas stroke risk 
decreased significantly two years after smoking cessation [323]. Evidence from pathological 
data and clinical research established that smoking causes mainly atherothrombotic strokes, as 
opposed to cardioembolic strokes due to AF [324,325]. Such strokes are shown to be 
effectively treated by APT therapy in preference to OAC therapy [326,327]. Further studies 
should investigate the differential relationship of smoking with the risk of cardioembolic stroke, 
and outcomes of OAC vs APT therapy in smoking patients with AF.  
Patients with advanced age, chronic renal diseases, prior IS/TIA, MI, and hospitalisation in the 
pre-DOAC era (relative to the later period) were significant risk factors for all-cause mortality 
in this study. Similarly, a meta-analysis study by Gomez-Outes et al. revealed that IS/TIA and 
bleeding accounted for 6% of all deaths, with aging and decreased creatinine clearance as 
significant risk factors for mortality in patients with AF. Unlike our data, however, congestive 
heart failure, diabetes mellitus, and male sex were also significant risk factors for mortality in 
their study [328]. In conclusion, our data suggests that, in addition to optimal anticoagulation 
of patients with AF, effective control of modifiable risk factors such as smoking and 
management of comorbidities are essential to further reducing thrombosis and mortality in 
patients with AF.    
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The major strength of our study is that we include a relatively large number of participants over 
an extended observation period comprising admissions form both the pre- and post-DOAC 
time periods. However, given the observational nature of our data, there are a number of 
limitations. First, there is a potential for selection bias inherent to retrospective observational 
studies; exposure to antithrombotic therapy at index admissions was not randomised. Second, 
we were not able to capture TEs resulting in readmission to other clinical settings, minor events 
managed in local general practices, severe thromboembolic complications leading to pre-
hospital death or death occurring outside our study setting. This may underestimate the overall 
TE and mortality incidence rates observed in this study. Third, as the study population was 
hospitalised AF patients, incidence rates may not reflect clinical outcomes of AF populations 
managed in community settings. Fourth, despite statistical adjustments, there is always a 
possibility of residual confounding limiting our ability to draw causal inferences. Moreover, 
adherence to OAC therapy and its impact on patient outcome was not assessed in this study 
population. Lastly, the number of patients who experienced MI and other systemic embolism 
in both time periods was small.  
5.6 Conclusion  
In this contemporary cohort of hospitalised patients with AF, the incidence rates of TE and all-
cause mortality improved significantly following the introduction of DOACs. These improved 
clinical outcomes are likely to be multifactorial, potentially including the recent increase in 
OAC prescribing, and the use of DOACs in preference to warfarin. Patients with a history of 
stroke, increasing age, and admissions in the pre-DOAC era were most vulnerable to incident 
TEs, IS/TIA and all-cause mortality in this population. Furthermore, the risk of IS/TIA was 
more than doubled in current smokers compared to ex- and non-smokers. The results suggest 
            
132 
 
there are further opportunities to improve patient outcomes through judicious use of OACs, 
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Table 16 (Supplementary). Baseline characteristics of patients newly initiated on 




(n = 465) 
Post-DOAC era 
(n = 477) 
 
p-value  
Age, mean (SD) 74.1 (11.5) 73.1 (10.7) 0.352 
Women  189 (40.6) 219 (45.9) 0.117 
Smoking history* 195 (41.9) 169 (35.4) 0.047 
Current smoking  43 (9.2) 48 (10.1) 0.754 
Alcohol (>8 units/week) 33 (7.1) 37 (7.8) 0.793 
CCI, mean (SD) 4.3 (2.1) 4.1 (2.2) 0.249 
Hypertension  323 (69.5) 278 (58.3) 0.001 
Ischaemic heart disease  155 (33.3) 107 (22.4) < 0.001 
Diabetes mellitus 98 (21.1) 99 (20.7) 0.967 
Chronic respiratory disease 95 (20.4) 95 (19.9) 0.908 
Congestive heart failure 68 (14.6) 73 (15.3) 0.840 
Renal diseases 30 (6.4) 42 (8.8) 0.216 
Valvular heart diseases 38 (8.2) 29 (6.1) 0.262 
History of stroke  19 (4.1) 44 (9.2) 0.002 
Peptic ulcer diseases 36 (7.7) 14 (2.9) 0.002 
Previous embolic diseases¥ 21 (4.5) 21 (4.4) 1.000 
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Characteristics  Pre-DOAC era Post-DOAC era p-value  
CHA2DS2-VASc, mean (SD) 3.1 (1.5) 3.1 (1.6) 0.708 
HAS-BLED, mean (SD) 2.2 (0.7) 2.1 (0.8) 0.656 
Abbreviations: DOAC, direct oral anticoagulant; CCI, Charlson comorbidity index; SD, standard 
deviation; *Includes current and ex-smokers. ¥Includes patients with history of deep venous thrombosis 
















6.  Bleeding-related remissions in patients with atrial fibrillation receiving 
antithrombotic therapy: results from the Tasmanian atrial fibrillation 
study. 
Overview  
This analysis aimed to address the fourth objective of the thesis, i.e. to quantify and compare 
bleeding rates among patients newly initiated on antithrombotic therapies (warfarin, DOACs, 
APT agents), and identify factors associated with bleeding. The results showed low overall and 
major bleeding rates relative to other observational data. The rate of major bleeding was lower 
in DOAC- than warfarin-treated patients. Increasing age, a history of prior bleeding, treatment 
using warfarin, and multiple antithrombotic therapies were independent predictors of bleeding. 
Our findings suggested that stroke prevention using DOACs, in preference to warfarin, and 
avoiding multiple antithrombotic therapies, especially in the elderly patients with AF, have the 
potential to reduce bleeding events. This analysis was published in the European Journal of 








Background and aims: Limited data is available from the Australian setting regarding 
bleeding in patients with atrial fibrillation (AF) receiving antithrombotic therapy. We aimed to 
investigate the incidence of hospital admissions due to bleeding and factors associated with 
bleeding in patients with AF who received antithrombotic therapy.  
Methods: A retrospective cohort study was conducted involving all patients with AF admitted 
to the Royal Hobart Hospital, Tasmania, Australia, between January 2011 and July 2015. 
Bleeding rates were calculated per 100 patient-years (PY) of follow-up, and multivariable 
modelling was used to identify predictors of bleeding.  
Results: Of 2,202 patients receiving antithrombotic therapy, 113 presented to the hospital with 
a major or minor bleeding event. These patients were older, had higher stroke and bleeding risk 
scores, and were more often treated with warfarin and multiple antithrombotic therapies than 
patients who did not experience bleeding. The combined incidence of major and minor 
bleeding was significantly higher in warfarin- versus DOAC- and APT-treated patients (4.1 vs 
3.0 vs 1.2 per 100 PY, respectively; p = 0.002). Similarly, the rate of major bleeding was higher 
in patients who received warfarin than in the DOAC and APT cohorts (2.4 vs 0.4 vs 0.6 per 
100 PY, respectively; p = 0.001). In multivariate analysis, increasing age, prior bleeding, 
warfarin, multiple antithrombotic therapy and high HAS-BLED scores were independently 
associated with bleeding.  
Conclusion: The overall rate of bleeding in this cohort was low relative to similar 
observational studies. The rate of major bleeding was higher in patients prescribed warfarin 
compared to DOACs, with a similar rate of major bleeding for DOACs and APT agents. Our 
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findings suggest potential strategies to reduce bleeding include using DOACs in preference to 
warfarin, and avoiding multiple antithrombotic therapy in patients with AF.     
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6.2 Introduction  
Atrial fibrillation (AF) is a major risk factor for stroke and judicious use of OACs is essential 
in its management. Bleeding events, however, are common complications of OAC therapy in 
patients with AF [329]. Major bleeding during OAC therapy is associated with high morbidity 
and mortality [330,331]. Minor bleeding events also have prognostic importance as they 
frequently lead to major bleeding, interruption of antithrombotic therapy, ischaemic stroke, and 
death [332]. In recent years, antithrombotic therapies have been increasingly used in patient 
groups at higher risk of bleeding [333]. This trend appears to be driven by improved AF 
screening practices [28,334], changes to AF treatment guidelines [9,10], and the availability of 
DOACs in clinical practice [269]. Moreover, observational studies showed hospitalisation due 
to antithrombotic-associated bleeding are increasing [335,336].     
DOACs became available in Australian clinical practice in 2011 with the uptake of the new 
agents increasing rapidly following their listing on the Australian Pharmaceutical Benefits 
Scheme (PBS) for subsidy by the government in August and September 2013 [309]. 
Nonetheless, little is known regarding characteristics of patients experiencing bleeding, and the 
comparative frequency of bleeding in patients with AF receiving DOACs, warfarin, and APT 
agents in the Australian clinical setting. In this study, we aimed to investigate: 1) the 
characteristics of patients with AF admitted with bleeding, 2) bleeding rates among patients 
newly initiated on antithrombotic therapies, and 3) factors associated with bleeding in patients 
with AF receiving antithrombotic therapy.  




6.3.1 Study design  
The Tasmanian Atrial Fibrillation (TAF) study is a retrospective cohort study, which followed 
patients with AF who were admitted to public hospitals in Tasmania, Australia between 2011 
and 2015. The aims and methods of the TAF study have previously been described [137,284]. 
For this analysis, all patients diagnosed with AF (Australian Redefined Diagnosis Related 
Groups, AR-DRG code I48), and admitted to the Royal Hobart Hospital (RHH) between 
January 2011 and July 2015 were included. The RHH is the largest referral hospital in 
Tasmania, and services a population of approximately 240,000 people in the south of the State. 
An index admission was defined as the patients’ first admission, with AF as a primary or 
secondary diagnosis, and readmissions were subsequent admissions after the index admission 
during our study period.    
6.3.2 Patient demography and comorbidities  
Demographic and medical data were obtained from the patients’ digital medical records and 
entered into an online database. Stroke risk score was calculated using the CHA2DS2-VASc 
(one point each for Congestive heart failure, Hypertension, Diabetes mellitus, Vascular 
diseases, Sex category-females, Age 65-74 years, and two points for Age ≥ 75 years and Stroke 
or transient ischaemic attack) method [125]. Bleeding risk was calculated using HAS-BLED 
(Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, 
Labile INR (if documented), Elderly age > 65 years, Drugs/APT agents, nonsteroidal anti-
inflammatory drugs or alcohol use > 8 units/week) method [127]. The Charlson Comorbidity 
Index (CCI) was calculated to compare comorbidity [273].   
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6.3.3 Readmissions and cohorts  
Patients who received antithrombotic medications (warfarin, DOACs, APT agents, heparin or 
derivatives) before, during, or at discharge of their index admission were reviewed 
retrospectively for bleeding-related hospitalisation. Major bleeding was defined according to 
the criteria of  the International Society of Thrombosis and Haemostasis (ISTH) [337] as fatal 
bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraocular, 
retroperitoneal, intraspinal, intra-articular), bleeding causing a decrease in haemoglobin level 
≥ 20 g/L, or documented transfusion of at least 2 units of whole blood or red blood cells (RBC). 
Minor bleeding included events such as epistaxis, haematuria, or other bleeding events not 
under the definition of major bleeding.  
To summarise and compare patient characteristics, patients were grouped according to the 
presence or absence of antithrombotic-related bleeding diagnosed at index admission or 
readmissions during the study period. The combined rate of bleeding events included both 
major and minor bleeding events diagnosed at index admission or readmissions. Only the first 
bleeding event was used to assess patient characteristics, and identify factors associated with 
bleeding. Analysis of the bleeding incidence rate was limited to patients newly initiated on 
antithrombotic therapies in three groups: i) warfarin, ii) DOACs (with or without APT therapy 
for both groups), and iii) single or dual-APT therapy.  Subjects were followed from treatment 
initiation to the first bleeding event, treatment discontinuation, antithrombotic switch, death or 
end of the study period, whichever occurred first.  
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6.3.4 Statistical analysis  
Baseline characteristics and treatment related information of patients with and without bleeding 
were presented using descriptive statistics. Continuous variables were presented as mean + 
standard deviations and categorical variables as frequencies and percentages. Comparative 
analyses were performed using the independent sample t-test and chi-square or Fisher’s exact 
test, as appropriate. The incidence rates of bleeding (combined, major, and minor bleeding) 
were calculated as the number of first bleeding events divided by the total time at risk for 
bleeding within the study period. Bleeding incidence rates were expressed as rates/100 patient-
years (PY) of follow-up. We calculated early bleeding rates by dividing bleeding events 
occurring within 90 days of follow-up after initiating therapy by the total time at risk of patients 
within three months.  
We used Kaplan-Meier curves to present the cumulative incidence of bleeding and the survival-
free rates between treatment groups were compared using the long-rank test. Multivariate 
logistic regression adjusted for a set of baseline variables was used to identify independent 
predictors of bleeding. We followed a purposeful selection of covariates and variables having 
a significant univariate test (p < 0.25) were included in the multivariate model. Collinearity 
among predictor variables was checked using the variance inflation factor (VIF), and variables 
with VIF ≤ 3 were included in the final model. All statistical analyses were conducted using R, 








6.4.1 Baseline patient characteristics   
Among the 2,202 patients with AF who received antithrombotic therapy, a bleeding event 
occurred in 113 patients, of whom 68 (60.2%) and 45 (39.8%) had major and minor bleeding 
events, respectively. The overall event rates were 5.1%, 3.1% and 2.0% for any bleeding-
related event, major bleeding and minor bleeding, respectively. The most frequent bleeding 
event by bleeding site was gastrointestinal (38.9%) followed by intracranial haemorrhage (ICH) 
(36.3%), while bleeding events from other sites accounted for 24.8% of cases. Bleeding was 
fatal in 14 (12.4%) patients; all of these patients suffered an ICH. The baseline characteristics 
of patients admitted due to bleeding or other causes are summarised in Table 17. 
There was no significant difference in the frequency of most characteristics between the two 
groups. However, patients with bleeding were older, suffered greater comorbidity (mean CCI 
score 4.9 vs 4.5, p = 0.047) and had higher stroke and bleeding risk scores (mean CHA2DS2-
VASc score 3.6 vs 3.3, p = 0.022, and mean HAS-BLED score 2.7 vs 2.3, p < 0.001, 
respectively) than patients who did not experience bleeding. Compared with those admitted for 
other reasons, patients admitted with bleeding were more frequently treated with warfarin and 
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Table 17. Baseline characteristics of study population by bleeding status.  
 
Characteristics  
Antithrombotic-related bleeding    
p-value   Yes (n = 113) No (n = 2089) 
Demographics  Age, mean (SD) 78.9 (8.4) 75.2 (11.0) < 0.001 
Sex, females, n (%) 42 (37.2) 923 (44.2) 0.172 
Smoking *, n (%) 38 (33.6) 796 (38.1) 0.392 
Alcohol ( > 8 units/week) 6 (5.3) 142 (6.8) 0.673 
Comorbidities 
    n (%) 
Hypertension  65 (57.5) 1321 (63.2) 0.261 
Ischaemic heart diseases 38 (33.6) 665 (31.8) 0.768 
Diabetes mellitus 29 (25.7) 469 (22.4) 0.497 
Congestive heart failure 22 (19.5) 409 (19.6) 1.000 
Myocardial infarction  17 (15.0) 239 (14.4) 0.311 
Valvular heart disease 14 (12.4) 204 (9.8) 0.454 
Renal diseases 13 (11.5) 206 (9.9) 0.684 
History of stroke 10 (8.8) 150 (7.2) 0.631 
Cerebrovascular disease 8 (7.1) 123 (5.9) 0.751 
History of bleeding  6 (6.2) 31 (1.5) 0.010 
 Peripheral vascular disease 3 (2.6) 84 (4.0) 0.623 
CCI, mean (SD) 4.9 (1.9) 4.5 (2.1) 0.047 
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Characteristics Antithrombotic-related bleeding   p-value 
  Yes (n = 113) No (n = 2089) 
CHA2DS2-VASc, mean (SD) 3.6 (1.5) 3.3 (1.5) 0.022 




Warfarin  79 (69.9) 900 (43.1) < 0.001 
DOAC 19 (16.8) 382 (18.3)  
APT 15 (13.3) 729 (34.9)  
Multiple antithrombotic ¥ 39 (34.5) 437 (20.9) < 0.001 
Abbreviations: CCI, Charlson comorbidity index; SD, standard deviation; * Includes current and ex-
smokers. ¥ Includes patients receiving oral anticoagulant-APT or dual antiplatelet combination therapy. 
6.4.2 Factors associated with bleeding  
The factors independently associated with bleeding are summarised in Table 18. After 
adjusting for baseline characteristics, increasing age, a history of prior bleeding, warfarin (vs 
DOACs and APT agents), and multiple antithrombotic therapy (vs single antithrombotic 
therapy) were independently associated with bleeding events. The factors most strongly 
associated with bleeding were a history of prior bleeding (odds ratio [OR] 3.25, 95% CI 1.12-
8.19), warfarin therapy (OR 2.47, 95% CI 1.46-4.41), and multiple antithrombotic therapy (OR 
2.45, 95% CI 1.61-3.71).  
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OR (95% CI) 
 
p–value 
Age  1.04 (1.02-1.06) < 0.001 1.05 (1.03-1.08) 0.001 
Sex (males) 1.34 (0.91-1.99) 0.144 1.53 (1.00-2.36) 0.051 
Smoking* (Yes) 0.82 (0.55-1.22) 0.340   










Ischaemic heart diseases 1.08 (0.72-1.61) 0.690   
Diabetes mellitus  1.19 (0.76-1.82) 0.427   
Congestive heart failure 0.99 (0.61-1.57) 0.977   
Myocardial infarction  1.37 (0.78-2.28) 0.256   
Peripheral vascular diseases  0.43 (0.07-1.39) 0.253   
History of stroke 1.25 (0.60-2.34) 0.506   








Prior bleeding  3.72 (1.38-8.52) 0.004 3.25 (1.12-8.19) 0.019 
     
















Warfarin  3.02 (2.03-4.58) < 0.001 2.47 (1.46-4.41) 0.001 
DOAC  0.98 (0.58-1.58) 0.946   
APT 0.40 (0.24-0.64) < 0.001 0.78 (0.40-1.51) 0.454 
 Multiple 
antithrombotic¥  
3.11 (2.11-4.57) < 0.001 2.45 (1.61-3.71) < 0.001 
Abbreviations: OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; 
DOAC, direct oral anticoagulant; APT, antiplatelet. * Includes current and ex-smokers. 
¥ Include OAC-APT combination and dual-APT therapy. 
6.4.3 Bleeding incidence rates among treatment groups 
A total of 942 patients newly initiated on antithrombotic therapy (warfarin = 431, DOAC = 
258, APT = 253) contributed 1,880 patient-years (PY) of on-treatment follow-up. Mean follow-
up durations by treatment category were 922 PY for warfarin, 462 PY for DOACs, and 496 PY 
for APT agents. Fifty-eight patients experienced bleeding events; approximately one-third of 
the bleeding events in the warfarin cohort (n = 13; 34.2%) and half of the events in the DOAC 
(n = 7; 50%) and APT (n = 3; 50%) cohorts occurred within 90 days of initiating therapy. The 
rates of bleeding, classified by severity and site of bleeding, are shown in Table 19. The 
combined rate of major and minor bleeding was higher in patients initiated on warfarin (rate, 
95% CI, 4.1 [2.9 - 5.7] per 100 PY) than those prescribed a DOAC (3.0 [1.7 - 5.2]) or APT 
agent (1.2 [0.5 - 2.7], p = 0.002). 
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When bleeding events were analysed by severity, the rate of major bleeding was significantly 
higher in patients who commenced warfarin compared to those who commenced a DOAC or 
APT agent (2.4 [1.5 - 3.7] vs 0.4 [0.1 - 1.7] and 0.6 [0.2 - 1.9], respectively; p = 0.001). The 
rate of minor bleeding, however, was non-significantly higher in the DOAC group compared 
to the warfarin and APT cohorts. Comparison by bleeding site showed both ICH and upper GI 
bleeding rates were higher in patients initiated on warfarin than both the DOAC- and APT-
treated patients. The Kaplan-Meier curves comparing event-free rates between antithrombotic 
therapies are shown in Figure 11. By the end of the study period, event-free rates for combined 
bleeding events were significantly higher in patients initiated on DOACs than in patients 
initiated on warfarin (log-rank p = 0.03). Similarly, event-free rates of patients initiated on APT 
agents were significantly higher compared to those initiated on OAC therapy (long-rank p = 
0.002). 
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Rate per 100 
PY (95% CI) 
 
Number 
Rate per 100 
PY (95% CI) 
 
Number 
Rate per 100 
PY (95% CI) 
All bleeding events during follow-up 38 4.1 (2.9 – 5.7 ) 14 3.0 (1.7 – 5.2) 6 1.2 (0.5 – 2.7) 0.002 
Early bleeding (within 90 days) 13 13.4 (7.6 – 22.2)  7 11.9 (5.3 – 23.5) 3 5.1 (1.3 – 15.1) 0.310 
Bleeding 
by severity 
Major (fatal + non-fatal) 22 2.4 (1.5 – 3.7) 2 0.4 (0.1 – 1.7) 3 0.6 (0.2 – 1.9) 0.001 




ICH 8 0.9 (0.4 – 1.8) 2 0.4 (0.1 –  1.7) 2 0.4 (0.1 – 1.6) 0.031 
Upper GI 13 1.3 (0.7 – 2.3) 2 0.4 (0.1 –  1.7) 2 0.4 (0.1 – 1.6) 0.043 
Lower GI and PR 4 0.4 (0.1 – 1.2) 2 0.4 (0.1 –  1.7) 2 0.4 (0.1 – 1.6) 0.971 
Other sites * 13 1.4 (0.8 – 2.5) 8 1.7 (0.8 – 3.5) 0 - 0.782 
 
 











Rate per 100 
PY (95% CI) 
 
Number 
Rate per 100 
PY (95% CI) 
 
Number 
Rate per 100 
PY (95% CI) 
Death All-cause mortality 28 3.0 (2.1 – 4.4) 10 2.2  (1.1 – 4.1) 16 3.2 (1.9 – 5.3) 0.321 
Cardiovascular death¥ 14 1.5 (0.9 – 2.6) 2 0.4 (0.1 – 1.7) 9 1.8 (0.9 – 3.5) 0.086 
Death due to bleeding 5 0.5 (0.2 – 1.3) 0 - 2 0.4 (0.1 – 1.6) 0.937 
Death due to other causes 14 1.5 (0.9 – 2.6) 8 1.7 (0.9 – 3.9) 7 1.4  (0.6 – 3.0) 0.939 
Abbreviations: DOAC, direct oral anticoagulant; APT, antiplatelet; PY, patient years; ICH, intracranial haemorrhage; GI, gastrointestinal; PR, per-rectal. 
* Epistaxis, hematuria, hematoma. ¥ Includes death due to cardiovascular diseases including fatal bleeding. 





Figure 11. Kaplan–Meir curves for all bleeding events among patients newly initiated on 
antithrombotic therapy. 
A) APT vs OAC; B) Warfarin vs DOACs. Abbreviations: APT, antiplatelet agents; DOAC, 
direct oral anticoagulants; OAC, oral anticoagulants; WAR, warfarin.   




In this analysis from the TAF study, we investigated bleeding events and factors associated 
with bleeding in patients with AF receiving antithrombotic therapy. This is one of the first 
follow-up studies involving a relatively large study population over an extended follow-up 
period featuring the introduction of DOACs into the Australian clinical setting. Both major and 
minor bleeding rates in this cohort were relatively low, especially in the DOAC-treated patients, 
while the rates of major bleeding, including ICH, in the DOAC and APT groups were lower 
than rates in the warfarin-treated patients. Increasing age, a history of prior bleeding, warfarin, 
and multiple antithrombotic therapy were independent predictors of bleeding.   
The combined, major, and minor bleeding incidence rates in this cohort were lower than in 
similar observational studies from other countries. Early bleeding rates, however, were 
considerably higher than bleeding rates for the entire follow-up period. The high early bleeding 
incidence rate in our study was consistent with other studies which reported higher rates of 
bleeding soon after initiating treatment than at the later stages of therapy [89,92]. This could 
be explained by the complexity of treatment initiation, poor understanding of instructions, 
inappropriate dosing, and fluctuations in the international normalised ratio (INR) values at the 
earlier stages of antithrombotic therapy in AF. 
Our data indicated higher major and combined bleeding rates among patients who received 
warfarin compared to those receiving DOAC and APT therapies. This variation was observed 
in the absence of significant differences in patient characteristics between patients prescribed 
warfarin or a DOAC (supplementary Table 20). We also noted more frequent major bleeding 
than minor bleeding events in the warfarin cohort. This was in contrast to findings from other 
            
152 
 
observational studies that showed more frequent minor bleeding than major bleeding events 
[332]. Conversely, minor bleeding events were more frequent in the DOAC-treated patients. 
Moreover, the rate of minor bleeding among patients initiated on DOACs was numerically 
higher than the rates in their warfarin- and APT-treated counterparts. Challenges in relation to 
the quality of anticoagulation with warfarin therapy, including suboptimal adherence, poor INR 
control, and interactions with drugs or food, could be among the potential reasons for the higher 
rate of major bleeding events observed in the warfarin-treated patients.   
The rates of bleeding in patients with AF receiving antithrombotic therapy vary widely in 
published studies. These differences may be the result of several factors including variations 
in study designs, patient populations and the quality of patient monitoring. Our estimate of the 
major bleeding incidence rate in the warfarin initiators (2.4 per 100 PY) was lower than other 
observational studies, which reported major bleeding rates in warfarin-treated patients in the 
range of 3-8% per 100 PY [215,318,338]. Conversely, the rate of major bleeding in this study 
corresponded well to the rates observed in randomised trials of warfarin therapy, which have 
ranged between 1-3% per 100 PY [99,100,339]. This contrasted with results from most 
observational studies that showed substantially higher bleeding incidence rates than observed 
in the clinical trials. The rate of major bleeding in the DOAC group was also lower than the 
rates reported from both observational and trial studies of 0.5-3.6% per 100 PY [99,340,341]. 
Our study population included hospitalised patients. Patients with minor bleeding managed by 
local general practices and major bleeding leading to pre-hospital death were not included in 
this study, and this is the possible explanation for the lower rates of bleeding events observed. 
One of the most feared complications of OAC in AF is ICH, particularly haemorrhagic stroke. 
In this study, the rate of ICH in the warfarin cohort was higher than the ICH rate observed in 
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randomised trial and large observational studies (0.9 vs 0.3-0.6 per 100 PY) [99,100,114]. The 
high ICH rate was probably due to the high use of combination warfarin-APT therapy. Further 
studies should investigate the appropriateness and clinical outcomes of using multiple 
antithrombotic therapies in AF. Conversely, the rate of ICH in the DOAC-treated patients was 
less than half the rate in patients who received warfarin (0.4 vs 0.9 per 100 PY, respectively). 
This corroborates other studies that showed a 50% reduction in the risk of ICH using DOACs 
in preference to warfarin in AF [342,343]. A meta-analysis of studies that evaluated DOACs 
for stroke prevention in NVAF also estimated a >50% relative reduction in the pooled 
incidence rate of ICH in the DOAC- vs warfarin-treated patients [102]. Few studies from 
clinical practice showed more frequent gastrointestinal (GI) bleeding in patients using DOACs 
than warfarin [332,344]. By contrast, upper GI bleeding rates were slightly higher in the 
warfarin than the rates in the DOAC and APT cohorts of our study.  
In summary, the relatively low bleeding incidence rates observed in our study, and the 
heterogeneity of bleeding rates reported from other studies could reflect variability in the 
standard of care, methodological differences, and variations in data sources.  
Identifying factors associated with bleeding is clinically important because interventions 
focused on modifiable factors may maximise the net therapeutic benefit of OAC therapy in 
patients with AF. After adjusting for differences in patient characteristics, we identified 
advanced age, a history of prior bleeding, treatment using warfarin (vs DOACs and APT 
therapy), and multiple antithrombotic (vs a single antithrombotic) as independent predictors of 
bleeding. Our results are consistent with other studies that examined factors associated with 
antithrombotic-associated bleeding in AF [244,345,346]. Some studies have identified female 
sex, a history of stroke, hypertension, and smoking or alcohol use as predictors of bleeding in 
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AF [347-349]. However, these variables were not significantly associated with bleeding in our 
study.  
Based on these findings, bleeding events in AF could be reduced by cautious use of OACs in 
elderly patients, closer monitoring of OAC therapy especially in patients with bleeding history, 
and avoiding OAC-APT therapy in AF where possible. Although we did not assess the 
appropriateness of antithrombotic prescribing in this study, our data revealed a relatively high 
proportion of patients being prescribed OAC-APT therapy prior to their bleeding-related 
admission. Data from the ORBIT-AF study showed that aspirin was often used with warfarin 
in AF without a clear indication for APT therapy [350]. However, OAC-APT combination 
therapy substantially increased the risk of bleeding without a net therapeutic benefit in reducing 
stroke.     
Our data also reinforce the safety of the DOACs relative to warfarin in terms of bleeding in 
general and ICH. Because DOACs have been shown to be relatively safer and more convenient 
than warfarin, they are recommended as first-line therapy in the contemporary European and 
Canadian guidelines for the management of AF [9,19]. Our data supports international findings 
and suggests that Australian guidelines could be revised with a clear recommendation to use 
DOACs as a first-line therapy for the majority of patients with NVAF. However, precaution 
should be taken while initiating DOACs in elderly AF patients with impaired renal function. 
This study has certain limitations. We assessed bleeding resulting in hospitalisation, and data 
regarding minor bleeding events managed in primary care or severe events leading to pre-
hospital death were not available. As a result, the rate of bleeding observed in our study may 
be an underestimate. However, the RHH is the largest referral centre in the region, and most 
patients requiring admission will be readmitted to the RHH. Our hospitalised population might 
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also have contributed to the higher rate of major than minor bleeding events, and for the high 
rate of ICH in the warfarin-treated patients. In addition, we did not investigate INR at 
presentation or time in the therapeutic range that could have an important role in warfarin-
related bleeding events. Furthermore, we did not determine bleeding incidence rates for 
individual DOACs due to the small numbers of patients initiated on each of the three DOACs. 
Finally, this study has the limitations of a retrospective study design and can be affected by 
missing values or incomplete documentations. Although statistical adjustments were used, we 
cannot rule out unmeasured or residual confounding in the multivariate analysis.  
6.6 Conclusion  
Our data indicated low overall and major bleeding incidence rates, particularly among DOAC-
treated patients. Increasing age, a history of prior bleeding, treatment using warfarin, and 
multiple antithrombotic therapy were independently associated with bleeding-related 
hospitalisation. These findings suggest that using DOACs in preference to warfarin and 
avoiding multiple antithrombotic therapies, especially in the elderly patients with AF, have the 
potential to reduce bleeding rates. Additional large-scale studies in the Australian clinical 
setting regarding comparative safety among the three DOACs, appropriateness of multiple 
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(n = 431) 
DOAC  
(n = 258) 
APT  
(n = 253) 
 
p-value  
Demographics Age, mean (SD) 74.6 (10.1) 72.9 (10.5) 73.1 (13.1) 0.074 
Sex, females, n (%) 178 (41.2) 124 (48.1) 106 (41.9) 0.082 
Smoking*, n (%) 180 (41.7) 95 (36.8) 89 (35.2) < 0.001 
Alcohol (>8 units/week) 29 (6.7) 18 (6.9) 23 (9.1) 0.4966 
Comorbidities 
  n (%) 
 
Hypertension 290 (67.3) 165 (63.9) 146 (57.7) 0.042 
Ischaemic heart disease 139 (32.2) 55 (21.3) 68 (26.9) 0.072 
Diabetes mellitus 100 (23.2) 52 (20.2) 45 (17.8) 0.229 
Congestive heart failure 67 (15.5) 42 (16.3) 32 (12.6) 0.465 
Myocardial infarction 56 (13.0) 24 (9.3) 21 (8.3) 0.3185 
Valvular heart disease 42 (9.7) 13 (5.0) 12 (4.7) 0.015 
Renal diseases 37 (8.6) 14 (5.4) 21 (8.3) 0.287 
History of stroke 32 (7.4) 22 (8.5) 9 (3.6) 0.049 
Cerebrovascular disease 19 (4.4) 4 (1.5) 5 (2.0) 0.056 






(n = 431) 
DOAC  
(n = 258) 
APT  
(n = 253) 
p-value  
 History of bleeding  7 (1.6) 2 (0.8) 5 (2.0) 0.511 
 PVD 18 (4.2) 4 (1.5) 5 (2.0) 0.083 
 CCI, mean (SD) 4.5 (1.9) 4.0 (2.2) 4.0 (2.4) 0.003 
 CHA2DS2-VASc,  
mean (SD) 
3.3 (1.4) 3.1 (1.6) 2.8 (1.5) < 0.001 
 HAS-BLED, mean (SD) 2.3 (0.7) 2.2 (0.7) 2.2 (0.7) 0.348 
Abbreviations: CCI, Charlson comorbidity index; PVD, peripheral vascular diseases; SD, 












7. General discussion and conclusions   
This thesis comprises a series of analyses addressing detailed investigations of antithrombotic 
therapy in contemporary patients with AF. Thromboprophylaxis is essential in the management 
of patients with AF, and effective stroke prevention can be achieved by optimal utilisation of 
OACs. For more than 60 years, VKAs such as warfarin were the only OAC agents available 
for stroke prevention in AF. Despite guideline recommendations, VKAs were often underused 
for stroke prevention in AF. The recent availability of DOACs as alternative agents to VKAs 
was anticipated to improve suboptimal use of OACs and clinical outcomes in patients with AF. 
The development and approval of DOACs heralded a new era for stroke prevention in AF and 
other embolic diseases. The four innovative RCTs have established that DOACs have similar 
efficacy, with superior safety profiles, compared to warfarin [98-101]. Given their multiple 
benefits over warfarin mainly with regard to safety and convenience, DOAC prescribing in AF 
was expected to grow with a profound impact in reducing suboptimal anticoagulation practices.  
Limited data was available from the Australian perspective regarding contemporary patterns 
of overall antithrombotic prescribing and clinical integration of DOACs for stroke prevention 
in AF. Moreover, it was not previously known if the introduction of DOACs would help to 
improve suboptimal anticoagulation practices in patients with AF and have positive impacts on 
clinical outcomes. Thus the TAFs was launched in 2011 to enhance understanding of evolving 
changes in stroke prevention in AF, and help in defining future treatment strategies that may 
influence clinical outcomes. The TAFs was among the first Australian studies to provide data 
concerning temporal patterns of antithrombotic prescribing in AF, the impact of the widespread 
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availability of DOAC on anticoagulation practices, and clinical outcomes in patients with AF. 
In this body of work, we undertook a literature review pertaining to antithrombotic prescribing 
for stroke prevention in patients with AF in relation to guideline recommendations. Moreover, 
we investigated anticoagulation practices and clinical outcomes in Tasmanian patients with AF.  
Our literature review (Chapter 2) summarises findings of some of the national and international 
observational AF registry studies. This review discusses pharmacological features of DOACs, 
contemporary anticoagulation practices, and early adoption patterns of DOACs. In addition to 
the positive trial results, variations in time of regulatory approval [351], lack of uniformity in 
the recommendations of guidelines [352], limited knowledge/experience for the new therapies 
[353], and marketing strategies/promotions [287] may influence uptake of DOACs. Indeed, 
contrasting results were evident from the various studies undertaken in our review. Early 
evidence (data between 2008 and 2013) suggests that slow adoption patterns with a limited 
impact on anticoagulation practice in AF were reported in most countries [181,230,243,354]. 
However, the majority of early investigations did not include study periods in which factor Xa 
inhibitors were largely available. More recent data, however, show profound changes in OAC 
prescribing in AF associated with the advent of DOACs. Since DOACs were introduced, AF 
guidelines have been revised [9,19], and there has been a significant increase in the overall rate 
of anticoagulation, primarily driven by the prescribing of DOACs [355-358]. Nevertheless, the 
impacts of general availability of DOACs on patient outcomes, and their role in reducing the 
overall burden of AF care remain to be investigated.  
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7.1 Antithrombotic prescribing patterns 
The first study in this thesis analysed overall patterns of antithrombotic prescribing and clinical 
adoption of DOACs for stroke prevention in contemporary patients with AF. This analysis adds 
to an earlier investigation conducted during the familiarisation phase of DOACs in Australia 
[137], by providing a comprehensive picture of OAC utilisation patterns during a time period 
in which the new therapies were subsidised by the Australian government. As such, it offers 
broad descriptions regarding temporal patterns of antithrombotic prescribing in AF in general, 
and DOAC adoption trends in particular.  
Our results revealed slow clinical integration of DOACs after they were approved by the TGA 
in 2011 until their listing on the PBS for subsidy by the government (mid-2013). Subsequently, 
rapid growth in the use of DOACs was noted soon after their listing on the PBS, with the main 
increase being driven by prescribing of apixaban and rivaroxaban. During the last quarter of 
this study, apixaban became the most commonly prescribed DOAC followed by rivaroxaban, 
while dabigatran prescribing remained stable at low proportions. This study also identified a 
progressive decline in the prescribing of APT therapy for stroke prevention in AF through time. 
The decreasing trend in APT prescribing may be driven in part by the widespread availability 
of DOACs, but also by the increasing realisation that APT agents are barely effective compared 
to OAC therapy [105,359,360]. Overall, this study showed a paradigm shift in the prescribing 
patterns of antithrombotic therapy for the prevention of thrombosis in AF over time. The new 
anticoagulants were broadly adopted, becoming more frequently prescribed than warfarin and 
APT therapies soon after they were listed on the Australian PBS.  
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Having observed that DOACs have been largely integrated for stroke prevention in AF, the 
second analysis in this section focused on investigating whether the availability of DOACs has 
increased the proportion of AF patients receiving guideline-recommended OAC therapy. We 
observed a significant increase in the proportion of patients with AF receiving OAC treatment 
in the post-DOAC compared to the pre-DOAC era; most importantly, anticoagulation of high-
risk patients with AF improved significantly in the post-DOAC era (55.2% vs 63.1%, p<0.001). 
This change was driven primarily by the increase in prescribing of DOACs. Indeed, our 
multiple regression analysis revealed DOAC availability (post-DOAC era) was an independent 
predictor of OAC prescribing, resulting in an approximately 40% increase in the odds of a 
patient being prescribed an OAC. Similar to our data, the introduction of DOACs in real-world 
practice was associated with improved rates of overall OAC use in the PINNACLE AF-registry 
data involving 655,000 patients with NVAF [361].  
The rate of OAC prescribing in AF varies widely depending on countries, study settings and 
study populations, ranging between 30% and 90% [95,362]. Overall, most observational data 
reported increasing trends of OAC prescribing in AF associated with the advent of DOACs. 
The GARFIELD-AF study showed temporal changes in the prescribing of antithrombotic 
therapy in AF in five sequential cohorts between 2010 and 2015. The rate of OAC prescribing 
increased from 54.7% in cohort-2 to 73.9% in cohort-5. The increase in OAC prescribing in 
this study was shown to be primarily driven by DOAC prescribing [357]. Similarly, data from 
GLORIA-AF, phase-2, revealed a significant increase in OAC prescribing after the 
introduction of DOACs [286]. Compared to the anticoagulation rate in the pre-DOAC era, the 
anticoagulation rate in the post-DOAC era markedly increased (from 64% to 80%, with DOAC 
prescribing greater than VKA prescribing overall).  
            
162 
 
This study also explored important factors associated with OAC prescribing in AF. The general 
availability of DOACs was identified as a significant positive predictor of OAC prescribing in 
this study population. Conversely, increasing age, female sex, and a history of prior bleeding 
were inversely associated with OAC prescribing. Advanced age (especially over the age of 80 
years), falls risk, prior bleeding, and perceived high risk of bleeding on anticoagulation have 
been identified as common barriers to OAC prescribing in AF [20,363]. However, the risk of 
stroke without any OAC often exceeds the bleeding risk on anticoagulation, even in the elderly 
patients, including those with frequent falls and frailty [298,364].On the other hand, the risk of 
bleeding on APT treatment, commonly prescribed in elderly AF patients, is not different to the 
bleeding risk on warfarin or DOAC treatment [365,366]. Accordingly, increasing age and 
associated frailty should not deter OAC prescribing in patients with AF. Overall, this analysis 
showed the clinical introduction of DOACs was associated with a significant increase in the 
rate of OAC prescribing in AF, but substantial gaps remain requiring further improvement.  
7.2 Clinical outcomes  
While the global burden of AF has increased in recent decades, the management of AF has also 
greatly evolved. The major advances pertaining to stroke prevention in AF include: the clinical 
introduction of DOACs, updates in treatment guidelines and stroke risk scoring methods, and 
associated increase in OAC prescribing practices [361]. These changes have been anticipated 
to bring about improvements in patient outcomes by reducing thromboembolism and all-cause 
mortality. However, inconsistent data has been reported regarding time-trends of TEs and all-
cause mortality in patients with AF. Some studies have shown declining rates in AF-related 
stroke and mortality in the population [28,307,367], while more recent data indicated a limited 
reduction in the risk of AF-related TEs over time [368,369].  
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Comparative studies about TEs and all-cause mortality between pre- and post-DOAC approval 
periods in the Australian AF population are limited. Our data from the preceding two analyses 
(Chapters 3 and 4) showed a major shift towards using DOACs, and a significant increase in 
the rate of OAC prescribing in AF. These results raised the critical question of whether the risk 
of TEs and all-cause mortality in AF had improved during the post-DOAC era. The subsequent 
analysis (described in Chapter 5) was a follow-up study that examined possible implications of 
the observed treatment changes by comparing clinical outcomes in two time-periods: prior to 
and following the general availability of DOACs in Australia. 
Interesting results emerged from this analysis suggesting a profound decline in the rates of TEs 
and all-cause mortality in the later than in the prior cohort. This was despite broad similarities 
in baseline demography, comorbidities, and stroke risk scores between the two cohorts. Given 
the increased morbidity and mortality associated with suboptimal anticoagulation in AF [370], 
the improved patient outcomes observed post-DOAC availability in our study are noteworthy. 
Increased DOAC prescribing in preference to warfarin, improved relative safety and efficacy 
of DOACs, and increased anticoagulation rates are among the likely explanations for the 
improved patient outcomes observed in this study. Indeed, our Cox-regression analysis showed 
hospitalisation post-DOAC availability was associated with a significant decrease in the risk 
of TEs. Our findings, however, should be interpreted with caution; although this study showed 
a reduction in the rates of TEs and all-cause mortality in the later study period, this data does 
not fully explain the reasons for the declining trends. Patient outcome in the real-world practice 
is a multifaceted issue that can be influenced by several confounding factors. Hence, neither 
the increase in prescribing of DOACs nor the increase in anticoagulation rates fully accounts 
for the reduction in TEs and all-cause mortality.  
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Bleeding is a major challenge and the most common ADR of antithrombotic therapy in AF. 
Major bleeding events such as ICHs are the most devastating complications of anticoagulation 
associated with significant morbidity and mortality [331,371,372]. Thus, reducing major 
bleeding represents an important step in improving the net clinical benefit of OAC treatment 
in AF. Understanding of rates and risk factors for bleeding in contemporary patients with AF 
receiving antithrombotic medications is essential in planning future research and designing 
management strategies tailored to individual patients. Furthermore, data pertaining bleeding-
related hospitalisation during antithrombotic treatment is important in light of the increased 
prescribing of DOACs for stroke prevention in NVAF. The last analysis in this thesis assessed 
bleeding incidence rates and identified factors associated with bleeding in patients with AF 
receiving warfarin, DOACs, and APT agents.  
The overall rates of bleeding in this cohort were low relative to similar observational data. Our 
study population involved hospitalised patients; patients with minor bleeds managed in general 
practice or those with severe bleeds leading to pre-hospital death were not included. This may 
be a potential explanation for the low rates of bleeding events in this study. The rate of ICH in 
warfarin-treated patients, however, was higher than rates reported from observational and trial 
data (0.9 vs 0.3-0.6 per 100 PY) [99,100,105,114]. Conversely, DOAC-treated patients had a 
lower rate of ICH than warfarin-treated patients (0.4% vs 0.9% PY). This was in agreement 
with other findings that showed a 50% reduction in the risk of ICH using DOACs in preference 
to warfarin therapy in AF [102,342]. Increasing age, history of prior bleeding, treatment using 
warfarin, and multiple antithrombotic therapies were significantly associated with bleeding 
events. Although we did not assess the appropriateness of multiple antithrombotic treatment in 
this study, our data revealed a relatively large proportion (34%) of AF patients being prescribed 
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OAC-APT or dual-APT treatment prior to their bleeding-related hospital admissions. Multiple 
antithrombotic use is not uncommon in AF, though largely inappropriate, and explained by 
coexistence of coronary artery diseases.  Data from the ORBIT-AF registry study also showed 
that aspirin was used with warfarin in about 40% AF patients without a clear indication [373]. 
However, antithrombotic combination substantially increases the risk of bleeding without a net 
benefit in reducing the risk of stroke [350]. Further studies are required to investigate the 
appropriateness and outcomes of multiple antithrombotic prescribing in patients with AF.   
7.3 Practice implications  
This study has several implications for clinical practice. Although a significant increase in 
OAC prescribing in AF was observed, substantial gaps remain requiring further improvement. 
Our data showed suboptimal adherence to guideline recommendations; a large proportion of 
low-risk patients received OAC therapy, whereas a considerable percentage of patients with a 
Class I indication for anticoagulation received APT agents or were discharged without any 
antithrombotic therapy. Despite regional and other differences, patients with AF worldwide 
demonstrate broadly similar risk profiles and suffer a significant burden of cardiovascular 
disease [356]. The prescribing of DOACs and the overall use of OACs in AF are increasing 
worldwide, with a concomitant decrease in the prescribing of VKAs and APT agents. However, 
international patterns of stroke prevention in AF vary widely. The rate of OAC prescribing in 
our study was lower than rates reported in Europe [176,278], whereas it was comparable to 
data observed from the United States of America [291]. Observational studies indicated that 
inadequate antithrombotic guideline adherence in AF leads to an unacceptably high number of 
potentially preventable strokes [374].  
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Defining an optimal target for OAC prescribing in AF could be challenging due to lack of 
global consensus on eligibility for anticoagulation, primarily in the intermediate-risk groups 
and frequent revision of AF treatment guidelines. Nonetheless, the net clinical benefit of OAC 
treatment in AF is almost universal, with the exception of patients at very low stroke risk. Thus 
it remains imperative to appropriately implement current guideline recommendations, and all 
intermediate or high-risk AF patients without contraindication to OACs should be targeted for 
anticoagulation.  
Studies have identified a broad range of barriers to optimal OAC prescribing in AF including: 
knowledge gaps regarding the risk of AF-related stroke, the benefits and risks of OAC therapies 
in general and DOACs in particular; lack of awareness pertaining the potential use of DOACs 
for warfarin-unsuitable patients; lack of recognition of expanded eligibility for OAC; lack of 
availability of reversal agents mainly for factor Xa inhibitors and the difficulty of anticoagulant 
monitoring for DOACs; and concerns about the bleeding risk of anticoagulant therapy, 
primarily with DOACs and in the setting of OAC-APT therapy [375,376]. Thus, several 
strategies have been proposed to improve anticoagulation in AF including [377,378]:  
• Increasing awareness about AF and the risk of AF-associated stroke, benefits and risks 
of OAC therapies via educational initiatives. 
•  Defining the role of warfarin in the DOAC era including eligibility and ineligibility for 
different anticoagulant agents. 
• Identifying DOAC reversal agents and monitoring strategies and making knowledge 
regarding their use publicly available.  
• Undertaking large observational studies to refine the understanding of anticoagulant 
utilisation patterns and patient outcomes in hospitals and community practice settings.  
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Our data also indicated a relative decrease in the incidence rates of TEs in the post-DOAC era. 
Furthermore, this study reinforced the relative safety of DOACs in terms of bleeding in general, 
and ICH in particular. Thus bleeding-related hospitalisation in AF can be significantly reduced 
by using DOACs in preference to warfarin, closer monitoring of OAC treatment especially in 
elderly patients and in those with a history of prior bleeding and avoiding/minimising the use 
of multiple antithrombotic therapies in AF where possible. Because DOACs have been shown 
to be safer and more convenient to use than warfarin, they are recommended as first-line agents 
for the prevention of stroke in NVAF in the European and Canadian AF guidelines [9,19]. Our 
findings support international studies and suggest that local management protocols could be 
developed with a clear recommendation to use the new OACs as a first-line therapy in patients 
with NVAF. The recently published Australian AF management guideline also recommends 
DOACs in preference to warfarin when initiating an OAC for stroke prevention in NVAF [118].    
This study demonstrated that shifting from VKAs and APT therapies to DOACs at a population 
level was associated with a decline in TE and bleeding rates for patients with AF. These 
findings can be used by policy makers at various levels of the health care system to introduce 
quality improvement programs, and to develop clinical performance measures such as 
implementation of consistent guideline-based recommendations for stroke prevention in 
patients with AF. Decision makers in hospitals and general practices can also develop treatment 
protocols pertaining to anticoagulant selection, patient education, and follow-up programs. 
Moreover, our data can serve as a basis for government research departments to undertake 
further studies regarding the financial burden of AF-related stroke, the role of DOACs in 
reducing this burden, and align health care system incentives to improve access to the new 
OACs.  
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Providing evidence about patterns of stroke prevention treatment and clinical outcomes in AF 
is important for rational use of anticoagulant agents. Accordingly, findings of this study can be 
used by clinicians for choosing antithrombotic therapies in agreement with current guideline 
recommendations, and patients with AF for additional information regarding the various OAC 
options available in clinical practice. Furthermore, systematic educational interventions can be 
designed for health professionals to enhance the understanding of the new OACs and treatment 
outcomes in AF. This can help to improve adherence to guidelines for stroke management in 
AF. Finally, shared decision-making tools can be developed to guide care providers and 
increase knowledge of patients about the new therapies. A primary focus should also be to 
develop a greater awareness about AF and the treatment options in the primary care setting.  
7.4 Limitations 
This study has certain limitations. The study involved hospitalised AF patients who could be 
relatively more comorbid than patients managed in primary care. Hence, our data may not fully 
reflect OAC prescribing practices in the community setting. Moreover, this was a single centre 
study conducted in one referral hospital in the Southern Tasmania. However, the relatively 
large number of participants over an extended study period, and the centre being the largest 
referral hospital in the region improved the robustness and representativeness of our data. 
Missing values and incomplete documentation inherent to retrospective studies were additional 
limitations. Another limitation is that we used the CHA2DS2-VASc score to analyse OAC 
prescribing. While widely used in practice, this scoring system was not universally accepted, 
with some controversy in female patients with intermediate risk of stroke. Anticoagulation of 
65-74 year-old women without additional clinical risk factors was debatable [379,380]. The 
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recent Australian and European AF guidelines do not recommend OAC in this group, and 
adherence to recommendations may have improved after the publication of these guidelines.   
Given the observational nature of our data, the clinical outcome analyses in this study also have 
some limitations that should be taken into consideration. First, there is a potential for selection 
bias inherent to retrospective observational studies; exposure to antithrombotic therapy at index 
admissions was not randomised. Second, we were not able to capture TEs or bleeding events 
resulting in admission to other settings, minor events managed in local general practices, severe 
complications leading to pre-hospital death or death occurring outside our study setting. This 
may underestimate TE, bleeding and mortality incidence rates observed in this study. Third, as 
the study population involved hospitalised AF patients, incidence rates may not reflect clinical 
outcomes of patients with AF managed in the community setting. Finally, the increased OAC 
prescribing rates observed in this study may not be fully explained by the availability of 
DOACs; other unaccounted factors such as marketing promotion of the new OACs, the 
increased research focus and global conferences pertaining AF, and increased awareness about 
AF may have also contributed to the improved rates of anticoagulation in AF.    
7.5 Conclusions 
In this real-world cohort of patients with AF, antithrombotic prescribing changed significantly 
over the study period, characterised by a major shift towards the prescribing of DOACs. The 
widespread availability of DOACs has been associated with a significant increase in the rates 
of OAC prescribing. However, a large proportion of at-risk patients received APT treatment or 
remained untreated highlighting the need for further improvement. Our data also suggested that 
stroke and all-cause mortality rates tended to decline during the post-DOAC era, possibly 
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driven by the increased anticoagulation practices and the use of DOACs in preference to 
warfarin. Furthermore, the rate of major bleeding and ICH, in particular, was lower in DOAC- 
than warfarin-treated patients. We also identified several factors associated with OAC 
prescribing, thromboembolism and bleeding events that can be targeted for future interventions. 
In summary, the findings from the sequence of analyses described in this thesis offer a number 
of real benefits to the various stakeholders involved in the management of AF. The findings 
reported in this thesis could also be used to promote understanding of the various OAC options 
including associated risks and benefits. In Australia, where anticoagulation of patients with AF 
remains suboptimal and awareness of patients regarding DOAC treatment is low [381], the 
impacts of our findings could be significant. 
7.6 Recommendations and future directions     
Results from this research will aid in the development of strategies to address the suboptimal 
management of at-risk patients with AF. Several issues for further investigation arose from this 
body of work, as outlined below.  
• Although there was an increase in OAC prescribing in the post-DOAC era, anticoagulation 
of high-risk patients in this study was lower than rates reported in recent large AF-registry 
data (63% vs 69% and 87% in GARFIELD-AF and ORBIT-AF II, respectively) [356]. 
Moreover, APT therapy was widely used among high-risk patients in both eras (38.9% and 
28.2% in the pre- and post-DOAC eras, respectively). These findings highlight the need for 
further research to identify barriers to OAC prescribing in AF and address them accordingly. 
• We have identified increasing age and prior bleeding as potent negative predictors of OAC 
prescribing. However, observational studies reported that bleeding risk in aging is 
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overestimated and should not discourage OAC prescribing in AF [141,298]. Thus, it would 
be worthwhile to investigate prescribers’ concerns regarding OAC therapy in AF, 
especially in the elderly patients and in those with a history of prior bleeding.  
• Prescribing OAC-APT or dual-APT therapy is common in clinical practice when patients 
are diagnosed with concomitant AF and coronary artery diseases. However, the safety and 
efficacy of using multiple antithrombotic therapies in patients with AF presenting with 
coronary heart diseases has always been debatable [382]. In our study, a large portion of 
patients hospitalised with bleeding were receiving OAC-APT or dual-APT treatment prior 
to their admission. Moreover, the use of multiple antithrombotics was associated with a 3-
fold increase in the risk of bleeding-related hospitalisation. Yet in this analysis, 
appropriateness of multiple antithrombotic treatment in AF was not evaluated. Given the 
clinical introduction of DOACs for stroke prevention in AF, the complexity of OAC-APT 
combination prescribing is increasing. Nonetheless, robust studies regarding the safety and 
effectiveness of OAC-APT in general and DOAC-APT combinations in particular are 
lacking. Future studies should investigate the appropriateness and outcomes of patients 
with AF prescribed multiple antithrombotic therapies.   
• There was a decline in the rates of TEs and all-cause mortality in AF during the post-DOAC 
study period relative to the pre-DOAC study period. Moreover, favourable outcomes were 
observed in DOAC-treated patients when compared to warfarin. However, head-to-head 
trials or indirect comparative analysis of the relative effectiveness and safety of individual 
DOACs needs larger number of participants and will be the subject of future investigations 
including more patients with an extended follow-up.  
• Lastly, this study focused on hospitalised AF patients while the majority AF management 
occurs in primary care settings. Accordingly, multicentre studies involving large numbers 
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of Australians with AF would be prudent to review the overall impact of the availability of 
DOACs on anticoagulation practices in AF, time-trends of clinical outcomes, and the 
overall burden of AF care. Results from such studies will provide robust information in 
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Appendix A. AF data collection guide 
The main objectives of this project are to: 
• Review overall antithrombotic prescribing patterns and clinical integration of DOACs 
for stroke prevention in Tasmanian patients with AF admitted to RHH between January 
2011 and July 2015. 
• Quantify and compare anticoagulation practices in patients with AF before and after 
the general availability of DOACs in Australia.  
• Investigate clinical outcomes of antithrombotic treatment in AF. 
 
Study time frame: 1 Jan 2011-30 July 2015  
   Inclusion criteria 
• All the patients diagnosed with AF as their primary diagnosis (i.e. AF is the presenting 
as a chief complaint) or secondary condition (i.e. AF is listed as a current illness in the 
medical history or discharge summary).   
• Patients with both valvular or non-valvular AF  
• Age > 18 years 
Exclusion criteria 
• Acute episode of AF that gets settled spontaneously or upon cardioversion without 
documented recurrences (e.g. Episode of AF post CABG that gets reverted to SR after 
certain antiarrhythmic drug administration). If the patient has been discharged without 
any notes, follow them up with their OPD records and try to track if they are still on 
antithrombotic therapy (include such uncertain cases as they have been discharged on 
antithrombotic therapy). If there is no evidence of continuing AF, the patient should be 
excluded.  
• Any acute AF admission due to illness/poisoning etc. that settles on its own without 
needing any antiarrhythmic/antithrombotic therapy. 
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Initial admission and readmissions 
We need to look at each and every admission that falls within our time frame and consider the 
earliest admission as Episode 1 (provided the patient has AF at that time and fulfils our 
inclusion criteria) and follow up all subsequent admissions as readmission regardless of the 
cause. Based on the primary readmission diagnosis enter them into the database e.g. if it was 
due to COPD mark it as ‘none of the above’ or if due to MI mark it as thromboembolism. 
Document the readmission as ‘bleeding’ only if they were receiving antithrombotic therapy at 
the time of the bleed; otherwise use ‘none of the above.’ Other readmission categories can be 
used regardless of whether or not the patient is receiving an antithrombotic. 
Types of AF  
i. Every patient who presents with AF for the first time is considered patient with first 
diagnosed AF, irrespective of the duration of the arrhythmia or the presence and 
severity of AF-related symptoms. 
ii. Paroxysmal AF is self-terminating, usually within 48 hours. Although AF paroxysms 
may continue for up to 7 days, the 48 hour time point is clinically important—after this 
the likelihood of spontaneous conversion is low and anticoagulation must be considered  
iii. Persistent AF is present when an AF episode either lasts longer than 7 days or requires 
termination by cardioversion, either with drugs or by direct current cardioversion 
(DCC). 
iv. Permanent AF is said to exist when the presence of the arrhythmia is accepted by the 
patient (and physician). Hence, rhythm control interventions are, by definition, not 
pursued in patients with permanent AF. Should a rhythm control strategy be adopted, 
the arrhythmia is redesignated as ‘longstanding persistent AF’. We can note down the 
types of AF as per the diagnosis (if mentioned) if not go through the medical progress 
and try to categorise it based on the definition.   
 
            
221 
 
Appendix B. Data collection tools/study database 
B.1. Demographics 
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 B 2. Medical history 
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B 3. Admission medications 
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B 4. Admission details  
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B 5. Bleeding events and management   
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B 6. Thromboembolic events  
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B 6. Antithrombotics (during hospital stay) 
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B 6. INRs (for patients taking warfarin) 
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B 7. Discharge details  
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B 8. Discharge medications 
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Appendix C. Ethics amendment approval letter  
Notification of Amendment Approval: H0012729 Outcomes of antithrombotic therapy in 
a new era: the Ta 
Lauren.Black@utas.edu.au 
Mon 19/01/2015 2:25 PM 
To: Leanne Chalmers <leanne.chalmers@utas.edu.au>; 
Cc: Luke Bereznicki <luke.bereznicki@utas.edu.au>; nicole.hancock@dhhs.tas.gov.au 
<nicole.hancock@dhhs.tas.gov.au>; prt@dhhs.tas.gov.au <prt@dhhs.tas.gov.au>; Durga Bista 
<durga.bista@utas.edu.au>; Endalkachew Alamneh <endalkachew.alamneh@utas.edu.au>; Lauren Black 
<lauren.dipalma@utas.edu.au>; 
Dear Dr Chalmers 
Ethics Ref: H0012729 
Title: Outcomes of antithrombotic therapy in a new era: the Tasmanian experience 
I wish to inform you that the Human Research Ethics Committee (Tasmania) Network has approved the 
following amendment for the above named study: 
Amendment Add new Investigator - E Alamneh 
All committees operating under the Human Research Ethics Committee (Tasmania) Network are 
registered and required to comply with the National Statement on Ethical Conduct in Human Research 
(NHMRC 2014). 
This email constitutes official approval and no hard copy notification will be sent.  It is the responsibility 
of the first-named investigator to ensure that their co-investigators are aware of the content of the 
correspondence. 
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